ASX Code,Company Name,Item,2000,2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015
1ST,1st Available Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"1,445,449.00","9,593,068.00"
1ST,1st Available Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"288,046.00"
1ST,1st Available Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"-3,203,236.00"
1ST,1st Available Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"-3,634,474.00"
1ST,1st Available Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-3,309,803.00"
1ST,1st Available Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
1ST,1st Available Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,"-1,149.05%"
1ST,1st Available Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-34.50%
1ST,1st Available Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"10,515,480.88"
ACG,AtCor Medical Holdings Limited,Annual Balance Sheet - Total Equity, , , , , ,"18,795,000.00","14,406,000.00","9,382,000.00","5,961,497.00","4,645,022.00","3,736,765.00","3,032,122.00","1,884,420.00","4,878,933.00","3,283,947.00","4,333,993.00"
ACG,AtCor Medical Holdings Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,"3,446,000.00","3,723,000.00","5,070,000.00","6,944,951.00","12,157,946.00","9,980,058.00","7,657,633.00","7,115,778.00","10,778,637.00","5,556,038.00","6,923,222.00"
ACG,AtCor Medical Holdings Limited,Annual Profit and Loss - EBITDA, , , , , ,"-2,982,000.00","-4,720,000.00","-5,917,000.00","-3,997,453.00","-1,749,824.00","-1,108,006.00","-2,948,043.00","-1,804,549.00","2,911,327.00","-2,573,086.00","-1,353,617.00"
ACG,AtCor Medical Holdings Limited,Annual Profit and Loss - EBIT, , , , , ,"-3,012,000.00","-4,801,000.00","-6,079,000.00","-4,145,441.00","-1,926,234.00","-1,273,840.00","-3,100,832.00","-1,986,733.00","2,732,862.00","-2,671,589.00","-1,441,673.00"
ACG,AtCor Medical Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-2,696,000.00","-4,005,000.00","-5,183,000.00","-3,792,731.00","-1,691,433.00","-1,220,057.00","-3,081,084.00","-1,985,519.00","2,734,023.00","-2,663,508.00","-1,440,177.00"
ACG,AtCor Medical Holdings Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
ACG,AtCor Medical Holdings Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,-86.80%,-120.13%,-106.34%,-58.80%,-15.09%,-13.26%,-41.31%,-30.82%,30.19%,-52.71%,-26.34%
ACG,AtCor Medical Holdings Limited,Annual Ratio Analysis - ROE, , , , , ,-14.34%,-27.80%,-55.24%,-63.62%,-36.41%,-32.65%,-101.61%,-105.36%,56.04%,-81.11%,-33.23%
ACG,AtCor Medical Holdings Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,0.00,"16,632,559.90","13,000,000.00","10,000,000.00","19,000,000.00","11,545,041.70","20,114,791.65","8,868,916.74","10,553,569.53","14,799,386.23","32,558,336.28"
ACL,Alchemia Limited,Annual Balance Sheet - Total Equity, , , ,"27,592,826.00","22,159,000.00","14,014,000.00","40,426,000.00","28,127,000.00","32,520,000.00","24,571,000.00","31,531,000.00","18,814,000.00","24,265,000.00","32,379,000.00","27,050,000.00","11,509,000.00"
ACL,Alchemia Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , ,"2,190,435.00","2,156,000.00","2,387,000.00","839,000.00","2,316,000.00","1,345,000.00","1,560,000.00","120,000.00","832,000.00","700,000.00","24,081,000.00","15,415,000.00","11,761,000.00"
ACL,Alchemia Limited,Annual Profit and Loss - EBITDA, , , ,"-5,460,960.00","-5,845,000.00","-8,610,000.00","-13,071,000.00","-12,392,000.00","-10,936,000.00","-7,752,000.00","-8,028,000.00","-12,595,000.00","-14,140,000.00","-3,656,000.00","-6,107,000.00","-3,891,000.00"
ACL,Alchemia Limited,Annual Profit and Loss - EBIT, , , ,"-6,913,253.00","-7,133,000.00","-9,817,000.00","-14,218,000.00","-14,266,000.00","-12,660,000.00","-9,448,000.00","-9,708,000.00","-14,319,000.00","-15,870,000.00","-5,259,000.00","-7,582,000.00","-4,678,000.00"
ACL,Alchemia Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-6,863,596.00","-6,522,000.00","-8,853,000.00","-12,732,000.00","-12,929,000.00","-10,943,000.00","-8,367,000.00","-8,801,000.00","-13,430,000.00","-15,083,000.00","-4,770,000.00","-6,924,000.00","-15,816,000.00"
ACL,Alchemia Limited,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
ACL,Alchemia Limited,Annual Ratio Analysis - Net Profit Margin, , , ,--,--,--,"-48,480.77%","-1,683.46%","-121,588.89%",--,--,--,"-251,383.33%",-46.93%,-85.11%,-28.25%
ACL,Alchemia Limited,Annual Ratio Analysis - ROE, , , ,-24.87%,-29.43%,-63.17%,-33.35%,-45.97%,-33.65%,-34.05%,-27.91%,-71.38%,-62.16%,-14.73%,-25.60%,-13.70%
ACL,Alchemia Limited,Annual Ratio Analysis - Market Cap.($), , , ,0.00,"61,464,391.78","54,979,000.39","147,935,363.90","121,132,301.18","47,955,453.90","56,961,200.53","97,978,248.39","117,095,992.84","126,277,685.55","103,694,022.08","180,047,662.66","10,391,155.87"
ACR,Acrux Limited,Annual Balance Sheet - Total Equity, , ,"17,485,116.00","11,664,921.00","8,408,905.00","29,481,791.00","20,583,000.00","18,246,000.00","38,109,000.00","31,223,000.00","80,469,000.00","45,712,000.00","53,103,000.00","46,753,000.00","42,057,000.00","40,625,000.00"
ACR,Acrux Limited,Annual Profit and Loss - Total Revenue Excluding Int, , ,--,"1,832,619.00","3,339,645.00","3,471,736.00","1,548,000.00","4,044,000.00","4,496,000.00","2,604,000.00","55,069,000.00","89,771,000.00","9,058,000.00","15,717,000.00","53,389,000.00","24,804,000.00"
ACR,Acrux Limited,Annual Profit and Loss - EBITDA, , ,"-3,081,892.00","-6,343,873.00","-4,368,242.00","-6,948,897.00","-10,752,000.00","-8,424,000.00","-6,848,000.00","-8,694,000.00","48,614,000.00","79,058,000.00","3,618,000.00","10,521,000.00","44,800,000.00","17,667,000.00"
ACR,Acrux Limited,Annual Profit and Loss - EBIT, , ,"-3,144,783.00","-6,587,141.00","-4,650,422.00","-7,369,402.00","-11,262,000.00","-8,943,000.00","-7,334,000.00","-9,293,000.00","48,139,000.00","78,812,000.00","3,269,000.00","9,098,000.00","43,387,000.00","16,242,000.00"
ACR,Acrux Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , ,"-3,144,783.00","-5,956,800.00","-4,232,632.00","-6,044,034.00","-9,939,000.00","-7,861,000.00","-5,026,000.00","-7,716,000.00","46,554,000.00","57,148,000.00","7,391,000.00","6,926,000.00","27,970,000.00","11,130,000.00"
ACR,Acrux Limited,Annual Profit and Loss - Total Operating Income (ban, , ,--,--,--,--,--,--,--,--,--,--,--,--,--,--
ACR,Acrux Limited,Annual Ratio Analysis - Net Profit Margin, , ,--,-799.51%,-129.55%,-173.40%,-671.17%,-194.36%,-111.79%,-583.22%,84.54%,63.78%,84.02%,44.44%,52.41%,45.21%
ACR,Acrux Limited,Annual Ratio Analysis - ROE, , ,-17.99%,-51.27%,-50.44%,-20.42%,-48.29%,-43.08%,-13.19%,-24.71%,57.85%,125.02%,13.92%,14.81%,66.50%,27.40%
ACR,Acrux Limited,Annual Ratio Analysis - Market Cap.($), , ,0.00,0.00,0.00,"65,942,374.50","98,276,066.77","219,198,029.16","194,357,243.52","180,919,245.16","290,606,750.96","564,423,850.29","699,286,186.20","584,491,205.61","167,354,319.56","141,543,454.35"
ACW,Actinogen Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,"2,859,172.00","1,902,230.00","1,168,259.00","1,046,127.00","346,990.00","194,353.00","1,211,812.00","15,356,608.00"
ACW,Actinogen Medical Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , ,"13,639.00","25,589.00","111,771.00","58,820.00","51,562.00","5,535.00","166,954.00","103,502.00"
ACW,Actinogen Medical Limited,Annual Profit and Loss - EBITDA, , , , , , , , ,"-575,823.00","-1,167,348.00","-943,694.00","-1,040,031.00","-1,111,556.00","-439,933.00","-417,633.00","-5,253,056.00"
ACW,Actinogen Medical Limited,Annual Profit and Loss - EBIT, , , , , , , , ,"-577,440.00","-1,181,173.00","-961,066.00","-1,059,576.00","-1,130,925.00","-456,858.00","-431,228.00","-5,474,482.00"
ACW,Actinogen Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"-435,658.00","-926,942.00","-737,471.00","-742,380.00","-1,529,156.00","-164,663.00","-440,222.00","-5,431,009.00"
ACW,Actinogen Medical Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , ,--,--,--,--,--,--,--,--
ACW,Actinogen Medical Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , ,"-3,194.21%","-3,622.42%","-1,523.35%","-1,262.12%","-1,671.18%",--,"-2,088.50%",--
ACW,Actinogen Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , ,-15.24%,-48.73%,-63.13%,-70.96%,-248.33%,-84.72%,-34.47%,-35.36%
ACW,Actinogen Medical Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , ,"2,392,199.88","3,787,649.81","1,076,489.95","1,533,397.21","2,659,881.33","1,785,294.18","2,228,955.72","43,643,416.18"
ADO,Anteo Diagnostics Limited,Annual Balance Sheet - Total Equity,"7,314,683.00","10,199,317.00","6,372,825.00","3,455,730.00","2,107,897.00","526,706.00","1,591,757.00","1,549,861.00","3,010,212.00","1,032,600.00","1,394,366.00","6,891,174.00","4,772,565.00","2,775,766.00","7,101,335.00","5,346,863.00"
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - Total Revenue Excluding Int,264.00,"55,880.00","1,346,896.00","4,106,855.00","4,402,484.00","2,008,728.00","811,617.00","1,856,642.00","1,135,462.00","674,615.00","572,143.00","813,814.00","1,194,391.00","1,674,709.00","2,462,755.00","2,309,829.00"
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - EBITDA,"-533,172.00","-1,391,994.00","-1,929,601.00","-2,071,019.00","-2,331,995.00","-1,317,382.00","-5,708,596.00","-1,109,935.00","-1,694,445.00","-1,973,514.00","-2,227,161.00","-2,337,781.00","-2,588,706.00","-2,222,241.00","-2,560,652.00","-4,192,090.00"
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - EBIT,"-636,779.00","-1,646,095.00","-3,712,926.00","-2,517,168.00","-2,731,279.00","-1,517,642.00","-6,088,783.00","-1,324,894.00","-1,844,348.00","-2,076,378.00","-2,299,277.00","-2,424,171.00","-2,697,077.00","-2,347,133.00","-2,665,188.00","-4,354,378.00"
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-546,592.00","-1,401,000.00","-9,163,678.00","-2,946,256.00","-2,829,397.00","-1,579,539.00","-6,245,124.00","-1,563,497.00","-1,762,320.00","-1,949,275.00","-2,255,405.00","-2,222,462.00","-2,380,199.00","-2,179,223.00","-2,492,150.00","-4,220,342.00"
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
ADO,Anteo Diagnostics Limited,Annual Ratio Analysis - Net Profit Margin,--,"-2,517.97%",-271.32%,-54.46%,-57.56%,-67.69%,-771.38%,"-1,715.47%","-2,172.65%",-861.32%,-848.69%,"-1,058.00%",-587.45%,-427.05%,-804.54%,-907.34%
ADO,Anteo Diagnostics Limited,Annual Ratio Analysis - ROE,-7.47%,-13.74%,-54.97%,-62.88%,-116.88%,-255.93%,-392.34%,-100.88%,-58.54%,-188.77%,-161.75%,-32.25%,-49.87%,-78.51%,-35.09%,-78.93%
ADO,Anteo Diagnostics Limited,Annual Ratio Analysis - Market Cap.($),"18,946,819.40","42,103,316.50","13,293,532.48","6,916,258.86","4,277,160.74","1,589,558.14","10,422,131.60","5,899,171.11","7,155,589.56","1,801,097.39","28,343,392.67","53,361,111.37","56,623,067.73","46,221,095.46","158,021,003.67","66,870,530.45"
ADR,Adherium Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"34,528,000.00"
ADR,Adherium Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,--
ADR,Adherium Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,0.00
ADR,Adherium Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,0.00
ADR,Adherium Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00
ADR,Adherium Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
ADR,Adherium Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
ADR,Adherium Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
ADR,Adherium Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
AGX,Agenix Limited,Annual Balance Sheet - Total Equity,"21,649,963.00","34,384,972.00","34,696,000.00","33,968,000.00","20,282,000.00","8,710,000.00","14,211,000.00","19,752,000.00","7,137,000.00","-490,000.00","2,846,399.00","1,987,201.00","1,038,009.00","210,933.00","1,387,079.00","848,719.00"
AGX,Agenix Limited,Annual Profit and Loss - Total Revenue Excluding Int,"27,104,524.00","29,297,398.00","40,513,000.00","37,230,000.00","37,186,000.00","24,691,000.00","1,074,000.00","473,000.00","955,000.00","5,902,000.00","4,640,916.00",--,"10,462.00","8,745.00","25,382.00","48,080.00"
AGX,Agenix Limited,Annual Profit and Loss - EBITDA,"3,757,491.00","5,757,034.00","7,725,000.00","3,459,000.00","-1,870,000.00","-5,036,000.00","-12,889,000.00","-10,631,000.00","-23,276,000.00","-6,745,000.00","2,590,904.00","-2,865,557.00","-1,364,863.00","-3,244,692.00","-1,931,122.00","-744,223.00"
AGX,Agenix Limited,Annual Profit and Loss - EBIT,"3,120,266.00","4,178,221.00","5,724,000.00","1,412,000.00","-3,755,000.00","-6,981,000.00","-13,172,000.00","-10,954,000.00","-23,555,000.00","-6,798,000.00","2,574,769.00","-2,875,409.00","-1,376,252.00","-3,259,865.00","-1,939,482.00","-744,739.00"
AGX,Agenix Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"4,923,828.00","4,200,596.00","161,000.00","-811,000.00","-14,336,000.00","-11,988,000.00","-3,721,000.00","-4,778,000.00","-23,283,000.00","-7,954,000.00","2,478,187.00","-2,707,451.00","-1,355,204.00","-3,258,469.00","786,160.00","-1,083,446.00"
AGX,Agenix Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
AGX,Agenix Limited,Annual Ratio Analysis - Net Profit Margin,2.22%,14.26%,4.38%,4.73%,-17.53%,-35.70%,"-2,458.39%","-3,419.88%","-9,367.21%",-978.94%,"6,579.37%",--,--,"-87,008.52%","-7,643.52%",--
AGX,Agenix Limited,Annual Ratio Analysis - ROE,2.96%,12.13%,4.73%,4.68%,-27.61%,-90.90%,-96.88%,-59.20%,-324.18%,"1,432.45%",87.06%,-136.24%,-130.56%,"-1,544.79%",-139.87%,-91.18%
AGX,Agenix Limited,Annual Ratio Analysis - Market Cap.($),"35,947,691.92","51,483,617.40","53,963,854.00","60,902,063.80","103,181,472.90","45,694,593.85","34,015,331.20","82,513,626.75","15,755,662.31","7,409,088.09","8,416,736.87","10,462,642.06","3,139,575.46","2,555,700.15","1,425,524.48","1,772,111.21"
AHZ,Admedus Ltd,Annual Balance Sheet - Total Equity, , , , ,"5,012,432.00","3,805,141.00","3,372,319.00","2,338,684.00","1,388,617.00","1,098,045.00","1,239,267.00","13,638,433.00","10,433,447.00","15,075,074.00","37,166,875.00","38,558,482.00"
AHZ,Admedus Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , , ,--,--,"3,000.00","12,000.00","44,189.00","12,000.00","43,885.00","6,850,998.00","6,574,084.00","9,974,811.00","12,505,920.00","11,306,245.00"
AHZ,Admedus Ltd,Annual Profit and Loss - EBITDA, , , , ,"-711,275.00","-1,963,750.00","-1,328,212.00","-2,890,248.00","-1,586,271.00","-1,329,755.00","-1,465,626.00","-1,958,670.00","-4,699,159.00","-2,762,744.00","-11,359,805.00","-21,873,071.00"
AHZ,Admedus Ltd,Annual Profit and Loss - EBIT, , , , ,"-715,351.00","-1,973,647.00","-1,339,389.00","-2,901,212.00","-1,594,053.00","-1,341,227.00","-1,474,857.00","-1,981,586.00","-4,974,758.00","-3,035,524.00","-12,822,832.00","-23,890,079.00"
AHZ,Admedus Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , ,"-650,347.00","-1,767,760.00","-1,177,080.00","-2,237,442.00","-1,275,942.00","-1,131,386.00","-1,312,566.00","-1,953,648.00","-10,222,135.00","-2,418,497.00","-8,207,715.00","-26,799,970.00"
AHZ,Admedus Ltd,Annual Profit and Loss - Total Operating Income (ban, , , , ,--,--,--,--,--,--,--,--,--,--,--,--
AHZ,Admedus Ltd,Annual Ratio Analysis - Net Profit Margin, , , , ,--,--,--,--,--,--,--,-28.93%,-71.28%,-25.56%,-117.73%,-249.21%
AHZ,Admedus Ltd,Annual Ratio Analysis - ROE, , , , ,-12.97%,-46.46%,-39.87%,-104.18%,-93.52%,-99.48%,-96.90%,-14.32%,-43.99%,-14.28%,-26.34%,-69.71%
AHZ,Admedus Ltd,Annual Ratio Analysis - Market Cap.($), , , , ,"11,919,762.67","3,188,981.30","3,259,847.55","11,803,169.84","4,725,048.30","5,668,216.97","3,096,774.84","45,729,469.27","14,392,239.17","50,723,387.87","194,546,869.34","129,177,932.52"
AJJ,Asian American Medical Group Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"1,356,377.00","370,251.00","1,794,022.00","1,499,138.00","2,141,063.00","3,581,986.00","6,928,720.00","4,521,330.00","8,393,344.00"
AJJ,Asian American Medical Group Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,"884,047.00","876,320.00","17,856,473.00","16,941,837.00","16,131,408.00","18,701,852.00","17,093,804.00","13,925,090.00","20,178,833.00"
AJJ,Asian American Medical Group Limited,Annual Profit and Loss - EBITDA, , , , , , , ,"-756,275.00","-1,573,188.00","2,324,404.00","2,367,858.00","1,640,601.00","2,457,028.00","390,188.00","-2,082,685.00","1,072,577.00"
AJJ,Asian American Medical Group Limited,Annual Profit and Loss - EBIT, , , , , , , ,"-786,661.00","-1,631,269.00","2,299,084.00","2,334,334.00","1,460,643.00","2,343,416.00","264,568.00","-2,241,443.00","974,977.00"
AJJ,Asian American Medical Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-781,209.00","-1,612,046.00","1,935,289.00","1,933,475.00","1,196,931.00","1,942,200.00","202,984.00","-2,135,444.00","553,232.00"
AJJ,Asian American Medical Group Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
AJJ,Asian American Medical Group Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,-88.37%,-183.96%,10.93%,11.42%,7.83%,10.57%,1.20%,-15.66%,5.59%
AJJ,Asian American Medical Group Limited,Annual Ratio Analysis - ROE, , , , , , , ,-57.60%,-435.39%,647.12%,128.97%,58.52%,54.90%,2.93%,-47.23%,13.02%
AJJ,Asian American Medical Group Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,"6,280,458.10","949,310.59","14,585.91","10,364,970.00","17,903,130.00","16,960,860.00","28,276,256.79","15,709,031.55","19,156,300.32"
ALC,Alcidion Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"5,715,533.00","5,138,102.00","2,526,150.00","4,175,336.00","4,026,748.00","3,748,327.00"
ALC,Alcidion Group Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , ,--,--,"107,621.00","110,245.00","136,267.00",--
ALC,Alcidion Group Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , ,0.00,"-709,883.00","-3,067,950.00","-1,881,494.00","-399,815.00","-391,898.00"
ALC,Alcidion Group Limited,Annual Profit and Loss - EBIT, , , , , , , , , , ,0.00,"-721,657.00","-3,108,021.00","-1,907,094.00","-402,019.00","-392,165.00"
ALC,Alcidion Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,0.00,"-721,657.00","-3,108,021.00","-1,193,789.00","-148,588.00","-278,421.00"
ALC,Alcidion Group Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , ,--,--,--,--,--,--
ALC,Alcidion Group Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , ,--,--,"-2,887.93%","-1,082.85%",--,--
ALC,Alcidion Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%,-28.09%,-123.03%,-28.59%,-3.69%,-7.43%
ALC,Alcidion Group Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , ,0.00,"9,745,018.58","2,376,833.80","2,627,012.75","3,041,804.24","5,668,816.99"
ALT,Analytica Limited,Annual Balance Sheet - Total Equity, , , , , ,"3,066,839.00","355,641.00","323,934.00","657,235.00","681,132.00","743,224.00","540,012.00","1,297,909.00","166,743.00","2,374,522.00","381,049.00"
ALT,Analytica Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,"796,348.00","266,199.00","288,299.00","114,046.00","191,394.00","254,942.00","648,868.00","162,693.00","541,262.00","565,174.00","1,119,378.00"
ALT,Analytica Limited,Annual Profit and Loss - EBITDA, , , , , ,"-1,629,283.00","-1,042,488.00","-594,997.00","-856,873.00","-1,918,611.00","-1,289,554.00","-190,329.00","-2,137,336.00","-1,120,126.00","-3,178,305.00","-5,221,855.00"
ALT,Analytica Limited,Annual Profit and Loss - EBIT, , , , , ,"-3,654,983.00","-3,104,056.00","-603,605.00","-867,799.00","-1,928,253.00","-1,302,801.00","-203,173.00","-2,235,267.00","-1,135,522.00","-3,195,213.00","-5,315,220.00"
ALT,Analytica Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-3,614,447.00","-3,076,454.00","-589,740.00","-829,457.00","-1,901,780.00","-1,287,837.00","-203,176.00","-2,222,009.00","-1,135,751.00","-3,176,008.00","-5,315,604.00"
ALT,Analytica Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
ALT,Analytica Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,-583.28%,"-1,583.75%",-236.08%,--,--,"-71,546.50%","-3,330.75%","-45,532.97%",-228.03%,--,"-7,200.37%"
ALT,Analytica Limited,Annual Ratio Analysis - ROE, , , , , ,-117.86%,-865.06%,-182.06%,-126.20%,-279.21%,-173.28%,-37.62%,-171.20%,-681.14%,-133.75%,"-1,394.99%"
ALT,Analytica Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,"5,196,572.83","3,962,415.57","3,151,060.06","6,411,792.16","7,514,293.42","10,688,708.73","12,333,125.46","9,518,058.50","11,199,776.30","35,060,557.79","10,331,424.83"
AMT,Allegra Orthopaedics Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"8,355,000.00","9,362,992.00","8,454,149.00","7,485,000.00","4,247,000.00","4,035,000.00","4,203,000.00","4,169,000.00","4,186,474.00"
AMT,Allegra Orthopaedics Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,--,"6,969,836.00","6,342,577.00","7,485,000.00","7,356,000.00","8,697,000.00","7,836,000.00","8,783,000.00","8,819,584.00"
AMT,Allegra Orthopaedics Limited,Annual Profit and Loss - EBITDA, , , , , , , ,0.00,"789,273.00","-803,538.00","601,000.00","-1,158,000.00","862,000.00","788,000.00","704,000.00","69,610.00"
AMT,Allegra Orthopaedics Limited,Annual Profit and Loss - EBIT, , , , , , , ,0.00,"163,914.00","-1,606,683.00","-523,000.00","-2,193,000.00","-79,000.00","-225,000.00","-79,000.00","-706,613.00"
AMT,Allegra Orthopaedics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,0.00,"180,005.00","-1,024,695.00","-896,000.00","-3,265,000.00","-173,000.00","-571,000.00","-64,000.00","-855,056.00"
AMT,Allegra Orthopaedics Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
AMT,Allegra Orthopaedics Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,--,2.64%,-16.56%,-12.26%,-37.25%,-2.03%,-6.82%,-3.78%,-11.69%
AMT,Allegra Orthopaedics Limited,Annual Ratio Analysis - ROE, , , , , , , ,0.00%,1.92%,-12.12%,-11.97%,-63.10%,-4.29%,-11.61%,-7.22%,-20.42%
AMT,Allegra Orthopaedics Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,0.00,"13,060,628.52","9,883,718.88","15,178,568.28","8,118,769.08","5,118,354.42","4,593,881.04","2,625,074.88","16,827,830.72"
ANN,Ansell Limited,Annual Balance Sheet - Total Equity,"1,499,900,000.00","1,066,200,000.00","876,000,000.00","844,500,000.00","811,800,000.00","602,800,000.00","653,700,000.00","613,600,000.00","546,000,000.00","639,100,000.00","664,600,000.00","677,600,000.00","720,800,000.00","833,300,000.00","1,210,721,868.00","1,519,010,416.00"
ANN,Ansell Limited,Annual Profit and Loss - Total Revenue Excluding Int,"5,814,200,000.00","5,222,400,000.00","3,174,900,000.00","1,308,800,000.00","1,136,400,000.00","1,097,600,000.00","1,138,200,000.00","1,239,200,000.00","1,244,700,000.00","1,352,100,000.00","1,230,600,000.00","1,219,800,000.00","1,218,300,000.00","1,340,000,000.00","1,688,110,403.00","2,142,057,291.00"
ANN,Ansell Limited,Annual Profit and Loss - EBITDA,"481,600,000.00","509,400,000.00","249,800,000.00","168,400,000.00","176,400,000.00","169,700,000.00","157,900,000.00","149,300,000.00","157,300,000.00","174,900,000.00","168,400,000.00","160,000,000.00","171,300,000.00","195,100,000.00","256,581,740.00","386,067,708.00"
ANN,Ansell Limited,Annual Profit and Loss - EBIT,"291,700,000.00","369,600,000.00","167,500,000.00","111,900,000.00","129,700,000.00","124,400,000.00","132,500,000.00","122,600,000.00","123,500,000.00","142,400,000.00","143,100,000.00","138,800,000.00","149,400,000.00","167,200,000.00","219,214,437.00","339,973,958.00"
ANN,Ansell Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-82,400,000.00","-135,800,000.00","-113,000,000.00","52,500,000.00","72,600,000.00","13,100,000.00","118,700,000.00","104,100,000.00","105,600,000.00","126,400,000.00","122,700,000.00","125,900,000.00","133,000,000.00","140,800,000.00","47,133,757.00","246,223,958.00"
ANN,Ansell Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
ANN,Ansell Limited,Annual Ratio Analysis - Net Profit Margin,2.77%,1.85%,3.12%,4.33%,6.50%,8.33%,10.20%,8.07%,8.24%,8.98%,9.70%,10.06%,10.67%,10.21%,9.86%,12.36%
ANN,Ansell Limited,Annual Ratio Analysis - ROE,10.69%,7.33%,8.05%,6.72%,9.03%,15.38%,18.15%,16.71%,19.24%,19.44%,18.35%,18.48%,18.40%,16.75%,13.94%,17.65%
ANN,Ansell Limited,Annual Ratio Analysis - Market Cap.($),"1,554,353,950.79","781,242,981.96","1,174,821,580.00","1,087,617,843.00","1,364,646,489.84","1,607,659,849.32","1,467,736,891.04","1,766,442,428.60","1,257,985,260.40","1,194,140,617.22","1,727,614,570.76","1,883,443,548.00","1,724,668,017.60","2,302,794,687.69","3,032,758,180.23","3,689,500,119.69"
ANP,Antisense Therapeutics Limited,Annual Balance Sheet - Total Equity, ,"20,033,762.00","13,481,712.00","11,617,746.00","17,132,983.00","10,864,344.00","8,793,236.00","6,017,376.00","6,334,646.00","3,927,502.00","1,344,099.00","2,018,122.00","5,265,844.00","4,647,055.00","2,086,891.00","7,091,598.00"
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - Total Revenue Excluding Int, ,--,"4,000.00","1,680.00","692,375.00","274,635.00","76,416.00","275,536.00","6,660,068.00","440,163.00","357,313.00","530,584.00","959,802.00","1,091,889.00","1,140,990.00","4,569,323.00"
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - EBITDA, ,"-402,894.00","-5,934,110.00","-5,156,174.00","-4,356,517.00","-5,540,622.00","-4,415,240.00","-4,861,862.00","-944,988.00","-4,151,324.00","-3,541,847.00","-1,898,006.00","-1,895,874.00","-2,650,086.00","-3,086,455.00","662,741.00"
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - EBIT, ,"-404,281.00","-6,606,110.00","-6,452,528.00","-5,655,239.00","-6,839,437.00","-5,870,847.00","-5,322,795.00","-953,628.00","-4,159,027.00","-3,548,833.00","-1,904,656.00","-1,902,999.00","-2,658,127.00","-3,096,208.00","654,569.00"
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, ,"-393,739.00","-6,321,006.00","-6,107,898.00","-4,609,624.00","-6,265,839.00","-5,462,401.00","-4,835,963.00","-2,136,886.00","-2,649,727.00","-3,424,875.00","-1,813,550.00","-1,801,278.00","-2,454,842.00","-3,013,272.00","706,918.00"
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - Total Operating Income (ban, ,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
ANP,Antisense Therapeutics Limited,Annual Ratio Analysis - Net Profit Margin, ,--,--,--,--,--,--,--,-33.39%,--,--,--,--,--,--,18.30%
ANP,Antisense Therapeutics Limited,Annual Ratio Analysis - ROE, ,-1.97%,-46.89%,-52.50%,-26.90%,-57.67%,-62.12%,-80.37%,-33.73%,-67.47%,-254.81%,-89.86%,-34.21%,-52.83%,-144.39%,9.97%
ANP,Antisense Therapeutics Limited,Annual Ratio Analysis - Market Cap.($), ,0.00,"24,725,357.65","28,904,568.84","51,512,011.25","14,920,965.78","12,073,164.97","19,734,060.96","42,243,121.93","21,121,560.96","7,674,263.99","7,608,630.50","22,772,003.76","14,379,545.66","20,173,457.92","20,298,935.54"
ANR,Anatara Lifesciences Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"7,226,054.00","5,480,816.00"
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"61,383.00"
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"-1,936,132.00"
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"-1,936,132.00"
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-1,795,228.00"
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
ANR,Anatara Lifesciences Ltd,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,--
ANR,Anatara Lifesciences Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-32.75%
ANR,Anatara Lifesciences Ltd,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"37,750,000.00"
API,Australian Pharmaceutical Industries Limited,Annual Balance Sheet - Total Equity,"154,644,000.00","257,300,000.00","266,402,000.00","343,186,000.00","338,408,000.00","443,614,000.00","428,897,000.00","406,935,000.00","418,964,000.00","434,527,000.00","591,175,000.00","554,367,000.00","568,308,000.00","584,120,000.00","480,737,000.00","505,402,000.00"
API,Australian Pharmaceutical Industries Limited,Annual Profit and Loss - Total Revenue Excluding Int,"1,249,033,000.00","1,646,690,000.00","1,908,017,000.00","2,474,886,000.00","2,943,746,000.00","3,416,265,000.00","2,586,472,000.00","949,971,000.00","3,250,582,000.00","3,555,815,000.00","3,717,022,000.00","3,495,025,000.00","3,233,169,000.00","3,202,804,000.00","3,352,584,000.00","3,457,857,000.00"
API,Australian Pharmaceutical Industries Limited,Annual Profit and Loss - EBITDA,"33,935,000.00","45,590,000.00","52,140,000.00","66,943,000.00","59,403,000.00","69,907,000.00","61,583,000.00","6,026,000.00","47,525,000.00","64,893,000.00","68,184,000.00","18,432,000.00","74,229,000.00","74,480,000.00","41,181,000.00","89,017,000.00"
API,Australian Pharmaceutical Industries Limited,Annual Profit and Loss - EBIT,"29,918,000.00","39,148,000.00","45,322,000.00","46,929,000.00","46,477,000.00","53,341,000.00","61,583,000.00","6,026,000.00","47,525,000.00","48,745,000.00","49,638,000.00","-1,807,000.00","54,064,000.00","56,311,000.00","22,936,000.00","68,636,000.00"
API,Australian Pharmaceutical Industries Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"26,578,000.00","28,586,000.00","34,657,000.00","23,567,000.00","18,444,000.00","29,721,000.00","20,374,000.00","-2,598,000.00","15,213,000.00","18,598,000.00","22,646,000.00","-23,310,000.00","30,283,000.00","24,292,000.00","-90,771,000.00","43,126,000.00"
API,Australian Pharmaceutical Industries Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
API,Australian Pharmaceutical Industries Limited,Annual Ratio Analysis - Net Profit Margin,1.71%,1.74%,1.82%,1.45%,1.11%,0.87%,1.72%,-0.28%,0.47%,0.52%,0.61%,-0.57%,0.49%,0.76%,-3.31%,1.25%
API,Australian Pharmaceutical Industries Limited,Annual Ratio Analysis - ROE,13.71%,11.11%,13.01%,10.44%,9.66%,6.70%,10.39%,-1.92%,3.63%,4.28%,3.83%,-3.55%,2.77%,4.16%,-23.06%,8.53%
API,Australian Pharmaceutical Industries Limited,Annual Ratio Analysis - Market Cap.($),"352,748,980.80","471,090,475.20","674,268,213.22","625,845,464.28","572,227,724.80","707,702,751.25","638,219,208.40","476,090,100.00","177,568,740.00","193,009,841.25","207,449,300.00","114,707,232.50","183,043,500.00","236,736,260.00","285,547,860.00","793,188,500.00"
AVH,Avita Medical Ltd,Annual Balance Sheet - Total Equity,"9,661,767.00","8,882,655.00","14,703,496.00","12,692,981.00","12,383,365.00","17,176,702.00","15,023,589.00","12,940,765.00","13,543,855.00","8,589,881.00","4,678,054.00","16,050,495.00","8,553,977.00","10,455,310.00","5,526,622.00","4,216,884.00"
AVH,Avita Medical Ltd,Annual Profit and Loss - Total Revenue Excluding Int,"-2,078,217.00","605,147.00","1,934,185.00","1,060,007.00","907,095.00","1,491,638.00","1,305,413.00","932,581.00","1,264,225.00","2,984,454.00","3,745,255.00","6,701,098.00","4,682,392.00","3,639,921.00","3,091,712.00","2,933,733.00"
AVH,Avita Medical Ltd,Annual Profit and Loss - EBITDA,"-3,145,555.00","-2,248,789.00","-2,743,836.00","-1,478,218.00","-6,201,566.00","-13,561,829.00","-11,811,957.00","-14,808,767.00","-12,739,665.00","-4,439,386.00","-2,486,945.00","-3,492,065.00","-7,625,195.00","-8,510,332.00","-6,755,728.00","-7,743,958.00"
AVH,Avita Medical Ltd,Annual Profit and Loss - EBIT,"-3,284,622.00","-2,776,204.00","-2,943,236.00","-2,063,713.00","-7,403,479.00","-15,482,034.00","-13,089,104.00","-16,078,962.00","-13,188,794.00","-5,365,711.00","-3,200,124.00","-4,214,999.00","-8,194,427.00","-8,633,256.00","-6,819,439.00","-7,806,582.00"
AVH,Avita Medical Ltd,Annual Profit and Loss - Reported NPAT After Abnorma,"-2,932,839.00","-2,529,112.00","-2,688,501.00","-1,983,430.00","-7,129,289.00","-14,156,687.00","-11,973,869.00","-15,065,061.00","-12,188,280.00","-5,128,292.00","-5,889,363.00","-1,796,920.00","-7,671,682.00","-8,092,939.00","-5,147,391.00","-7,107,496.00"
AVH,Avita Medical Ltd,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
AVH,Avita Medical Ltd,Annual Ratio Analysis - Net Profit Margin,--,--,-794.76%,-379.34%,"-1,281.08%",-985.23%,"-1,005.81%","-1,615.42%",-969.95%,-211.03%,-105.05%,-128.99%,-224.54%,-287.49%,-191.84%,-258.44%
AVH,Avita Medical Ltd,Annual Ratio Analysis - ROE,-29.46%,-24.66%,-18.73%,-31.25%,-57.57%,-82.42%,-79.70%,-116.42%,-89.99%,-59.70%,-60.68%,-25.08%,-88.00%,-77.41%,-93.14%,-168.55%
AVH,Avita Medical Ltd,Annual Ratio Analysis - Market Cap.($),"8,440,306.95","23,569,798.07","14,148,176.96","16,818,250.14","73,569,699.12","69,055,391.65","24,546,147.01","16,176,861.71","9,253,917.39","9,347,391.30","12,405,582.56","26,200,081.16","44,063,772.86","42,290,092.52","32,530,840.40","30,596,400.94"
AVX,Avexa Limited,Annual Balance Sheet - Total Equity, , , , , ,"21,112,000.00","16,920,000.00","91,290,000.00","55,776,000.00","42,783,000.00","24,369,000.00","26,355,000.00","17,029,000.00","13,539,000.00","11,471,000.00","6,374,000.00"
AVX,Avexa Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,"669,000.00",--,"287,000.00","1,359,000.00","1,838,000.00","701,000.00","470,000.00","1,087,000.00","1,897,000.00","295,000.00","1,445,000.00"
AVX,Avexa Limited,Annual Profit and Loss - EBITDA, , , , , ,"-7,518,000.00","-12,511,000.00","-16,721,000.00","-40,234,000.00","-37,316,000.00","-16,327,000.00","-6,011,000.00","-3,168,000.00","-2,571,000.00","-2,551,000.00","-2,154,000.00"
AVX,Avexa Limited,Annual Profit and Loss - EBIT, , , , , ,"-13,530,000.00","-18,563,000.00","-16,799,000.00","-40,421,000.00","-37,579,000.00","-16,564,000.00","-6,234,000.00","-3,312,000.00","-2,735,000.00","-2,566,000.00","-2,162,000.00"
AVX,Avexa Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-13,536,000.00","-17,830,000.00","-15,218,000.00","-36,093,000.00","-36,218,000.00","-41,488,000.00","-4,402,000.00","-3,513,000.00","-2,977,000.00","-2,897,000.00","-6,610,000.00"
AVX,Avexa Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
AVX,Avexa Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,"-2,023.32%",--,--,"-4,050.84%",--,"-3,951.26%",--,--,--,-982.03%,--
AVX,Avexa Limited,Annual Ratio Analysis - ROE, , , , , ,-64.12%,-105.38%,-16.67%,-64.71%,-84.66%,-64.53%,-16.70%,-20.63%,-21.99%,-25.25%,-25.26%
AVX,Avexa Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,"19,997,885.54","45,506,547.42","257,723,116.12","125,870,284.25","78,324,261.98","27,973,729.71","35,602,928.72","15,258,398.02","11,867,642.91","12,959,107.92","6,865,452.48"
AXP,"AirXpanders, Inc.",Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"36,738,000.00","17,045,215.00"
AXP,"AirXpanders, Inc.",Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"633,662.00"
AXP,"AirXpanders, Inc.",Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"-10,653,730.00"
AXP,"AirXpanders, Inc.",Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"-10,739,349.00"
AXP,"AirXpanders, Inc.",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-11,161,345.00"
AXP,"AirXpanders, Inc.",Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
AXP,"AirXpanders, Inc.",Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,"-3,814.44%"
AXP,"AirXpanders, Inc.",Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-65.48%
AXP,"AirXpanders, Inc.",Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"220,789,256.32"
AZV,Azure Healthcare Limited,Annual Balance Sheet - Total Equity, , , , ,"7,374,193.00","9,477,000.00","12,441,000.00","35,283,000.00","35,724,000.00","26,547,000.00","16,679,000.00","6,749,000.00","9,464,000.00","10,635,000.00","14,374,000.00","15,537,000.00"
AZV,Azure Healthcare Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , ,--,"10,055,000.00","22,094,000.00","39,963,000.00","47,759,000.00","47,137,000.00","43,021,000.00","16,767,000.00","18,201,000.00","22,475,000.00","31,308,000.00","36,404,000.00"
AZV,Azure Healthcare Limited,Annual Profit and Loss - EBITDA, , , , ,0.00,"1,645,000.00","3,340,000.00","2,919,000.00","4,337,000.00","-8,593,000.00","-8,274,000.00","1,053,000.00","940,000.00","1,556,000.00","3,880,000.00","708,000.00"
AZV,Azure Healthcare Limited,Annual Profit and Loss - EBIT, , , , ,0.00,"1,287,000.00","3,136,000.00","2,507,000.00","3,492,000.00","-9,686,000.00","-9,176,000.00","483,000.00","501,000.00","1,108,000.00","3,394,000.00","188,000.00"
AZV,Azure Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , ,0.00,"879,000.00","2,205,000.00","1,715,000.00","2,349,000.00","-8,864,000.00","-9,681,000.00","-11,050,000.00","744,000.00","1,040,000.00","3,865,000.00","1,093,000.00"
AZV,Azure Healthcare Limited,Annual Profit and Loss - Total Operating Income (ban, , , , ,--,--,--,--,--,--,--,--,--,--,--,--
AZV,Azure Healthcare Limited,Annual Ratio Analysis - Net Profit Margin, , , , ,--,8.74%,10.03%,4.22%,4.54%,-19.11%,-22.50%,-0.93%,2.01%,4.43%,12.31%,3.10%
AZV,Azure Healthcare Limited,Annual Ratio Analysis - ROE, , , , ,0.00%,9.28%,17.72%,4.82%,6.10%,-33.69%,-58.04%,-2.31%,3.86%,9.08%,26.81%,6.96%
AZV,Azure Healthcare Limited,Annual Ratio Analysis - Market Cap.($), , , , ,0.00,"19,731,583.80","28,608,392.00","37,303,715.20","21,003,964.88","9,241,744.54","9,335,095.50","5,048,334.52","5,490,063.78","12,873,252.99","62,473,139.52","26,559,616.16"
BIT,Biotron Limited,Annual Balance Sheet - Total Equity,"42,221,000.00","10,080,657.00","8,489,713.00","5,761,012.00","2,955,897.00","2,278,730.00","4,495,848.00","1,356,015.00","1,843,377.00","841,506.00","1,717,558.00","2,400,300.00","8,269,547.00","4,475,110.00","1,389,296.00","4,143,026.00"
BIT,Biotron Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,"13,060.00","62,740.00",--,"520,198.00","621,099.00","794,862.00","402,457.00","431,409.00","5,000.00",--,"447,490.00","503,700.00","891,951.00","1,722,481.00","1,672,265.00"
BIT,Biotron Limited,Annual Profit and Loss - EBITDA,0.00,"-1,527,987.00","-2,182,196.00","-2,442,190.00","-2,809,497.00","-1,878,858.00","-2,215,832.00","-3,338,475.00","-1,916,782.00","-1,787,343.00","-1,892,128.00","-1,959,295.00","-2,578,871.00","-4,054,249.00","-3,144,593.00","-2,753,955.00"
BIT,Biotron Limited,Annual Profit and Loss - EBIT,0.00,"-1,533,104.00","-2,408,539.00","-2,653,772.00","-2,992,345.00","-2,016,520.00","-2,298,872.00","-3,389,967.00","-1,957,226.00","-1,835,074.00","-1,915,250.00","-1,973,733.00","-2,589,742.00","-4,062,462.00","-3,155,786.00","-2,770,912.00"
BIT,Biotron Limited,Annual Profit and Loss - Reported NPAT After Abnorma,0.00,"-1,279,663.00","-1,667,894.00","-2,728,701.00","-2,805,115.00","-1,883,575.00","-2,198,973.00","-3,234,004.00","-1,882,093.00","-1,776,099.00","-1,872,244.00","-1,907,527.00","-2,378,052.00","-3,850,745.00","-3,085,814.00","-2,723,221.00"
BIT,Biotron Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
BIT,Biotron Limited,Annual Ratio Analysis - Net Profit Margin,--,"-9,798.34%","-2,658.42%",--,--,--,-276.65%,-803.57%,--,--,--,--,--,--,--,--
BIT,Biotron Limited,Annual Ratio Analysis - ROE,0.00%,-12.69%,-19.65%,-47.36%,-94.90%,-82.66%,-48.91%,-238.49%,-102.10%,-211.06%,-109.01%,-79.47%,-28.76%,-86.05%,-222.11%,-65.73%
BIT,Biotron Limited,Annual Ratio Analysis - Market Cap.($),0.00,"19,202,625.00","22,419,512.50","19,857,282.50","12,170,592.50","9,074,071.50","17,499,995.18","22,435,891.25","15,666,534.75","9,735,671.78","8,035,854.02","15,536,336.34","23,971,179.12","18,720,349.41","23,971,179.12","37,050,363.75"
BLT,Benitec Biopharma Limited,Annual Balance Sheet - Total Equity,"460,361.00","993,995.00","15,132,693.00","6,903,026.00","24,226,535.00","24,879,189.00","62,637.00","3,643,393.00","1,358,035.00","1,148,784.00","-696,674.00","5,204,348.00","2,662,914.00","640,340.00","33,540,522.00","23,878,000.00"
BLT,Benitec Biopharma Limited,Annual Profit and Loss - Total Revenue Excluding Int,"838,425.00","239,968.00","333,938.00","752,172.00","716,849.00","972,518.00","3,690,112.00","402,589.00","364,098.00","284,165.00","151,784.00","297,373.00","335,333.00","1,345,473.00","1,052,657.00","3,198,000.00"
BLT,Benitec Biopharma Limited,Annual Profit and Loss - EBITDA,"-688,724.00","-1,052,653.00","-496,282.00","-6,999,544.00","-7,203,452.00","-13,270,621.00","-599,182.00","-2,087,491.00","-2,956,104.00","-2,632,008.00","-2,606,002.00","-2,883,912.00","-4,257,026.00","-2,071,271.00","-7,801,782.00","-12,186,000.00"
BLT,Benitec Biopharma Limited,Annual Profit and Loss - EBIT,"-1,005,536.00","-1,433,412.00","-967,847.00","-7,900,930.00","-8,044,268.00","-14,658,727.00","-599,182.00","-2,089,627.00","-2,960,891.00","-2,637,424.00","-2,609,688.00","-2,892,965.00","-4,269,848.00","-2,101,065.00","-7,814,590.00","-12,283,000.00"
BLT,Benitec Biopharma Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,110,000.00","-1,539,561.00","-1,124,036.00","-8,229,667.00","-7,827,227.00","-14,562,565.00","-7,676,840.00","-2,746,753.00","-2,774,690.00","-2,470,671.00","-4,640,671.00","-3,534,874.00","-4,112,617.00","-3,487,960.00","-7,039,109.00","-11,509,000.00"
BLT,Benitec Biopharma Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
BLT,Benitec Biopharma Limited,Annual Ratio Analysis - Net Profit Margin,-162.96%,-641.57%,-336.60%,"-1,198.72%","-8,548.83%","-1,577.40%",-13.40%,-498.86%,--,--,--,--,--,--,"-2,542.81%","-3,748.86%"
BLT,Benitec Biopharma Limited,Annual Ratio Analysis - ROE,-241.12%,-154.89%,-7.43%,-116.87%,-32.31%,-58.53%,-789.36%,-55.12%,-204.32%,-215.07%,378.34%,-55.22%,-154.44%,-309.94%,-20.99%,-48.20%
BLT,Benitec Biopharma Limited,Annual Ratio Analysis - Market Cap.($),"6,974,060.80","3,238,446.31","2,644,029.25","44,419,660.32","69,377,138.55","19,012,745.75","6,900,985.48","32,964,575.32","21,896,615.92","8,812,505.75","13,280,135.84","25,937,461.48","16,500,684.99","16,126,796.60","132,133,840.80","79,958,416.47"
BNO,Bionomics Limited,Annual Balance Sheet - Total Equity,"5,062,021.00","10,186,951.00","9,988,858.00","6,715,090.00","8,930,891.00","10,679,038.00","10,946,278.00","22,698,596.00","21,527,425.00","18,694,568.00","25,465,888.00","28,699,180.00","25,899,117.00","41,406,983.00","44,818,607.00","31,965,825.00"
BNO,Bionomics Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,"188,807.00","1,655,728.00","1,274,737.00","1,659,432.00","2,853,548.00","4,212,762.00","3,088,528.00","6,513,363.00","4,320,966.00","3,395,701.00","3,658,907.00","8,901,599.00","11,181,330.00","26,982,422.00","15,667,949.00"
BNO,Bionomics Limited,Annual Profit and Loss - EBITDA,"-1,492,043.00","-3,435,873.00","-4,196,762.00","-3,889,995.00","-3,048,594.00","-4,114,099.00","-4,614,480.00","-6,958,211.00","-4,315,899.00","-5,869,329.00","-7,499,197.00","-9,335,988.00","-3,603,676.00","-9,283,788.00","5,493,809.00","-16,188,255.00"
BNO,Bionomics Limited,Annual Profit and Loss - EBIT,"-1,563,686.00","-3,689,437.00","-4,630,394.00","-4,571,563.00","-3,566,367.00","-4,634,489.00","-5,584,303.00","-7,929,770.00","-5,398,285.00","-6,902,957.00","-8,453,618.00","-10,278,494.00","-4,300,393.00","-10,529,603.00","3,992,873.00","-17,901,747.00"
BNO,Bionomics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,418,874.00","-3,279,252.00","-3,489,730.00","-4,540,955.00","-3,574,582.00","-4,632,314.00","-5,396,950.00","-5,449,798.00","-4,783,917.00","-6,862,299.00","-8,214,082.00","-9,356,497.00","-3,136,238.00","-10,001,350.00","3,206,616.00","-16,949,405.00"
BNO,Bionomics Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
BNO,Bionomics Limited,Annual Ratio Analysis - Net Profit Margin,--,--,-266.80%,-441.62%,--,"-1,567.34%",-827.28%,-666.81%,-424.86%,-190.07%,-274.41%,-293.94%,-278.50%,-610.88%,16.75%,-263.83%
BNO,Bionomics Limited,Annual Ratio Analysis - ROE,-28.03%,-32.19%,-43.05%,-67.62%,-40.02%,-43.38%,-49.30%,-24.01%,-22.22%,-36.71%,-32.26%,-32.60%,-12.11%,-24.15%,7.15%,-54.71%
BNO,Bionomics Limited,Annual Ratio Analysis - Market Cap.($),"23,602,545.40","31,772,195.85","27,922,984.37","10,890,844.00","14,241,206.48","12,419,119.46","27,110,725.60","81,536,617.69","79,879,788.70","53,297,914.11","85,955,655.33","191,326,137.34","103,615,385.70","141,399,014.70","229,546,111.85","173,552,530.64"
BOT,Botanix Pharmaceuticals Ltd,Annual Balance Sheet - Total Equity,"5,150,000.00","5,694,532.00","4,047,275.00","2,648,704.00","2,244,515.00","3,456,604.00","2,223,949.00","2,896,755.00","1,286,083.00","877,740.00","-1,796,608.00","-2,231,289.00","-2,333,643.00","-2,501,176.00","2,243,523.00","1,228,982.00"
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - Total Revenue Excluding Int,"13,253,000.00","195,061.00","379,050.00","945,827.00","2,135,732.00","217,825.00","33,039.00",--,--,--,--,--,--,--,"1,053,712.00",--
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - EBITDA,"-1,061,000.00","-676,903.00","-1,211,471.00","-962,148.00","-387,175.00","-3,023,871.00","-3,129,094.00","-3,709,635.00","-3,165,748.00","-3,152,840.00","-3,941,568.00","-1,515,906.00","-1,488,441.00","-1,825,088.00","-1,246,842.00","-569,512.00"
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - EBIT,"-1,935,000.00","-676,903.00","-1,447,394.00","-1,478,467.00","-648,819.00","-3,025,285.00","-3,134,028.00","-3,716,873.00","-3,172,485.00","-3,158,152.00","-3,945,765.00","-1,519,886.00","-1,490,566.00","-1,825,088.00","-1,246,842.00","-569,512.00"
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - Reported NPAT After Abnorma,"-3,172,000.00","-353,018.00","-1,409,920.00","-1,398,571.00","-958,586.00","-29,766,350.00","-2,782,476.00","-3,416,963.00","-2,825,253.00","-3,043,463.00","-3,945,207.00","-1,519,744.00","-1,568,030.00","-1,849,884.00","-1,131,036.00","-1,014,541.00"
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
BOT,Botanix Pharmaceuticals Ltd,Annual Ratio Analysis - Net Profit Margin,-16.95%,--,-340.14%,-151.14%,-130.18%,--,--,--,--,--,--,--,--,--,--,--
BOT,Botanix Pharmaceuticals Ltd,Annual Ratio Analysis - ROE,-30.10%,-6.20%,-31.04%,-52.80%,-26.53%,-84.27%,-125.11%,-117.96%,-219.68%,-346.74%,219.59%,68.11%,67.19%,73.96%,-50.41%,-42.92%
BOT,Botanix Pharmaceuticals Ltd,Annual Ratio Analysis - Market Cap.($),"7,507,617.58","4,327,197.13","1,856,293.30","1,670,663.97","3,374,965.58","16,594,492.94","14,786,776.36","22,899,307.20","19,315,590.48","18,151,014.20","8,701,889.76","1,595,990.79","1,450,213.44","1,024,663.82","4,640,338.24","2,320,169.12"
BPH,BPH Energy Ltd,Annual Balance Sheet - Total Equity, , , , , ,"2,932,527.00","4,413,773.00","3,802,187.00","3,338,480.00","716,488.00","15,697,202.00","50,893,918.00","48,789,149.00","48,197,297.00","46,947,298.00","20,739,418.00"
BPH,BPH Energy Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,--,"10,000.00","436,183.00","1,063,617.00","134,335.00","164,645.00","252,625.00","114,100.00","114,100.00","114,100.00",--
BPH,BPH Energy Ltd,Annual Profit and Loss - EBITDA, , , , , ,"-835,968.00","-1,084,785.00","-1,420,357.00","-1,074,220.00","-1,594,599.00","-1,343,371.00","-2,443,933.00","-1,228,460.00","-1,213,668.00","-994,935.00","-2,338,325.00"
BPH,BPH Energy Ltd,Annual Profit and Loss - EBIT, , , , , ,"-838,212.00","-1,089,585.00","-1,436,130.00","-1,273,328.00","-1,640,938.00","-1,370,603.00","-2,445,606.00","-1,229,249.00","-1,214,468.00","-995,237.00","-2,338,400.00"
BPH,BPH Energy Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-727,639.00","-986,613.00","-1,339,391.00","-1,178,893.00","-2,240,611.00","-234,457.00","-267,884.00","-764,478.00","-594,908.00","-1,266,079.00","-26,490,513.00"
BPH,BPH Energy Ltd,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
BPH,BPH Energy Ltd,Annual Ratio Analysis - Net Profit Margin, , , , , ,--,"-9,866.13%",-290.25%,--,"-1,171.62%",-710.82%,-159.47%,--,--,--,--
BPH,BPH Energy Ltd,Annual Ratio Analysis - ROE, , , , , ,-24.81%,-22.35%,-33.85%,-35.23%,-225.56%,-7.45%,-0.43%,-1.51%,-1.18%,-1.10%,7.06%
BPH,BPH Energy Ltd,Annual Ratio Analysis - Market Cap.($), , , , , ,"3,807,800.64","7,663,007.50","13,488,543.20","3,229,696.25","1,649,560.35","14,072,888.73","6,483,186.21","2,933,558.16","1,725,622.45","1,380,497.96","1,650,367.09"
BRC,Brain Resource Limited,Annual Balance Sheet - Total Equity,"6,344,256.00","1,268,141.00","5,904,679.00","6,828,647.00","9,142,027.00","8,019,054.00","9,855,965.00","8,761,738.00","7,343,958.00","11,598,690.00","13,867,300.00","15,840,227.00","17,939,531.00","17,511,850.00","17,227,845.00","22,421,206.00"
BRC,Brain Resource Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,--,"323,972.00","295,136.00","654,376.00","1,357,265.00","1,566,519.00","2,536,393.00","3,338,553.00","6,518,696.00","7,874,925.00","5,459,443.00","5,868,650.00","3,965,949.00","2,537,603.00","3,429,109.00"
BRC,Brain Resource Limited,Annual Profit and Loss - EBITDA,0.00,"-30,308.00","-1,118,097.00","-1,468,561.00","-1,856,751.00","-1,850,816.00","-1,950,803.00","-2,189,576.00","-2,755,065.00","3,432,913.00","2,514,582.00","178,941.00","-1,260,098.00","-279,980.00","-1,116,342.00","-1,615,689.00"
BRC,Brain Resource Limited,Annual Profit and Loss - EBIT,0.00,"-30,308.00","-1,502,854.00","-1,809,711.00","-2,095,686.00","-2,102,262.00","-2,044,637.00","-2,290,660.00","-2,863,382.00","3,292,687.00","2,365,251.00","18,390.00","-1,523,861.00","-543,689.00","-1,394,688.00","-1,948,802.00"
BRC,Brain Resource Limited,Annual Profit and Loss - Reported NPAT After Abnorma,0.00,"-30,155.00","-1,351,996.00","-1,326,032.00","-1,498,646.00","-1,122,980.00","-1,438,283.00","-1,454,578.00","-1,505,014.00","4,195,463.00","2,213,505.00","269,487.00","388,425.00","-1,459,681.00","-1,997,880.00","-2,595,316.00"
BRC,Brain Resource Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
BRC,Brain Resource Limited,Annual Ratio Analysis - Net Profit Margin,--,--,--,-538.63%,-296.49%,-81.61%,-109.25%,-60.95%,-46.32%,66.40%,29.06%,4.87%,-41.33%,-45.25%,-78.92%,-98.38%
BRC,Brain Resource Limited,Annual Ratio Analysis - ROE,0.00%,-4.76%,-22.90%,-19.42%,-16.39%,-14.00%,-14.59%,-16.60%,-20.49%,36.17%,15.96%,1.70%,-8.57%,-8.34%,-11.60%,-11.58%
BRC,Brain Resource Limited,Annual Ratio Analysis - Market Cap.($),0.00,0.00,"14,760,000.00","26,596,415.08","26,812,781.14","24,446,947.51","19,898,879.88","32,059,808.90","30,265,769.82","24,762,902.58","19,718,607.61","29,348,625.28","22,011,468.96","25,662,902.49","25,937,185.77","32,147,628.96"
BXN,Bioxyne Limited,Annual Balance Sheet - Total Equity,"12,431,420.00","9,024,579.00","4,257,592.00","967,783.00","1,175,273.00","186,976.00","410,583.00","218,646.00","-623,122.00","43,145.00","123,289.00","124,343.00","5,887,883.00","-210,729.00","1,071,915.00","1,283,666.00"
BXN,Bioxyne Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,--,"261,472.00","1,640,371.00","1,812,547.00","1,457,640.00","1,768,209.00","837,092.00","932,089.00","1,147,695.00","853,146.00","984,982.00","1,661,270.00","1,278,233.00","3,321,337.00","1,645,238.00"
BXN,Bioxyne Limited,Annual Profit and Loss - EBITDA,"-1,434,594.00","-3,426,770.00","-5,051,125.00","-5,162,000.00","-4,069,821.00","-3,955,485.00","-2,138,322.00","-2,031,526.00","-1,278,397.00","-171,477.00","97,807.00","7,736.00","-4,231,120.00","-1,952,079.00","267,174.00","395,454.00"
BXN,Bioxyne Limited,Annual Profit and Loss - EBIT,"-1,435,682.00","-3,438,416.00","-5,121,569.00","-5,217,626.00","-4,106,646.00","-3,990,424.00","-2,176,090.00","-2,048,541.00","-1,292,805.00","-175,683.00","95,310.00","6,174.00","-4,232,002.00","-1,954,239.00","266,843.00","194,415.00"
BXN,Bioxyne Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,426,259.00","-3,109,026.00","-4,803,987.00","-5,103,987.00","-4,337,044.00","-3,933,058.00","-1,877,981.00","-1,763,157.00","-1,331,146.00","-210,906.00","80,144.00","1,054.00","-1,784,131.00","-6,191,113.00","1,190,827.00","201,039.00"
BXN,Bioxyne Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
BXN,Bioxyne Limited,Annual Ratio Analysis - Net Profit Margin,--,--,"-1,837.29%",-362.38%,-368.38%,-283.20%,-111.48%,-224.32%,-197.33%,-19.12%,10.66%,0.11%,-221.46%,-703.14%,11.33%,13.47%
BXN,Bioxyne Limited,Annual Ratio Analysis - ROE,-11.47%,-34.45%,-112.83%,-527.39%,-341.97%,"-2,103.51%",-457.39%,-806.40%,213.63%,-488.83%,65.00%,0.85%,-4.64%,"2,937.95%",24.37%,15.66%
BXN,Bioxyne Limited,Annual Ratio Analysis - Market Cap.($),0.00,"30,391,053.16","40,961,433.10","18,554,891.10","8,817,178.34","10,173,993.93","5,808,561.02","7,058,403.08","2,629,056.00","2,059,645.54","3,236,585.85","2,648,115.69","6,624,228.04","652,238.35","3,806,518.92","2,604,460.31"
CAJ,Capitol Health Limited,Annual Balance Sheet - Total Equity, , , , , , ,"1,631,749.00","669,120.00","18,681,976.00","17,663,858.00","19,255,855.00","20,211,755.00","24,464,973.00","34,105,286.00","38,664,771.00","93,883,665.00"
CAJ,Capitol Health Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , ,"154,551.00","1,512,114.00","13,413,336.00","29,499,180.00","35,405,104.00","45,578,545.00","52,256,294.00","62,393,546.00","90,196,463.00","110,642,466.00"
CAJ,Capitol Health Limited,Annual Profit and Loss - EBITDA, , , , , , ,"-389,477.00","-931,623.00","953,183.00","155,708.00","2,598,294.00","3,874,661.00","5,616,049.00","7,861,384.00","14,416,254.00","21,642,041.00"
CAJ,Capitol Health Limited,Annual Profit and Loss - EBIT, , , , , , ,"-389,477.00","-931,623.00","290,185.00","-1,170,362.00","1,083,691.00","2,010,386.00","3,487,195.00","5,678,113.00","10,881,614.00","16,712,971.00"
CAJ,Capitol Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,"-391,153.00","-966,327.00","214,521.00","-1,018,218.00","705,232.00","962,009.00","2,134,225.00","3,627,361.00","7,232,870.00","3,863,653.00"
CAJ,Capitol Health Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , ,--,--,--,--,--,--,--,--,--,--
CAJ,Capitol Health Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , ,-253.09%,-63.91%,1.10%,-4.67%,1.99%,2.11%,4.14%,5.89%,8.16%,10.73%
CAJ,Capitol Health Limited,Annual Ratio Analysis - ROE, , , , , , ,-95.89%,-144.42%,0.79%,-7.48%,3.66%,4.76%,8.72%,10.64%,18.73%,12.60%
CAJ,Capitol Health Limited,Annual Ratio Analysis - Market Cap.($), , , , , , ,"14,866,500.26","5,329,500.10","19,489,136.87","16,983,390.70","7,593,170.22","12,452,799.17","16,904,603.98","101,151,548.44","191,875,151.18","399,733,134.34"
CDY,Cellmid Limited,Annual Balance Sheet - Total Equity, , , , , , ,"5,513,521.00","1,532,962.00","615,630.00","738,649.00","2,848,939.00","2,037,968.00","2,089,484.00","5,305,157.00","5,663,726.00","3,773,909.00"
CDY,Cellmid Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , ,"37,899.00","57,279.00","668,547.00","160,287.00","269,739.00","101,234.00","165,903.00","730,455.00","2,743,894.00","2,940,266.00"
CDY,Cellmid Limited,Annual Profit and Loss - EBITDA, , , , , , ,"-2,667,679.00","-4,198,241.00","-1,436,058.00","-1,859,453.00","-1,576,518.00","-2,755,917.00","-2,663,240.00","-2,340,248.00","-2,165,345.00","-3,202,134.00"
CDY,Cellmid Limited,Annual Profit and Loss - EBIT, , , , , , ,"-2,834,160.00","-4,562,490.00","-2,563,121.00","-3,426,346.00","-1,590,239.00","-2,766,173.00","-2,674,659.00","-2,356,882.00","-2,277,485.00","-3,333,472.00"
CDY,Cellmid Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,"-2,760,092.00","-4,554,782.00","-2,688,804.00","-3,334,546.00","-1,339,948.00","-2,269,637.00","-1,972,483.00","-1,541,307.00","-1,480,836.00","-3,337,348.00"
CDY,Cellmid Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , ,--,--,--,--,--,--,--,--,--,--
CDY,Cellmid Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , ,--,--,--,--,--,"-7,224.00%","-1,395.45%",-281.90%,-67.09%,-181.10%
CDY,Cellmid Limited,Annual Ratio Analysis - ROE, , , , , , ,-50.06%,-297.12%,-436.76%,-451.44%,-47.03%,-111.37%,-93.63%,-28.65%,-26.02%,-88.43%
CDY,Cellmid Limited,Annual Ratio Analysis - Market Cap.($), , , , , , ,"15,854,687.66","6,967,185.00","4,074,709.32","3,376,282.79","6,189,844.59","9,030,584.97","8,333,489.87","15,611,281.90","19,125,228.25","23,855,015.25"
CGS,Cogstate Limited,Annual Balance Sheet - Total Equity, , , ,"6,299,513.00","6,054,606.00","3,830,458.00","3,096,056.00","1,583,702.00","1,925,329.00","4,936,178.00","7,020,957.00","6,303,131.00","10,222,314.00","8,809,317.00","13,015,259.00","10,114,938.00"
CGS,Cogstate Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , ,"608,582.00","247,603.00","1,304,981.00","2,288,713.00","2,499,856.00","3,873,020.00","8,996,596.00","9,655,183.00","8,189,276.00","13,521,804.00","13,006,750.00","12,663,686.00","17,350,092.00"
CGS,Cogstate Limited,Annual Profit and Loss - EBITDA, , , ,"-1,219,881.00","-2,097,613.00","-2,728,499.00","-1,937,120.00","-1,816,856.00","-859,175.00","1,465,415.00","769,133.00","-576,243.00","3,273,788.00","-1,029,129.00","-3,964,690.00","-2,320,203.00"
CGS,Cogstate Limited,Annual Profit and Loss - EBIT, , , ,"-1,305,093.00","-2,189,080.00","-2,842,551.00","-2,012,917.00","-1,907,568.00","-985,882.00","1,208,021.00","336,256.00","-999,497.00","2,687,865.00","-1,740,637.00","-4,649,353.00","-3,056,840.00"
CGS,Cogstate Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-1,311,795.00","-1,833,827.00","-2,224,148.00","-1,602,918.00","-1,653,257.00","-746,496.00","1,429,634.00","1,637,615.00","-846,206.00","2,451,962.00","-1,957,233.00","-3,888,395.00","-5,062,222.00"
CGS,Cogstate Limited,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
CGS,Cogstate Limited,Annual Ratio Analysis - Net Profit Margin, , , ,-433.83%,"-1,203.68%",-253.51%,-77.21%,-66.13%,-19.73%,17.05%,17.27%,-10.40%,20.41%,-15.70%,-31.70%,-18.03%
CGS,Cogstate Limited,Annual Ratio Analysis - ROE, , , ,-20.82%,-38.19%,-67.89%,-51.77%,-104.39%,-38.77%,28.96%,23.32%,-13.43%,23.99%,-22.22%,-29.88%,-28.65%
CGS,Cogstate Limited,Annual Ratio Analysis - Market Cap.($), , , ,0.00,"8,911,917.25","3,743,005.24","7,117,497.92","8,229,606.97","6,745,929.32","15,754,340.64","16,588,229.25","11,314,687.79","22,434,991.80","27,796,710.60","29,686,442.40","22,571,012.73"
CLV,Clover Corporation Limited,Annual Balance Sheet - Total Equity,"26,862,000.00","22,126,000.00","16,554,000.00","17,358,000.00","19,013,000.00","22,225,000.00","22,761,000.00","23,668,000.00","26,957,000.00","28,274,000.00","25,627,000.00","28,070,000.00","29,900,000.00","32,409,000.00","30,134,000.00","29,388,000.00"
CLV,Clover Corporation Limited,Annual Profit and Loss - Total Revenue Excluding Int,"13,437,000.00","9,035,000.00","9,827,000.00","11,480,000.00","17,470,000.00","14,822,000.00","18,037,000.00","16,851,000.00","22,071,000.00","22,271,000.00","35,422,000.00","35,451,000.00","38,387,000.00","44,703,000.00","27,190,000.00","29,924,000.00"
CLV,Clover Corporation Limited,Annual Profit and Loss - EBITDA,"-3,585,000.00","-4,978,000.00","-3,071,000.00","725,000.00","1,812,000.00","870,000.00","481,000.00","781,000.00","2,488,000.00","4,151,000.00","1,391,000.00","5,934,000.00","7,793,000.00","8,798,000.00","1,612,000.00","577,000.00"
CLV,Clover Corporation Limited,Annual Profit and Loss - EBIT,"-5,298,000.00","-5,920,000.00","-3,869,000.00","150,000.00","1,188,000.00","231,000.00","260,000.00","483,000.00","2,186,000.00","3,848,000.00","1,138,000.00","5,544,000.00","7,284,000.00","8,300,000.00","1,114,000.00","-72,000.00"
CLV,Clover Corporation Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-299,000.00","-4,845,000.00","-5,572,000.00","604,000.00","1,503,000.00","938,000.00","678,000.00","907,000.00","4,375,000.00","3,082,000.00","-967,000.00","4,603,000.00","4,371,000.00","6,078,000.00","967,000.00","100,000.00"
CLV,Clover Corporation Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
CLV,Clover Corporation Limited,Annual Ratio Analysis - Net Profit Margin,-57.55%,-54.81%,-33.87%,3.10%,7.18%,5.32%,2.60%,3.84%,19.13%,14.59%,-2.77%,12.92%,14.56%,13.78%,3.56%,0.33%
CLV,Clover Corporation Limited,Annual Ratio Analysis - ROE,-17.28%,-21.90%,-19.80%,2.06%,6.60%,3.51%,2.05%,2.79%,15.34%,10.90%,-3.77%,16.40%,18.70%,18.75%,3.21%,0.34%
CLV,Clover Corporation Limited,Annual Ratio Analysis - Market Cap.($),"63,785,416.52","33,850,627.42","26,328,265.78","71,023,266.51","45,629,355.00","28,080,888.32","23,125,437.44","17,344,078.08","26,429,071.36","35,514,064.64","46,250,874.88","47,076,783.36","66,072,678.40","90,849,932.80","69,376,312.32","28,080,888.32"
CMP,Compumedics Limited,Annual Balance Sheet - Total Equity,"30,067,000.00","32,163,292.00","30,226,035.00","11,675,217.00","13,945,095.00","9,347,435.00","6,717,000.00","6,914,000.00","8,507,000.00","11,479,000.00","12,196,000.00","12,755,000.00","9,215,000.00","8,353,000.00","9,162,000.00","11,268,000.00"
CMP,Compumedics Limited,Annual Profit and Loss - Total Revenue Excluding Int,"10,399,000.00","16,978,110.00","19,848,924.00","32,203,791.00","34,144,136.00","38,289,262.00","39,034,000.00","36,787,000.00","38,955,000.00","38,970,000.00","32,607,000.00","31,262,000.00","28,501,000.00","27,931,000.00","31,742,000.00","34,262,000.00"
CMP,Compumedics Limited,Annual Profit and Loss - EBITDA,"260,000.00","3,857,195.00","-791,293.00","17,199,190.00","2,941,159.00","-2,561,113.00","-126,000.00","1,365,000.00","1,943,000.00","3,688,000.00","1,334,000.00","599,000.00","-156,000.00","342,000.00","2,969,000.00","5,157,000.00"
CMP,Compumedics Limited,Annual Profit and Loss - EBIT,"-118,000.00","2,674,557.00","-2,755,730.00","-1,211,660.00","2,481,127.00","-3,557,487.00","-1,071,000.00","910,000.00","1,391,000.00","3,285,000.00","982,000.00","-356,000.00","-1,272,000.00","-868,000.00","1,583,000.00","2,686,000.00"
CMP,Compumedics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-95,000.00","1,971,000.00","-1,897,773.00","-18,556,660.00","2,396,683.00","-3,897,660.00","-1,595,000.00","123,000.00","756,000.00","2,727,000.00","414,000.00","81,000.00","-2,829,000.00","-1,489,000.00","909,000.00","1,970,000.00"
CMP,Compumedics Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
CMP,Compumedics Limited,Annual Ratio Analysis - Net Profit Margin,-1.06%,11.85%,-9.61%,-2.36%,7.06%,-10.21%,-4.12%,0.33%,1.96%,7.00%,1.28%,0.26%,-10.13%,-5.48%,3.13%,5.88%
CMP,Compumedics Limited,Annual Ratio Analysis - ROE,-0.32%,6.13%,-6.28%,-6.48%,17.19%,-41.70%,-23.75%,1.78%,8.89%,23.76%,3.39%,0.64%,-30.70%,-17.83%,9.92%,17.48%
CMP,Compumedics Limited,Annual Ratio Analysis - Market Cap.($),0.00,"106,400,000.00","44,100,000.00","49,700,000.00","37,800,000.00","31,500,000.00","8,820,000.00","21,376,417.05","23,711,120.10","22,382,614.94","21,057,817.17","13,282,623.14","10,366,912.58","9,178,684.35","24,198,349.65","45,058,995.90"
COH,Cochlear Limited,Annual Balance Sheet - Total Equity,"42,829,000.00","55,495,000.00","75,416,000.00","119,687,000.00","145,529,000.00","165,870,000.00","209,778,000.00","260,809,000.00","319,341,000.00","364,234,000.00","438,308,000.00","503,283,000.00","384,880,000.00","356,913,000.00","329,205,000.00","355,386,000.00"
COH,Cochlear Limited,Annual Profit and Loss - Total Revenue Excluding Int,"144,963,000.00","221,074,000.00","255,511,000.00","289,388,000.00","283,234,000.00","345,817,000.00","456,190,000.00","560,545,000.00","608,938,000.00","706,475,000.00","745,025,000.00","820,055,000.00","780,741,000.00","755,100,000.00","807,468,000.00","930,058,000.00"
COH,Cochlear Limited,Annual Profit and Loss - EBITDA,"37,411,000.00","49,026,000.00","61,466,000.00","87,896,000.00","67,432,000.00","92,323,000.00","127,618,000.00","170,686,000.00","188,661,000.00","183,524,000.00","220,526,000.00","236,568,000.00","231,116,000.00","194,261,000.00","153,946,000.00","236,660,000.00"
COH,Cochlear Limited,Annual Profit and Loss - EBIT,"34,768,000.00","45,513,000.00","56,719,000.00","80,149,000.00","57,980,000.00","78,892,000.00","111,543,000.00","153,581,000.00","167,329,000.00","183,340,000.00","220,510,000.00","236,568,000.00","215,290,000.00","178,860,000.00","127,091,000.00","206,408,000.00"
COH,Cochlear Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"20,167,000.00","31,178,000.00","40,110,000.00","58,213,000.00","36,134,000.00","53,352,000.00","78,225,000.00","97,676,000.00","115,234,000.00","130,540,000.00","155,152,000.00","180,114,000.00","56,803,000.00","132,563,000.00","93,709,000.00","145,840,000.00"
COH,Cochlear Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
COH,Cochlear Limited,Annual Ratio Analysis - Net Profit Margin,17.03%,14.16%,17.11%,20.17%,19.52%,18.34%,18.54%,18.44%,19.85%,18.34%,22.29%,23.81%,22.45%,18.54%,11.64%,15.76%
COH,Cochlear Limited,Annual Ratio Analysis - ROE,57.33%,56.18%,57.96%,48.64%,35.45%,36.19%,38.56%,38.39%,36.08%,35.84%,35.40%,34.94%,41.09%,37.14%,28.47%,41.04%
COH,Cochlear Limited,Annual Ratio Analysis - Market Cap.($),"1,470,935,752.50","2,028,677,001.00","1,787,629,937.25","1,714,178,765.00","1,230,553,596.80","2,128,147,498.40","2,984,819,036.85","3,340,947,552.00","2,423,655,162.90","3,234,185,571.10","4,202,305,562.32","4,085,641,656.00","3,748,233,802.88","3,519,995,913.72","3,520,726,634.00","4,575,104,266.25"
CSL,CSL Limited,Annual Balance Sheet - Total Equity,"793,580,000.00","875,958,000.00","1,273,131,000.00","1,282,698,000.00","2,074,042,000.00","2,074,512,000.00","1,989,804,000.00","2,268,849,000.00","2,806,125,000.00","5,462,895,000.00","4,215,194,000.00","3,644,360,000.00","3,428,300,000.00","3,241,832,884.00","3,356,687,898.00","3,576,692,708.00"
CSL,CSL Limited,Annual Profit and Loss - Total Revenue Excluding Int,"501,714,000.00","848,281,000.00","1,346,353,000.00","1,311,518,000.00","1,829,557,000.00","3,236,780,000.00","2,880,147,000.00","3,280,269,000.00","3,768,197,000.00","4,975,961,000.00","4,586,459,000.00","4,293,214,000.00","4,582,600,000.00","5,498,760,107.00","5,843,099,787.00","7,307,812,500.00"
CSL,CSL Limited,Annual Profit and Loss - EBITDA,"110,840,000.00","208,282,000.00","299,217,000.00","255,065,000.00","228,480,000.00","557,379,000.00","631,095,000.00","900,634,000.00","1,108,444,000.00","1,503,845,000.00","1,513,742,000.00","1,350,338,000.00","1,386,300,000.00","1,819,191,374.00","1,944,904,458.00","2,496,484,375.00"
CSL,CSL Limited,Annual Profit and Loss - EBIT,"77,156,000.00","128,685,000.00","186,081,000.00","135,269,000.00","98,485,000.00","386,678,000.00","515,031,000.00","768,065,000.00","966,645,000.00","1,338,112,000.00","1,357,127,000.00","1,184,246,000.00","1,214,800,000.00","1,601,832,884.00","1,738,004,246.00","2,260,416,666.00"
CSL,CSL Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"54,402,000.00","78,241,000.00","123,808,000.00","70,423,000.00","219,625,000.00","546,518,000.00","117,357,000.00","539,299,000.00","701,802,000.00","1,145,932,000.00","1,052,901,000.00","940,601,000.00","982,600,000.00","1,311,374,663.00","1,387,473,460.00","1,795,572,916.00"
CSL,CSL Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
CSL,CSL Limited,Annual Ratio Analysis - Net Profit Margin,12.07%,9.28%,9.26%,5.40%,4.63%,10.77%,12.32%,16.43%,19.73%,21.98%,23.53%,22.41%,22.11%,24.48%,24.50%,24.86%
CSL,CSL Limited,Annual Ratio Analysis - ROE,6.86%,8.93%,9.72%,5.49%,3.69%,14.31%,17.63%,22.98%,25.01%,18.67%,24.98%,25.81%,28.66%,40.45%,41.33%,49.40%
CSL,CSL Limited,Annual Ratio Analysis - Market Cap.($),"4,924,725,660.00","7,139,128,015.80","5,099,580,400.38","1,911,266,987.00","4,380,798,807.10","6,348,544,316.40","9,776,534,771.25","16,107,697,936.00","19,649,301,634.20","19,265,547,610.20","17,908,994,225.88","17,351,227,987.92","19,983,174,568.74","30,011,147,367.56","31,597,159,301.95","40,194,094,550.69"
CTE,Cryosite Limited,Annual Balance Sheet - Total Equity, ,"3,868,363.00","3,889,894.00","2,769,834.00","3,038,890.00","2,477,872.00","2,813,290.00","3,735,965.00","4,321,088.00","4,340,310.00","4,354,687.00","4,691,383.00","5,480,664.00","6,264,228.00","6,135,137.00","3,544,435.00"
CTE,Cryosite Limited,Annual Profit and Loss - Total Revenue Excluding Int, ,"2,427.00","460,919.00","1,914,860.00","2,094,094.00","2,955,056.00","4,143,556.00","4,722,572.00","6,467,582.00","6,158,392.00","5,968,601.00","6,432,973.00","7,757,568.00","8,497,803.00","9,171,014.00","9,633,398.00"
CTE,Cryosite Limited,Annual Profit and Loss - EBITDA, ,"-1,008,624.00","-1,215,643.00","-1,019,685.00","-731,864.00","-406,202.00","322,840.00","393,434.00","682,054.00","-168,120.00","141,549.00","591,803.00","1,331,803.00","1,504,994.00","1,032,316.00","1,056,275.00"
CTE,Cryosite Limited,Annual Profit and Loss - EBIT, ,"-1,061,437.00","-1,439,533.00","-1,274,838.00","-1,015,378.00","-716,149.00","1,104.00","203,816.00","237,612.00","-357,709.00","-144,672.00","89,883.00","769,166.00","922,167.00","434,732.00","398,533.00"
CTE,Cryosite Limited,Annual Profit and Loss - Reported NPAT After Abnorma, ,"-984,991.00","-1,224,325.00","-1,170,000.00","-950,038.00","-620,311.00","101,374.00","922,744.00","447,059.00","7,249.00","4,612.00","334,305.00","1,022,479.00","1,249,961.00","505,602.00","455,170.00"
CTE,Cryosite Limited,Annual Profit and Loss - Total Operating Income (ban, ,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
CTE,Cryosite Limited,Annual Ratio Analysis - Net Profit Margin, ,"-40,584.71%",-305.73%,-61.49%,-45.39%,-20.99%,2.47%,19.54%,6.91%,0.12%,0.08%,5.20%,13.18%,14.71%,5.51%,4.74%
CTE,Cryosite Limited,Annual Ratio Analysis - ROE, ,-25.46%,-36.23%,-42.24%,-31.26%,-25.03%,3.60%,24.70%,10.35%,0.17%,0.11%,7.13%,18.66%,19.95%,8.24%,12.84%
CTE,Cryosite Limited,Annual Ratio Analysis - Market Cap.($), ,0.00,"21,225,000.00","7,075,000.00","9,451,145.76","9,001,091.20","5,596,747.56","7,462,330.08","6,995,934.45","4,663,956.30","5,596,747.56","3,964,362.86","9,794,308.23","20,055,012.09","16,869,442.68","16,400,847.05"
CUV,Clinuvel Pharmaceuticals Limited,Annual Balance Sheet - Total Equity,"15,317,497.00","13,450,758.00","10,309,534.00","7,530,715.00","8,854,501.00","7,454,262.00","13,988,832.00","65,391,816.00","51,814,516.00","37,051,184.00","26,426,163.00","16,408,101.00","13,637,336.00","13,839,290.00","15,427,732.00","11,205,291.00"
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,--,--,--,--,"124,622.00","754,846.00","315,025.00",--,"236,997.00","372,056.00","1,091,916.00","722,801.00","2,490,024.00","2,663,110.00","3,317,679.00"
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - EBITDA,"-394,150.00","-1,183,074.00","-2,612,708.00","-3,234,953.00","-7,154,674.00","-10,682,121.00","-10,301,264.00","-10,509,812.00","-18,111,131.00","-17,210,268.00","-12,278,556.00","-13,517,274.00","-10,440,457.00","-7,371,860.00","-5,814,886.00","-10,736,246.00"
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - EBIT,"-514,150.00","-1,966,279.00","-3,398,731.00","-4,029,210.00","-7,944,965.00","-11,505,968.00","-11,215,937.00","-11,414,999.00","-18,952,894.00","-18,040,827.00","-12,994,704.00","-13,609,174.00","-10,502,956.00","-7,429,832.00","-5,852,358.00","-10,762,785.00"
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-374,150.00","-1,557,582.00","-3,141,224.00","-3,976,770.00","-7,589,730.00","-11,029,031.00","-10,768,981.00","-9,176,123.00","-14,655,791.00","-15,372,907.00","-11,521,040.00","-11,409,089.00","-9,767,228.00","-6,802,823.00","-5,525,889.00","-10,414,376.00"
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
CUV,Clinuvel Pharmaceuticals Limited,Annual Ratio Analysis - Net Profit Margin,--,--,--,--,--,"-8,849.99%","-1,426.65%","-3,238.92%",--,--,--,"-1,193.54%","-1,374.06%",-451.99%,-251.17%,-357.69%
CUV,Clinuvel Pharmaceuticals Limited,Annual Ratio Analysis - ROE,-2.44%,-11.58%,-30.47%,-52.81%,-85.72%,-147.96%,-76.98%,-14.03%,-28.29%,-41.49%,-43.60%,-75.72%,-72.83%,-50.72%,-35.82%,-92.94%
CUV,Clinuvel Pharmaceuticals Limited,Annual Ratio Analysis - Market Cap.($),0.00,"5,789,755.02","9,505,567.94","24,688,754.64","105,293,158.20","43,706,688.90","68,442,342.85","277,976,771.80","93,976,086.15","84,881,626.20","68,217,449.62","50,281,723.43","55,096,479.66","69,172,838.78","72,065,439.50","126,535,595.08"
CYC,Cyclopharm Limited,Annual Balance Sheet - Total Equity, , , , , , ,"11,339,680.00","7,342,144.00","13,055,556.00","13,928,641.00","13,766,154.00","14,604,799.00","15,608,433.00","6,550,493.00","7,756,160.00","13,102,243.00"
CYC,Cyclopharm Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , ,--,"11,128,224.00","10,888,269.00","13,501,669.00","9,464,605.00","10,314,506.00","10,743,824.00","12,044,933.00","14,941,717.00","14,687,208.00"
CYC,Cyclopharm Limited,Annual Profit and Loss - EBITDA, , , , , , ,0.00,"1,827,330.00","2,432,242.00","3,062,047.00","1,288,281.00","-184,426.00",969.00,"-8,888,261.00","1,172,967.00","2,109,036.00"
CYC,Cyclopharm Limited,Annual Profit and Loss - EBIT, , , , , , ,0.00,"1,511,939.00","2,101,058.00","2,611,818.00","937,735.00","-854,034.00","-651,014.00","-9,531,344.00","907,005.00","1,964,860.00"
CYC,Cyclopharm Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,0.00,"1,131,239.00","1,757,062.00","2,044,490.00","450,106.00","-956,220.00","-1,044,127.00","-9,640,117.00","4,065,563.00","4,793,047.00"
CYC,Cyclopharm Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , ,--,--,--,--,--,--,--,--,--,--
CYC,Cyclopharm Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , ,--,10.17%,16.14%,15.59%,4.76%,-9.27%,-9.72%,-81.13%,11.75%,21.37%
CYC,Cyclopharm Limited,Annual Ratio Analysis - ROE, , , , , , ,0.00%,10.27%,13.46%,14.68%,3.27%,-6.55%,-6.69%,-147.17%,18.25%,20.52%
CYC,Cyclopharm Limited,Annual Ratio Analysis - Market Cap.($), , , , , , ,0.00,"32,597,464.76","17,111,261.60","18,822,387.76","13,852,021.90","8,943,176.72","9,881,851.12","14,362,134.00","16,067,840.04","30,986,141.16"
CYP,Cynata Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"3,409,742.00","2,210,670.00","961,980.00","932,005.00","971,930.00","853,753.00","1,642,843.00","9,854,632.00","8,749,959.00"
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,--,"350,565.00","252,091.00","114,161.00","352,630.00","356,712.00","33,964.00","25,058.00","285,584.00"
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - EBITDA, , , , , , , ,0.00,"-2,129,509.00","-1,510,029.00","-2,128,328.00","-2,554,599.00","-1,134,420.00","-951,777.00","-3,122,152.00","-3,353,437.00"
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - EBIT, , , , , , , ,0.00,"-2,135,085.00","-1,514,549.00","-2,131,350.00","-2,564,549.00","-1,547,812.00","-951,777.00","-3,122,360.00","-3,801,382.00"
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,0.00,"-2,034,852.00","-1,450,271.00","-2,116,125.00","-2,564,979.00","-1,542,307.00","-915,701.00","-3,039,663.00","-3,712,077.00"
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
CYP,Cynata Therapeutics Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,--,-580.45%,--,"-1,858.22%","-1,150.54%",-949.39%,"-2,696.09%",--,--
CYP,Cynata Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , ,0.00%,-92.05%,-150.76%,-227.05%,-263.91%,-180.65%,-55.74%,-30.85%,-42.42%
CYP,Cynata Therapeutics Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,0.00,"4,068,494.88","3,051,371.16","7,267,826.63","4,017,971.58","2,026,117.30","5,052,234.61","21,983,661.20","61,116,047.78"
DVL,Dorsavi Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"18,492,815.00","14,620,000.00","6,616,716.00"
DVL,Dorsavi Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , ,--,"540,000.00","1,596,192.00"
DVL,Dorsavi Ltd,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , ,0.00,"-4,306,000.00","-8,850,146.00"
DVL,Dorsavi Ltd,Annual Profit and Loss - EBIT, , , , , , , , , , , , , ,0.00,"-4,348,000.00","-8,937,734.00"
DVL,Dorsavi Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"-3,562,000.00","-8,036,161.00"
DVL,Dorsavi Ltd,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , ,--,--,--
DVL,Dorsavi Ltd,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , ,--,-673.35%,-544.10%
DVL,Dorsavi Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,-24.36%,-121.45%
DVL,Dorsavi Ltd,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , ,0.00,"55,867,000.00","32,886,000.00"
DXB,Dimerix Limited,Annual Balance Sheet - Total Equity,"5,240,203.00","640,427.00","282,886.00","-565,025.00","-170,377.00","10,280,504.00","2,694,481.00","1,414,772.00","1,008,159.00","341,976.00","1,560,180.00","1,565,836.00","1,179,766.00","1,707,138.00","1,179,160.00","2,777,090.00"
DXB,Dimerix Limited,Annual Profit and Loss - Total Revenue Excluding Int,"8,135,897.00","6,661,165.00","4,177,347.00","2,637,935.00","2,794,587.00","1,404,101.00","2,492.00","771,044.00","904,133.00",--,"28,808.00","416,308.00","-126,401.00","-153,667.00","21,573.00","68,339.00"
DXB,Dimerix Limited,Annual Profit and Loss - EBITDA,"-27,662.00","-1,301,897.00","-606,139.00","10,458.00","-468,261.00","-1,142,548.00","-3,081,219.00","-1,907,994.00","-3,052,283.00","-512,429.00","-374,928.00","-58,576.00","-543,844.00","-614,680.00","-568,625.00","-609,944.00"
DXB,Dimerix Limited,Annual Profit and Loss - EBIT,"-291,662.00","-1,486,677.00","-679,520.00","-54,705.00","-530,393.00","-1,154,756.00","-3,087,123.00","-2,389,445.00","-3,598,873.00","-512,429.00","-376,605.00","-58,576.00","-543,844.00","-614,680.00","-568,625.00","-610,962.00"
DXB,Dimerix Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-516,948.00","-4,349,865.00","-739,658.00","-945,668.00","-676,149.00","-595,797.00","-11,161,018.00","-2,421,661.00","-3,557,390.00","-4,128,738.00","-347,767.00","5,656.00","-386,070.00","-517,098.00","-527,978.00","-679,539.00"
DXB,Dimerix Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
DXB,Dimerix Limited,Annual Ratio Analysis - Net Profit Margin,-3.61%,-48.18%,-18.08%,-40.08%,-25.00%,-86.42%,"-535,917.55%",-369.16%,-469.96%,--,--,7.74%,--,--,--,--
DXB,Dimerix Limited,Annual Ratio Analysis - ROE,-5.58%,-401.98%,-261.47%,176.44%,396.85%,-11.51%,-112.18%,-171.17%,-352.86%,-140.10%,-22.29%,0.36%,-32.72%,-30.29%,-44.78%,-20.87%
DXB,Dimerix Limited,Annual Ratio Analysis - Market Cap.($),"2,309,291.68","700,236.83","1,299,497.86","1,112,816.67","3,259,319.60","15,344,186.16","9,841,356.43","2,943,446.05","4,768,444.66","1,550,358.76","2,317,969.63","2,317,969.63","2,317,969.63","1,324,560.03","2,317,980.06","4,736,400.08"
EBO,EBOS Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"979,039,000.00","930,607,402.00"
EBO,EBOS Group Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,"5,757,234,000.00","5,373,121,126.00"
EBO,EBOS Group Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,"175,422,000.00","174,158,845.00"
EBO,EBOS Group Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,"152,839,000.00","152,804,143.00"
EBO,EBOS Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"92,069,000.00","93,802,904.00"
EBO,EBOS Group Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
EBO,EBOS Group Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,1.60%,1.75%
EBO,EBOS Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,9.40%,10.08%
EBO,EBOS Group Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,"1,368,224,000.00","1,393,854,750.00"
EHE,Estia Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"577,100,000.00","563,913,936.00"
EHE,Estia Health Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"284,815,613.00"
EHE,Estia Health Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"60,537,076.00"
EHE,Estia Health Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"53,193,850.00"
EHE,Estia Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-22,523,276.00"
EHE,Estia Health Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
EHE,Estia Health Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,2.90%
EHE,Estia Health Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,1.46%
EHE,Estia Health Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"1,085,313,480.00"
ELX,Ellex Medical Lasers Limited,Annual Balance Sheet - Total Equity,"333,160.00","789,861.00","30,806,000.00","30,590,000.00","30,478,000.00","28,990,000.00","35,144,000.00","43,380,000.00","47,941,000.00","30,051,000.00","33,187,000.00","30,322,000.00","32,058,000.00","30,829,000.00","36,950,000.00","39,794,000.00"
ELX,Ellex Medical Lasers Limited,Annual Profit and Loss - Total Revenue Excluding Int,"12,438.00",160.00,"27,633,000.00","26,110,000.00","26,545,000.00","28,437,000.00","37,625,000.00","48,417,000.00","51,752,000.00","59,457,000.00","49,845,000.00","43,593,000.00","47,840,000.00","43,074,000.00","54,774,000.00","64,258,000.00"
ELX,Ellex Medical Lasers Limited,Annual Profit and Loss - EBITDA,"-354,503.00","-484,362.00","6,109,000.00","3,832,000.00","1,307,000.00","869,000.00","4,987,000.00","4,596,000.00","3,860,000.00","1,620,000.00","6,345,000.00","1,095,000.00","3,148,000.00","1,725,000.00","2,978,000.00","5,363,000.00"
ELX,Ellex Medical Lasers Limited,Annual Profit and Loss - EBIT,"-371,250.00","-496,021.00","4,778,000.00","2,414,000.00","-241,000.00","-812,000.00","4,188,000.00","3,321,000.00","2,455,000.00","-237,000.00","3,951,000.00","-673,000.00","1,465,000.00","416,000.00","1,554,000.00","2,831,000.00"
ELX,Ellex Medical Lasers Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-368,000.00","-462,497.00","3,281,000.00","1,632,000.00","-206,000.00","-1,102,000.00","3,693,000.00","4,368,000.00","4,834,000.00","-22,615,000.00","3,760,000.00","-700,000.00","1,050,000.00","-816,000.00","788,000.00","1,680,000.00"
ELX,Ellex Medical Lasers Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
ELX,Ellex Medical Lasers Limited,Annual Ratio Analysis - Net Profit Margin,"-5,380.90%","-289,060.63%",11.39%,6.26%,-0.84%,-3.89%,10.65%,9.38%,9.27%,-0.42%,7.87%,-1.52%,1.94%,-1.91%,1.45%,2.68%
ELX,Ellex Medical Lasers Limited,Annual Ratio Analysis - ROE,-110.46%,-58.55%,10.11%,5.34%,-0.68%,-3.80%,10.51%,9.86%,9.94%,-0.83%,11.56%,-2.19%,2.87%,-2.65%,2.13%,4.22%
ELX,Ellex Medical Lasers Limited,Annual Ratio Analysis - Market Cap.($),"1,047,717.68","4,190,870.70","69,032,830.00","18,983,470.00","17,758,687.37","15,615,397.52","38,579,217.39","57,795,893.42","19,873,943.31","11,038,344.85","12,736,551.75","15,283,862.10","9,764,689.68","16,982,069.00","40,367,586.38","35,523,476.01"
FFC,Farmaforce Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"7,503,317.00", 
FFC,Farmaforce Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--, 
FFC,Farmaforce Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00, 
FFC,Farmaforce Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00, 
FFC,Farmaforce Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00, 
FFC,Farmaforce Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--, 
FFC,Farmaforce Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--, 
FFC,Farmaforce Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%, 
FFC,Farmaforce Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00, 
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Balance Sheet - Total Equity, ,"125,500,453.00","142,204,848.00","176,717,991.00","166,688,458.00","176,726,486.00","174,352,991.00","171,099,911.00","169,303,452.00","168,927,567.00","227,170,864.00","230,361,029.00","274,351,457.00","298,644,897.00","380,941,750.00","462,177,538.00"
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Profit and Loss - Total Revenue Excluding Int, ,"159,126,990.00","188,557,127.00","191,124,553.00","187,308,228.00","221,922,510.00","277,313,675.00","315,176,834.00","309,676,386.00","381,773,606.00","393,328,942.00","372,995,588.00","411,862,884.00","449,307,605.00","589,095,769.00","664,392,349.00"
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Profit and Loss - EBITDA, ,"70,491,789.00","108,079,755.00","106,918,705.00","76,181,136.00","91,258,972.00","97,099,145.00","90,943,412.00","63,757,030.00","98,968,910.00","93,211,158.00","96,541,176.00","93,713,947.00","112,729,460.00","163,474,345.00","197,872,486.00"
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Profit and Loss - EBIT, ,"65,696,014.00","102,752,544.00","99,176,060.00","68,876,394.00","83,117,062.00","88,944,444.00","79,224,580.00","50,300,250.00","84,662,642.00","79,689,267.00","80,311,029.00","75,942,474.00","91,543,645.00","135,434,762.00","166,829,818.00"
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Profit and Loss - Reported NPAT After Abnorma, ,"8,009,736.00","39,817,986.00","66,816,973.00","47,680,439.00","56,511,135.00","59,799,145.00","50,932,802.00","30,523,492.00","51,457,747.00","55,506,392.00","38,577,941.00","50,520,094.00","61,820,442.00","91,035,550.00","111,008,337.00"
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Profit and Loss - Total Operating Income (ban, ,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Ratio Analysis - Net Profit Margin, ,36.58%,43.11%,34.96%,25.46%,25.46%,24.16%,16.49%,10.20%,12.82%,15.09%,13.64%,13.74%,15.19%,17.07%,17.57%
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Ratio Analysis - ROE, ,46.39%,53.76%,37.81%,28.60%,31.98%,34.30%,29.77%,18.03%,30.46%,24.43%,20.41%,18.41%,20.70%,23.90%,24.02%
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Ratio Analysis - Market Cap.($), ,0.00,"828,914,172.30","870,712,791.50","1,065,517,512.78","1,424,179,083.60","1,792,848,428.80","1,651,333,388.21","1,294,010,155.18","1,324,780,371.20","1,301,254,321.54","1,202,246,829.63","930,243,715.24","1,137,783,183.60","2,196,165,461.91","3,588,725,606.76"
FTT,Factor Therapeutics Limited,Annual Balance Sheet - Total Equity, , , ,"3,497,712.00","3,325,709.00","3,829,662.00","5,227,194.00","6,658,310.00","3,759,058.00","3,688,189.00","7,942,395.00","17,033,436.00","10,466,891.00","13,968,238.00","16,859,743.00","13,325,214.00"
FTT,Factor Therapeutics Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , ,--,"68,927.00","209,185.00","24,016.00","37,144.00","155,640.00","252,948.00","229,484.00","232,024.00","336,637.00","95,153.00",--,"355,122.00"
FTT,Factor Therapeutics Limited,Annual Profit and Loss - EBITDA, , , ,"-8,878.00","-285,735.00","-1,346,793.00","-2,389,308.00","-2,208,104.00","-5,202,911.00","-4,667,121.00","-3,831,057.00","-5,848,557.00","-7,694,433.00","-6,072,420.00","-7,466,708.00","-11,279,857.00"
FTT,Factor Therapeutics Limited,Annual Profit and Loss - EBIT, , , ,"-8,878.00","-285,935.00","-1,347,893.00","-2,391,584.00","-2,215,362.00","-5,211,092.00","-4,679,336.00","-3,839,618.00","-5,862,393.00","-7,731,837.00","-6,223,280.00","-7,550,207.00","-11,360,507.00"
FTT,Factor Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-8,878.00","-181,281.00","-926,847.00","-1,861,242.00","-1,710,280.00","-4,865,418.00","-4,473,196.00","-3,486,399.00","-5,340,548.00","-6,769,382.00","-5,740,094.00","-6,829,591.00","-11,218,514.00"
FTT,Factor Therapeutics Limited,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
FTT,Factor Therapeutics Limited,Annual Ratio Analysis - Net Profit Margin, , , ,--,--,"-15,781.49%","-19,365.75%","-4,604.46%","-6,026.63%","-1,768.43%","-1,519.23%","-2,301.72%","-2,010.88%",--,--,--
FTT,Factor Therapeutics Limited,Annual Ratio Analysis - ROE, , , ,-0.25%,-8.18%,-24.20%,-35.61%,-25.69%,-129.43%,-121.28%,-43.90%,-31.35%,-64.67%,-41.09%,-40.51%,-84.19%
FTT,Factor Therapeutics Limited,Annual Ratio Analysis - Market Cap.($), , , ,0.00,"11,033,100.00","9,273,000.00","8,283,472.72","14,950,657.71","2,942,921.59","12,502,104.80","24,876,260.46","97,025,167.65","80,444,666.20","24,638,819.46","77,618,503.44","10,297,880.39"
GBI,Genera Biosystems Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"6,528,938.00","5,899,532.00","6,977,378.00","7,549,351.00","6,911,184.00","5,733,233.00","4,244,670.00","3,082,748.00","2,710,210.00"
GBI,Genera Biosystems Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,--,"18,376.00","36,500.00","602,253.00","765,611.00","281,058.00","46,568.00","205,468.00","1,320,722.00"
GBI,Genera Biosystems Limited,Annual Profit and Loss - EBITDA, , , , , , , ,0.00,"-2,715,087.00","-2,121,018.00","-2,407,546.00","-2,527,944.00","-1,712,876.00","-1,880,059.00","-2,007,634.00","-1,307,308.00"
GBI,Genera Biosystems Limited,Annual Profit and Loss - EBIT, , , , , , , ,0.00,"-2,859,945.00","-2,368,597.00","-2,840,788.00","-3,119,206.00","-2,374,960.00","-2,625,840.00","-2,684,132.00","-1,907,980.00"
GBI,Genera Biosystems Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,0.00,"-3,239,917.00","-1,614,506.00","-2,486,813.00","-2,934,769.00","-2,087,566.00","-2,262,872.00","-2,461,958.00","-2,789,474.00"
GBI,Genera Biosystems Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
GBI,Genera Biosystems Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,--,--,"-4,423.30%","-6,295.73%","-5,307.00%",-901.96%,"-4,859.29%","-1,202.54%",-809.18%
GBI,Genera Biosystems Limited,Annual Ratio Analysis - ROE, , , , , , , ,0.00%,-109.84%,-23.14%,-32.94%,-42.46%,-36.41%,-53.31%,-79.86%,-102.92%
GBI,Genera Biosystems Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,0.00,"15,357,505.20","30,828,342.52","28,201,625.55","12,610,525.86","13,181,291.02","8,724,524.34","30,619,346.68","32,832,360.33"
GID,"GI Dynamics, Inc",Annual Balance Sheet - Total Equity, , , , , , , , , , ,"86,828,000.00","64,544,111.00","40,165,639.00","69,719,490.00","61,177,761.00","24,990,418.00"
GID,"GI Dynamics, Inc",Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , ,--,"230,405.00","3,236,710.00","2,520,116.00","3,834,430.00","1,813,577.00"
GID,"GI Dynamics, Inc",Annual Profit and Loss - EBITDA, , , , , , , , , , ,0.00,"-26,230,799.00","-26,183,551.00","-39,564,148.00","-58,194,342.00","-47,437,722.00"
GID,"GI Dynamics, Inc",Annual Profit and Loss - EBIT, , , , , , , , , , ,0.00,"-26,448,404.00","-26,440,677.00","-40,056,995.00","-58,994,147.00","-48,102,929.00"
GID,"GI Dynamics, Inc",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,0.00,"-25,953,131.00","-25,795,454.00","-39,760,840.00","-58,772,250.00","-48,126,197.00"
GID,"GI Dynamics, Inc",Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , ,--,--,--,--,--,--
GID,"GI Dynamics, Inc",Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , ,--,"-11,264.10%","-4,009.88%","-1,577.74%","-1,704.56%","-2,671.81%"
GID,"GI Dynamics, Inc",Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%,-40.21%,-64.22%,-57.03%,-96.07%,-192.58%
GID,"GI Dynamics, Inc",Annual Ratio Analysis - Market Cap.($), , , , , , , , , , ,0.00,"261,296,571.15","158,029,858.25","299,925,555.00","113,762,079.60","13,648,484.02"
GLH,Global Health Limited,Annual Balance Sheet - Total Equity,"11,957,004.00","5,190,232.00","4,768,281.00","4,581,809.00","5,075,374.00","6,071,537.00","1,702,326.00","-1,557,953.00","-1,005,370.00","297,418.00","-556,582.00","301,210.00","-310,234.00","1,203,045.00","2,675,052.00","3,628,006.00"
GLH,Global Health Limited,Annual Profit and Loss - Total Revenue Excluding Int,"2,143,367.00","5,337,419.00","6,120,590.00","6,688,296.00","6,403,092.00","8,991,374.00","5,184,764.00","5,572,356.00","6,539,682.00","6,839,704.00","5,043,704.00","5,246,073.00","5,080,142.00","4,539,302.00","5,236,165.00","4,626,843.00"
GLH,Global Health Limited,Annual Profit and Loss - EBITDA,"510,893.00","-353,277.00","-1,050,796.00","753,330.00","975,554.00","2,138,520.00","-3,112,386.00","-1,131,342.00","-411,423.00","-37,880.00","-732,452.00","-141,621.00","-608,015.00","1,278,817.00","1,615,550.00","1,314,033.00"
GLH,Global Health Limited,Annual Profit and Loss - EBIT,"295,433.00","-8,811,479.00","-1,617,244.00","243,686.00","441,525.00","1,574,831.00","-3,279,311.00","-1,277,448.00","-543,526.00","-149,482.00","-828,572.00","-219,737.00","-639,283.00","1,159,284.00","1,397,195.00","1,055,160.00"
GLH,Global Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"242,999.00","-7,941,925.00","-1,319,462.00","-695,498.00","457,459.00","987,572.00","-2,529,410.00","-3,446,595.00","-542,226.00","-301,306.00","-812,789.00","-230,821.00","-657,797.00","1,096,848.00","1,443,513.00","1,059,907.00"
GLH,Global Health Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
GLH,Global Health Limited,Annual Ratio Analysis - Net Profit Margin,36.26%,-149.78%,-13.15%,-2.99%,7.15%,10.79%,-47.17%,-62.60%,-8.21%,-4.72%,-17.30%,-4.31%,-13.08%,24.39%,30.27%,26.81%
GLH,Global Health Limited,Annual Ratio Analysis - ROE,2.03%,-152.49%,-16.91%,-4.36%,9.01%,16.03%,-134.07%,232.50%,58.18%,-68.76%,197.12%,-50.86%,380.37%,81.82%,51.32%,28.15%
GLH,Global Health Limited,Annual Ratio Analysis - Market Cap.($),"35,340,000.00","7,860,000.00","4,317,660.00","8,383,223.39","6,137,890.04","9,764,825.07","5,418,415.13","12,217,994.91","5,680,143.31","3,704,530.26","2,083,798.27","3,383,763.60","1,409,901.50","816,493.95","17,636,269.32","12,247,409.25"
GSS,Genetic Signatures Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"16,177,239.00","7,056,969.00"
GSS,Genetic Signatures Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"2,012,364.00"
GSS,Genetic Signatures Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"-2,494,120.00"
GSS,Genetic Signatures Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"-2,699,673.00"
GSS,Genetic Signatures Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-2,659,120.00"
GSS,Genetic Signatures Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
GSS,Genetic Signatures Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,-254.88%
GSS,Genetic Signatures Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-37.68%
GSS,Genetic Signatures Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"36,467,495.00"
GTG,Genetic Technologies Limited,Annual Balance Sheet - Total Equity,"7,577,124.00","38,067,754.00","31,136,174.00","27,276,860.00","34,224,047.00","36,959,339.00","30,242,139.00","26,102,809.00","20,785,073.00","14,112,045.00","5,717,696.00","6,813,995.00","14,402,642.00","5,758,287.00","1,827,519.00","18,959,248.00"
GTG,Genetic Technologies Limited,Annual Profit and Loss - Total Revenue Excluding Int,"3,972,555.00","5,523,327.00","13,513,260.00","9,406,657.00","4,923,650.00","10,213,224.00","9,952,026.00","14,830,325.00","15,058,643.00","11,592,038.00","9,759,113.00","18,275,701.00","11,508,683.00","8,399,002.00","7,144,498.00","5,115,719.00"
GTG,Genetic Technologies Limited,Annual Profit and Loss - EBITDA,"-106,834.00","-73,925.00","-4,894,312.00","-958,558.00","-6,850,617.00","-6,296,678.00","-3,783,852.00","-140,761.00","-1,550,019.00","-4,555,420.00","-4,495,285.00","1,378,560.00","-10,412,649.00","-9,129,647.00","-9,167,872.00","-9,694,204.00"
GTG,Genetic Technologies Limited,Annual Profit and Loss - EBIT,"-396,753.00","-3,540,360.00","-8,988,562.00","-4,442,384.00","-10,561,734.00","-10,732,263.00","-8,601,129.00","-4,743,753.00","-6,305,174.00","-8,543,416.00","-8,201,615.00","761,690.00","-10,974,593.00","-9,527,956.00","-9,506,317.00","-9,982,225.00"
GTG,Genetic Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-2,809,410.00","-3,443,603.00","-8,888,430.00","-4,325,345.00","-10,467,207.00","-10,420,232.00","-7,908,123.00","-4,345,702.00","-5,451,638.00","-7,858,321.00","-9,355,209.00","901,341.00","-5,296,828.00","-9,349,483.00","-10,134,469.00","-8,810,170.00"
GTG,Genetic Technologies Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
GTG,Genetic Technologies Limited,Annual Ratio Analysis - Net Profit Margin,"48,345.13%",-67.50%,-544.45%,-48.96%,-340.03%,-116.78%,-85.74%,-35.64%,-39.38%,-149.12%,-139.16%,19.34%,-281.77%,-275.33%,-221.84%,-507.33%
GTG,Genetic Technologies Limited,Annual Ratio Analysis - ROE,5.21%,-8.93%,-28.37%,-15.19%,-31.38%,-28.45%,-26.34%,-16.68%,-26.38%,-57.50%,-146.01%,13.44%,-73.00%,-164.93%,-554.04%,-53.84%
GTG,Genetic Technologies Limited,Annual Ratio Analysis - Market Cap.($),"79,154,793.00","157,254,220.44","122,824,382.78","129,806,040.38","108,335,124.76","123,205,765.66","126,836,464.65","52,546,535.36","32,615,090.91","16,859,016.04","14,161,180.32","84,967,081.92","55,772,618.28","45,169,822.80","24,051,831.91","47,997,365.67"
HSO,Healthscope Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"2,183,400,000.00", ,"2,305,746,000.00"
HSO,Healthscope Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , ,--, ,"2,156,681,000.00"
HSO,Healthscope Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , ,0.00, ,"380,292,000.00"
HSO,Healthscope Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , ,0.00, ,"290,444,000.00"
HSO,Healthscope Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00, ,"140,848,000.00"
HSO,Healthscope Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , ,--, ,--
HSO,Healthscope Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , ,--, ,7.42%
HSO,Healthscope Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%, ,4.49%
HSO,Healthscope Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , ,0.00, ,"4,711,297,959.36"
ICS,ICSGlobal Limited,Annual Balance Sheet - Total Equity,"7,456,025.00","1,784,506.00","1,521,156.00","1,745,268.00","975,675.00","654,650.00","911,789.00","3,429,653.00","5,865,806.00","4,505,463.00","2,715,893.00","3,234,852.00","3,679,011.00","4,093,038.00","4,382,195.00","5,080,842.00"
ICS,ICSGlobal Limited,Annual Profit and Loss - Total Revenue Excluding Int,"6,821,078.00","1,595,857.00","731,966.00","338,331.00","317,741.00","512,366.00","749,891.00","1,471,584.00","1,645,394.00","3,756,951.00","1,214,610.00","1,687,928.00","1,988,940.00","2,278,505.00","3,034,121.00","3,940,383.00"
ICS,ICSGlobal Limited,Annual Profit and Loss - EBITDA,"-1,313,389.00","-4,511,672.00","-3,116,791.00","-3,176,654.00","-2,781,892.00","-2,796,807.00","-3,073,059.00","-2,983,673.00","-2,314,154.00","-3,319,551.00","5,942.00","-104,589.00","215,100.00","404,256.00","676,347.00","977,120.00"
ICS,ICSGlobal Limited,Annual Profit and Loss - EBIT,"-1,313,389.00","-4,819,494.00","-3,391,922.00","-3,442,953.00","-2,984,428.00","-2,929,085.00","-3,191,831.00","-3,036,152.00","-2,348,285.00","-3,375,806.00","-23,997.00","-175,114.00","133,935.00","310,845.00","554,040.00","796,949.00"
ICS,ICSGlobal Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,030,800.00","-5,671,519.00","-3,344,633.00","-2,995,266.00","-2,559,882.00","-2,479,495.00","-2,789,133.00","-2,574,724.00","-1,786,600.00","-2,951,751.00","-3,525,835.00","203,650.00","448,169.00","532,403.00","624,662.00","1,003,640.00"
ICS,ICSGlobal Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
ICS,ICSGlobal Limited,Annual Ratio Analysis - Net Profit Margin,-15.11%,-292.73%,-456.94%,-885.31%,-805.65%,-711.28%,-645.89%,-227.93%,-114.38%,-80.12%,27.51%,-9.89%,16.07%,17.28%,21.00%,23.27%
ICS,ICSGlobal Limited,Annual Ratio Analysis - ROE,-13.83%,-261.78%,-219.87%,-171.62%,-262.37%,-378.75%,-305.90%,-75.07%,-30.46%,-65.51%,12.29%,-5.16%,8.58%,9.38%,14.04%,17.63%
ICS,ICSGlobal Limited,Annual Ratio Analysis - Market Cap.($),"16,585,000.00","3,477,500.00","11,673,637.29","23,279,388.12","14,429,409.21","25,973,614.63","21,684,387.72","30,808,597.40","24,629,451.00","23,247,825.66","1,704,859.72","3,659,855.90","1,733,615.96","3,811,855.90","9,075,199.92","12,339,427.23"
IDT,IDT Australia Limited,Annual Balance Sheet - Total Equity,"10,483,474.00","20,471,400.00","23,259,721.00","26,412,000.00","27,890,000.00","29,148,000.00","28,692,000.00","30,390,000.00","32,861,000.00","34,212,000.00","30,142,000.00","29,972,000.00","28,135,000.00","26,029,000.00","25,551,000.00","39,205,000.00"
IDT,IDT Australia Limited,Annual Profit and Loss - Total Revenue Excluding Int,"15,053,651.00","19,227,104.00","21,060,959.00","25,686,000.00","25,354,000.00","26,742,000.00","24,938,000.00","26,560,000.00","31,235,000.00","26,568,000.00","12,191,000.00","13,031,000.00","9,973,000.00","10,660,000.00","13,310,000.00","15,708,000.00"
IDT,IDT Australia Limited,Annual Profit and Loss - EBITDA,"5,627,248.00","6,987,758.00","7,687,835.00","8,190,000.00","8,366,000.00","8,841,000.00","7,164,000.00","9,943,000.00","12,169,000.00","11,241,000.00","-104,000.00","2,352,000.00","-763,000.00","-2,143,000.00","-4,323,000.00","-936,000.00"
IDT,IDT Australia Limited,Annual Profit and Loss - EBIT,"4,466,134.00","5,546,425.00","5,912,566.00","5,997,000.00","6,025,000.00","6,301,000.00","5,036,000.00","7,751,000.00","9,953,000.00","8,893,000.00","-2,668,000.00","-781,000.00","-3,627,000.00","-5,289,000.00","-6,616,000.00","-3,176,000.00"
IDT,IDT Australia Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"3,005,152.00","3,696,650.00","4,222,107.00","4,223,000.00","4,260,000.00","4,471,000.00","3,613,000.00","5,467,000.00","7,110,000.00","6,416,000.00","-1,577,000.00","-236,000.00","-1,837,000.00","-5,354,000.00","-6,626,000.00","-2,992,000.00"
IDT,IDT Australia Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
IDT,IDT Australia Limited,Annual Ratio Analysis - Net Profit Margin,20.68%,19.70%,20.22%,16.54%,16.88%,16.84%,14.56%,20.79%,23.03%,24.28%,-13.34%,-1.85%,-18.73%,-50.54%,-50.31%,-19.05%
IDT,IDT Australia Limited,Annual Ratio Analysis - ROE,28.67%,18.06%,18.15%,15.99%,15.27%,15.34%,12.59%,17.99%,21.64%,18.75%,-5.23%,-0.79%,-6.53%,-20.57%,-25.93%,-7.63%
IDT,IDT Australia Limited,Annual Ratio Analysis - Market Cap.($),"166,892,589.00","212,039,385.00","104,619,512.90","76,925,287.80","77,011,093.80","77,072,077.80","47,799,491.38","91,036,213.20","79,516,331.85","61,965,649.44","26,719,702.28","15,117,220.65","10,366,094.16","10,638,411.80","15,474,849.60","43,994,637.36"
IDX,Integral Diagnostics Limited,Annual Balance Sheet - Total Equity, ,"15,964,851.00","14,824,890.00", , , , , , , , , , , , ,"68,000,000.00"
IDX,Integral Diagnostics Limited,Annual Profit and Loss - Total Revenue Excluding Int, ,--,--, , , , , , , , , , , , ,--
IDX,Integral Diagnostics Limited,Annual Profit and Loss - EBITDA, ,--,--, , , , , , , , , , , , ,0.00
IDX,Integral Diagnostics Limited,Annual Profit and Loss - EBIT, ,--,--, , , , , , , , , , , , ,0.00
IDX,Integral Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, ,"1,021,253.00","-776,484.00", , , , , , , , , , , , ,0.00
IDX,Integral Diagnostics Limited,Annual Profit and Loss - Total Operating Income (ban, ,--,--, , , , , , , , , , , , ,--
IDX,Integral Diagnostics Limited,Annual Ratio Analysis - Net Profit Margin, ,--,--, , , , , , , , , , , , ,--
IDX,Integral Diagnostics Limited,Annual Ratio Analysis - ROE, ,6.40%,-5.24%, , , , , , , , , , , , ,0.00%
IDX,Integral Diagnostics Limited,Annual Ratio Analysis - Market Cap.($), ,"15,843,761.10","14,815,873.56", , , , , , , , , , , , ,0.00
IIL,Innate Immunotherapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"11,235,000.00","9,772,478.00","4,866,037.00"
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , ,--,"28,240.00","30,309.00"
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , ,0.00,"-2,585,692.00","-3,849,966.00"
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , ,0.00,"-4,060,686.00","-5,398,244.00"
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"-4,495,458.00","-5,236,578.00"
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , ,--,--,--
IIL,Innate Immunotherapeutics Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , ,--,--,"-17,277.30%"
IIL,Innate Immunotherapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,-61.33%,-107.61%
IIL,Innate Immunotherapeutics Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , ,0.00,"43,119,955.50","31,908,767.07"
IMC,Immuron Limited,Annual Balance Sheet - Total Equity,"4,441,918.00","7,475,121.00","6,322,947.00","5,043,363.00","4,031,328.00","6,940,452.00","5,178,647.00","1,920,473.00","1,087,316.00","-184,871.00","3,363,291.00","1,732,379.00","2,049,981.00","144,986.00","6,786,945.00","3,340,839.00"
IMC,Immuron Limited,Annual Profit and Loss - Total Revenue Excluding Int,"55,400.00","488,232.00","1,981,753.00","3,285,611.00","4,198,284.00","5,554,972.00","4,707,205.00","5,243,861.00","1,059,299.00","843,798.00","524,027.00","245,285.00","1,551,324.00","442,444.00","1,710,793.00","1,846,157.00"
IMC,Immuron Limited,Annual Profit and Loss - EBITDA,"-1,245,688.00","-1,870,508.00","-1,754,038.00","-1,595,835.00","-1,395,601.00","-1,678,883.00","-3,491,960.00","-3,449,984.00","-3,140,452.00","-2,577,662.00","-2,162,994.00","-2,838,102.00","-2,128,092.00","-2,214,159.00","-1,359,682.00","-3,556,672.00"
IMC,Immuron Limited,Annual Profit and Loss - EBIT,"-1,248,389.00","-1,917,663.00","-1,904,553.00","-1,758,216.00","-1,578,942.00","-1,867,888.00","-3,666,147.00","-3,606,694.00","-3,225,791.00","-2,650,797.00","-2,202,342.00","-2,857,949.00","-2,200,658.00","-2,948,529.00","-2,044,259.00","-3,560,391.00"
IMC,Immuron Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-993,546.00","-1,553,517.00","-1,699,112.00","-1,279,584.00","-1,162,035.00","-1,333,389.00","-3,559,931.00","-3,281,236.00","-2,858,337.00","-2,317,814.00","-1,905,807.00","-2,595,179.00","-2,297,520.00","-3,539,117.00","-2,544,550.00","-3,447,951.00"
IMC,Immuron Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
IMC,Immuron Limited,Annual Ratio Analysis - Net Profit Margin,"-1,793.40%",-318.19%,-85.74%,-38.95%,-31.60%,-27.39%,-88.95%,-77.22%,"-1,002.30%",-500.85%,-412.61%,"-1,212.98%",-511.68%,"-2,363.27%",-243.70%,-306.84%
IMC,Immuron Limited,Annual Ratio Analysis - ROE,-22.37%,-20.78%,-26.87%,-25.37%,-28.83%,-19.21%,-68.74%,-170.86%,-270.00%,"1,419.89%",-56.66%,-149.80%,-112.08%,"-2,441.01%",-37.49%,-103.21%
IMC,Immuron Limited,Annual Ratio Analysis - Market Cap.($),"26,647,650.00","32,188,812.24","23,537,386.87","12,580,327.46","35,115,263.29","36,308,054.77","21,127,491.64","15,735,384.48","6,590,103.83","3,758,796.81","21,462,584.41","20,520,032.40","7,453,738.03","4,141,800.57","14,978,310.60","17,241,773.36"
IMI,IM Medical Ltd,Annual Balance Sheet - Total Equity,"12,081,646.00","8,073,073.00","4,004,809.00","-948,205.00","696,048.00","1,394,935.00","2,665,950.00","3,110,851.00","1,899,968.00","824,471.00","65,451.00","592,893.00","672,221.00","226,007.00","54,834.00","-471,188.00"
IMI,IM Medical Ltd,Annual Profit and Loss - Total Revenue Excluding Int,"1,705,019.00","1,762,815.00","2,708,991.00","786,586.00","957,895.00","31,966.00","569,351.00","1,105,142.00","955,743.00","406,795.00","66,066.00","6,015.00","5,493.00",--,--,--
IMI,IM Medical Ltd,Annual Profit and Loss - EBITDA,"-1,291,369.00","-3,234,442.00","-1,587,628.00","-1,003,722.00","-480,606.00","-2,928,197.00","-3,053,570.00","-3,018,962.00","-5,310,860.00","-2,146,556.00","-1,461,454.00","-1,280,979.00","-746,727.00","-390,342.00","-404,342.00","-497,890.00"
IMI,IM Medical Ltd,Annual Profit and Loss - EBIT,"-1,330,619.00","-4,075,131.00","-4,700,168.00","-1,477,617.00","-487,023.00","-3,213,586.00","-3,226,830.00","-3,307,725.00","-5,612,556.00","-2,445,496.00","-1,688,964.00","-1,451,199.00","-746,727.00","-390,342.00","-404,342.00","-497,890.00"
IMI,IM Medical Ltd,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,257,000.00","-4,087,548.00","-4,701,985.00","-4,955,829.00","491,639.00","-3,137,155.00","-3,192,485.00","-3,187,099.00","-5,468,358.00","-2,451,565.00","-1,686,566.00","-4,068,842.00","-883,813.00","-446,489.00","-404,293.00","-523,762.00"
IMI,IM Medical Ltd,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
IMI,IM Medical Ltd,Annual Ratio Analysis - Net Profit Margin,-404.93%,-380.70%,-321.09%,-337.06%,--,"-9,814.04%",-560.72%,-288.39%,-572.16%,"-2,701.81%","-1,980.28%","-24,770.75%","-13,684.73%",--,--,--
IMI,IM Medical Ltd,Annual Ratio Analysis - ROE,-10.50%,-50.63%,-117.41%,156.62%,-66.99%,-224.90%,-119.75%,-102.45%,-287.81%,-297.35%,"-2,576.84%",-247.13%,-111.82%,-171.01%,-737.30%,111.16%
IMI,IM Medical Ltd,Annual Ratio Analysis - Market Cap.($),"8,565,159.30","2,519,314.50","1,074,617.87","1,343,272.34","7,002,977.73","6,313,056.27","7,232,676.05","19,595,800.96","19,310,532.85","6,392,820.32","1,947,430.08","5,527,476.89","2,485,313.08","828,465.19","952,465.22","952,465.22"
IMU,Imugene Limited,Annual Balance Sheet - Total Equity,"2,778,850.00","-226,543.00","792,831.00","7,443,323.00","5,431,668.00","8,652,660.00","6,462,381.00","4,699,818.00","4,670,062.00","5,326,348.00","3,791,307.00","4,206,846.00","1,073,413.00","1,886,466.00","6,732,242.00","7,732,003.00"
IMU,Imugene Limited,Annual Profit and Loss - Total Revenue Excluding Int,"1,729,754.00","116,023.00","1,295,576.00","509,074.00","43,000.00","254,772.00","169,773.00","374,564.00","340,630.00","3,171,830.00","312,117.00","4,414,918.00","282,358.00","184,012.00","511,211.00","600,321.00"
IMU,Imugene Limited,Annual Profit and Loss - EBITDA,"-3,838,119.00","-3,413,755.00","789,865.00","-1,167,078.00","-2,517,633.00","-1,904,024.00","-2,289,192.00","-2,317,297.00","-1,873,032.00","519,067.00","-1,466,051.00","512,445.00","-880,830.00","-1,582,098.00","-2,143,065.00","-2,205,051.00"
IMU,Imugene Limited,Annual Profit and Loss - EBIT,"-4,453,043.00","-3,853,390.00","460,788.00","-1,299,306.00","-2,866,227.00","-2,251,697.00","-2,635,840.00","-2,663,002.00","-2,216,878.00","175,892.00","-1,809,059.00","169,292.00","-1,052,937.00","-1,582,774.00","-2,143,065.00","-2,205,051.00"
IMU,Imugene Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-4,419,408.00","-4,041,485.00","-782,385.00","-2,044,118.00","-2,115,675.00","-1,794,208.00","-2,187,219.00","-2,304,263.00","-1,910,925.00","650,286.00","-1,535,041.00","415,539.00","-3,133,433.00","-1,559,566.00","-2,115,964.00","-2,440,789.00"
IMU,Imugene Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
IMU,Imugene Limited,Annual Ratio Analysis - Net Profit Margin,"-1,304.84%","-3,537.75%",36.64%,--,--,--,--,"-146,581.62%",--,--,--,9.33%,-442.65%,--,--,--
IMU,Imugene Limited,Annual Ratio Analysis - ROE,-159.04%,"1,783.98%",59.70%,-7.67%,-38.95%,-20.74%,-33.85%,-49.03%,-40.92%,12.21%,-40.49%,9.88%,-97.28%,-82.67%,-31.43%,-28.02%
IMU,Imugene Limited,Annual Ratio Analysis - Market Cap.($),"19,051,640.79","3,788,464.80","2,554,280.82","19,291,034.88","22,704,796.80","16,975,343.32","13,710,854.22","31,991,993.18","10,054,605.40","9,767,330.96","4,883,665.48","4,309,116.60","1,149,097.76","1,504,650.06","12,305,312.71","14,629,037.68"
IPD,ImpediMed Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"19,403,537.00","12,300,369.00","10,067,104.00","22,230,000.00","20,683,000.00","17,310,000.00","10,594,000.00","13,532,000.00","34,837,000.00"
IPD,ImpediMed Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,--,"3,493,512.00","3,352,286.00","3,691,000.00","3,971,000.00","3,722,000.00","3,524,000.00","3,540,000.00","5,109,000.00"
IPD,ImpediMed Limited,Annual Profit and Loss - EBITDA, , , , , , , ,0.00,"-8,363,210.00","-13,529,141.00","-10,832,000.00","-14,429,000.00","-12,007,000.00","-8,404,000.00","-7,810,000.00","-14,698,000.00"
IPD,ImpediMed Limited,Annual Profit and Loss - EBIT, , , , , , , ,0.00,"-8,718,255.00","-14,300,896.00","-11,569,000.00","-15,094,000.00","-12,581,000.00","-8,656,000.00","-7,992,000.00","-14,880,000.00"
IPD,ImpediMed Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,0.00,"-9,754,128.00","-14,027,655.00","-11,402,000.00","-14,822,000.00","-12,342,000.00","-8,464,000.00","-7,935,000.00","-14,797,000.00"
IPD,ImpediMed Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
IPD,ImpediMed Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,--,-279.21%,-468.48%,-313.33%,-381.32%,-418.09%,-309.70%,-225.36%,-305.47%
IPD,ImpediMed Limited,Annual Ratio Analysis - ROE, , , , , , , ,0.00%,-79.30%,-139.34%,-51.29%,-71.66%,-71.30%,-79.89%,-58.64%,-42.47%
IPD,ImpediMed Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,0.00,"63,740,708.46","62,722,240.64","76,848,074.42","89,203,324.77","47,141,654.30","16,318,264.95","44,154,468.37","253,693,981.60"
ITD,ITL Limited,Annual Balance Sheet - Total Equity, , , , ,"24,961,554.00","25,111,916.00","29,006,704.00","38,256,431.00","38,916,719.00","35,747,181.00","14,610,000.00","15,048,000.00","12,807,000.00","10,799,000.00","9,995,000.00","11,879,000.00"
ITD,ITL Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , ,"17,321,895.00","23,984,002.00","31,115,147.00","35,090,005.00","38,283,372.00","43,733,315.00","41,317,000.00","41,081,000.00","28,626,000.00","24,950,000.00","25,962,000.00","28,638,000.00"
ITD,ITL Limited,Annual Profit and Loss - EBITDA, , , , ,"1,554,186.00","-710,410.00","4,440,355.00","3,034,148.00","2,480,397.00","-693,787.00","-143,000.00","3,482,000.00","3,352,000.00","3,501,000.00","3,235,000.00","2,787,000.00"
ITD,ITL Limited,Annual Profit and Loss - EBIT, , , , ,"351,171.00","-1,880,968.00","3,718,019.00","2,246,804.00","1,636,548.00","-1,632,612.00","-1,963,000.00","1,721,000.00","3,018,000.00","2,544,000.00","2,324,000.00","1,860,000.00"
ITD,ITL Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , ,"-2,032,501.00","-139,043.00","3,257,385.00","1,742,917.00","763,633.00","-3,481,751.00","-12,861,000.00","940,000.00","1,323,000.00","2,458,000.00","2,021,000.00","2,121,000.00"
ITD,ITL Limited,Annual Profit and Loss - Total Operating Income (ban, , , , ,--,--,--,--,--,--,--,--,--,--,--,--
ITD,ITL Limited,Annual Ratio Analysis - Net Profit Margin, , , , ,3.17%,-4.60%,10.48%,4.97%,3.65%,-0.33%,-3.74%,2.30%,9.73%,9.88%,7.81%,7.49%
ITD,ITL Limited,Annual Ratio Analysis - ROE, , , , ,2.17%,-4.39%,11.23%,4.56%,3.59%,-0.41%,-10.51%,6.25%,21.48%,22.76%,20.22%,17.86%
ITD,ITL Limited,Annual Ratio Analysis - Market Cap.($), , , , ,"34,864,900.00","17,432,450.00","34,446,760.00","46,204,489.50","13,164,538.60","10,399,985.49","7,503,787.00","9,215,177.02","20,929,515.16","24,247,160.00","17,379,600.00","16,935,600.00"
IVQ,Invitrocue Limited,Annual Balance Sheet - Total Equity,"5,545,770.00","15,174,000.00","23,781,000.00","5,981,000.00","-16,029,000.00","7,869,000.00","-1,121,000.00","-12,804,000.00","-29,052,000.00","-4,809,594.00","-4,378,391.00","-4,544,198.00","-4,275,725.00","-150,698.00","-591,503.00","-176,510.00"
IVQ,Invitrocue Limited,Annual Profit and Loss - Total Revenue Excluding Int,"50,100,782.00","71,587,000.00","88,882,000.00","33,004,000.00","33,632,000.00","50,630,000.00","30,567,000.00","16,915,000.00","11,302,000.00","8,071,668.00","605,778.00",--,"375,151.00","4,174,039.00",--,"1,713,943.00"
IVQ,Invitrocue Limited,Annual Profit and Loss - EBITDA,"8,247,127.00","12,488,000.00","16,200,000.00","826,000.00","-25,838,000.00","2,216,000.00","-8,696,000.00","-8,385,000.00","-13,047,000.00","7,349,324.00","476,827.00","-165,919.00","-106,691.00","-167,685.00","-456,773.00","-519,268.00"
IVQ,Invitrocue Limited,Annual Profit and Loss - EBIT,"6,311,913.00","9,850,000.00","11,206,000.00","-16,357,000.00","-28,035,000.00","502,000.00","-9,272,000.00","-8,556,000.00","-13,184,000.00","7,310,118.00","476,827.00","-165,919.00","-106,691.00","-167,685.00","-456,773.00","-519,268.00"
IVQ,Invitrocue Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"10,054,455.00","9,409,000.00","7,006,000.00","-17,935,000.00","-40,932,000.00","-929,000.00","-10,527,000.00","-10,864,000.00","-16,435,000.00","12,325,409.00","431,203.00","-165,807.00","268,473.00","3,839,027.00","-580,805.00","-66,387.00"
IVQ,Invitrocue Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
IVQ,Invitrocue Limited,Annual Ratio Analysis - Net Profit Margin,10.63%,14.38%,7.96%,-25.75%,-110.70%,-2.89%,-35.39%,-69.28%,-145.42%,"17,723.59%",--,--,--,--,--,--
IVQ,Invitrocue Limited,Annual Ratio Analysis - ROE,95.09%,62.01%,29.46%,-141.03%,234.15%,-11.81%,939.07%,84.85%,56.57%,-153.56%,-11.36%,3.65%,2.49%,111.11%,77.22%,294.19%
IVQ,Invitrocue Limited,Annual Ratio Analysis - Market Cap.($),"160,355,119.50","249,918,318.16","92,627,475.00","46,858,605.00","24,487,320.00","27,686,440.10","21,975,400.00","5,146,858.61","2,081,875.39","222,698.52","222,698.52","222,698.52","222,698.52","3,606,698.52","5,564,198.52","6,444,098.96"
IVX,Invion Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"12,138,420.00","-4,776,893.00","-2,142,416.00","6,013,240.00","11,035,582.00","10,159,077.00","6,860,171.00"
IVX,Invion Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , ,--,"734,509.00","486,199.00","5,945,238.00","1,744,365.00","836,602.00","2,585,335.00"
IVX,Invion Limited,Annual Profit and Loss - EBITDA, , , , , , , , , ,0.00,"-13,466,616.00","-11,936,109.00","-4,793,082.00","-4,312,940.00","-5,765,770.00","-11,094,035.00"
IVX,Invion Limited,Annual Profit and Loss - EBIT, , , , , , , , , ,0.00,"-13,699,305.00","-12,080,529.00","-4,876,880.00","-5,907,503.00","-7,720,416.00","-12,437,244.00"
IVX,Invion Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,0.00,"-16,787,189.00","-13,679,994.00","-5,540,923.00","-5,174,080.00","-6,883,937.00","-13,041,233.00"
IVX,Invion Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , ,--,--,--,--,--,--,--
IVX,Invion Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , ,--,--,--,--,--,--,--
IVX,Invion Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,0.00%,351.42%,638.53%,-92.15%,-46.89%,-67.76%,-190.10%
IVX,Invion Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , ,0.00,"21,227,799.82","100,708,500.06","14,348,697.78","14,710,286.72","37,885,780.80","15,632,194.29"
JHC,Japara Healthcare Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"509,700,000.00","513,987,000.00","530,039,000.00"
JHC,Japara Healthcare Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , ,--,"48,978,000.00","281,344,000.00"
JHC,Japara Healthcare Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , ,0.00,"-1,282,000.00","50,062,000.00"
JHC,Japara Healthcare Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , ,0.00,"-2,864,000.00","40,344,000.00"
JHC,Japara Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"-2,938,000.00","28,839,000.00"
JHC,Japara Healthcare Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , ,--,--,--
JHC,Japara Healthcare Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , ,--,-6.07%,10.14%
JHC,Japara Healthcare Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,-1.14%,5.32%
JHC,Japara Healthcare Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , ,0.00,"616,875,000.00","676,030,790.00"
JHL,Jayex Healthcare Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"13,808,000.00"
JHL,Jayex Healthcare Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,"1,181,000.00"
JHL,Jayex Healthcare Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,"-1,246,000.00"
JHL,Jayex Healthcare Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,"-1,643,000.00"
JHL,Jayex Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-2,902,000.00"
JHL,Jayex Healthcare Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
JHL,Jayex Healthcare Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
JHL,Jayex Healthcare Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
JHL,Jayex Healthcare Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
KKT,Konekt Limited,Annual Balance Sheet - Total Equity,"5,547,892.00","7,555,060.00","1,549,405.00","-671,079.00","7,029,190.00","11,591,397.00","9,188,116.00","8,828,005.00","1,798,813.00","3,397,798.00","7,469,000.00","7,434,000.00","8,055,000.00","7,886,000.00","8,916,000.00","10,204,000.00"
KKT,Konekt Limited,Annual Profit and Loss - Total Revenue Excluding Int,"2,199,486.00","1,536,963.00","2,849,003.00","792,689.00","11,689,362.00","29,239,156.00","30,169,847.00","27,296,406.00","27,231,992.00","32,284,175.00","36,185,000.00","34,300,000.00","33,196,000.00","30,826,000.00","33,211,000.00","35,285,000.00"
KKT,Konekt Limited,Annual Profit and Loss - EBITDA,"-2,107,778.00","-1,056,038.00","-3,016,546.00","-1,954,234.00","-1,245,181.00","349,023.00","-223,829.00","-637,251.00","-396,174.00","1,814,386.00","2,594,000.00","576,000.00","1,129,000.00","53,000.00","1,705,000.00","2,384,000.00"
KKT,Konekt Limited,Annual Profit and Loss - EBIT,"-2,164,549.00","-2,153,141.00","-5,825,620.00","-2,286,729.00","-2,028,860.00","-1,128,133.00","-1,277,514.00","-1,450,911.00","-960,098.00","1,347,537.00","2,208,000.00","256,000.00","887,000.00","-249,000.00","1,378,000.00","1,839,000.00"
KKT,Konekt Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-2,115,276.00","-2,102,857.00","-6,010,022.00","-2,405,106.00","-11,139,622.00","-1,340,115.00","-1,468,340.00","-1,526,469.00","-7,228,980.00","1,174,095.00","3,880,000.00","205,000.00","610,000.00","-184,000.00","1,020,000.00","1,478,000.00"
KKT,Konekt Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
KKT,Konekt Limited,Annual Ratio Analysis - Net Profit Margin,--,-136.82%,-966.51%,-315.64%,-20.01%,-4.59%,-4.88%,-5.60%,-3.74%,3.64%,10.79%,0.60%,1.85%,-0.60%,3.11%,4.22%
KKT,Konekt Limited,Annual Ratio Analysis - ROE,-38.13%,-27.83%,-387.89%,372.84%,-33.20%,-11.56%,-15.98%,-17.29%,-56.09%,34.55%,51.95%,2.76%,7.57%,-2.33%,11.44%,14.48%
KKT,Konekt Limited,Annual Ratio Analysis - Market Cap.($),"22,509,042.95","14,130,459.92","1,942,979.90","4,100,987.11","36,409,434.12","29,162,825.76","17,141,545.40","8,786,609.60","2,692,271.02","3,521,370.10","10,847,273.25","4,153,768.80","4,531,384.14","2,039,122.86","9,806,161.56","14,671,426.80"
LBT,LBT Innovations Limited,Annual Balance Sheet - Total Equity, , , , , ,"4,678,434.00", ,"12,137,608.00","12,886,000.00","13,237,000.00","14,678,000.00","13,468,000.00","12,312,000.00","12,850,000.00","13,564,000.00","15,684,000.00"
LBT,LBT Innovations Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,--, ,"3,394,097.00","1,868,000.00","1,992,000.00","3,776,000.00","931,000.00","842,000.00","4,339,000.00","3,877,000.00","2,324,000.00"
LBT,LBT Innovations Limited,Annual Profit and Loss - EBITDA, , , , , ,0.00, ,"-2,237,018.00","-1,839,000.00","75,000.00","1,920,000.00","-1,915,000.00","-1,211,000.00","-3,111,000.00","-3,875,000.00","-583,000.00"
LBT,LBT Innovations Limited,Annual Profit and Loss - EBIT, , , , , ,0.00, ,"-2,257,371.00","-1,868,000.00","34,000.00","1,826,000.00","-2,098,000.00","-1,918,000.00","-3,815,000.00","-4,591,000.00","-1,347,000.00"
LBT,LBT Innovations Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,0.00, ,"965,338.00","722,000.00","337,000.00","1,488,000.00","-1,162,000.00","-1,156,000.00","531,000.00","292,000.00","321,000.00"
LBT,LBT Innovations Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--, ,--,--,--,--,--,--,--,--,--
LBT,LBT Innovations Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,--, ,-75.77%,-51.82%,16.92%,43.04%,-232.40%,-137.29%,-82.44%,-84.73%,-35.33%
LBT,LBT Innovations Limited,Annual Ratio Analysis - ROE, , , , , ,0.00%, ,-10.59%,-7.51%,2.55%,10.14%,-8.63%,-9.39%,-27.84%,-24.22%,-4.33%
LBT,LBT Innovations Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,0.00, ,"24,332,549.36","19,874,972.20","12,421,857.62","6,459,365.96","4,471,868.74","4,571,243.61","9,440,611.80","14,381,843.70","6,883,402.02"
LCT,Living Cell Technologies Limited,Annual Balance Sheet - Total Equity, , , ,--,"-1,325,415.00","3,135,554.00","1,743,610.00","1,401,328.00","11,527,248.00","5,527,390.00","6,239,622.00","6,760,236.00","14,353,000.00","13,252,000.00","8,431,577.00","5,126,863.00"
LCT,Living Cell Technologies Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , ,68.00,"72,714.00","65,796.00","188,525.00","1,156,590.00","1,062,873.00","790,248.00","1,507,176.00","1,921,168.00","15,779,000.00","10,747,000.00","7,950,588.00","840,952.00"
LCT,Living Cell Technologies Limited,Annual Profit and Loss - EBITDA, , , ,"-3,599.00","-2,109,548.00","-6,103,169.00","-6,732,927.00","-5,592,972.00","-6,689,396.00","-6,257,507.00","-5,472,712.00","-6,594,233.00","5,673,000.00","-3,116,000.00","-6,974,985.00","-7,235,801.00"
LCT,Living Cell Technologies Limited,Annual Profit and Loss - EBIT, , , ,"-3,599.00","-2,163,418.00","-6,249,725.00","-6,921,271.00","-5,790,528.00","-6,883,943.00","-6,514,462.00","-5,840,352.00","-6,937,613.00","5,560,000.00","-3,122,000.00","-6,982,116.00","-7,239,613.00"
LCT,Living Cell Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-3,609.00","-10,307,766.00","-6,097,309.00","-6,819,611.00","-5,987,322.00","-6,794,037.00","-6,123,562.00","-5,674,059.00","-6,795,708.00","5,676,000.00","-2,979,000.00","-6,778,896.00","-7,043,402.00"
LCT,Living Cell Technologies Limited,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
LCT,Living Cell Technologies Limited,Annual Ratio Analysis - Net Profit Margin, , , ,--,"-2,967.34%","-9,321.39%","-521,775.90%","-32,731.92%","-13,079.04%","-3,284.06%","-1,097.31%","-3,849.43%",153.07%,-39.30%,-91.68%,"-1,150.97%"
LCT,Living Cell Technologies Limited,Annual Ratio Analysis - ROE, , , ,--,162.79%,-194.46%,-391.12%,-427.26%,-58.94%,-110.79%,-90.94%,-100.52%,39.55%,-22.48%,-80.40%,-137.38%
LCT,Living Cell Technologies Limited,Annual Ratio Analysis - Market Cap.($), , , ,0.00,0.00,"19,960,746.42","16,609,590.62","19,105,863.75","58,389,319.24","42,898,275.36","58,967,232.14","21,606,797.88","17,849,788.65","14,636,826.69","18,206,784.42","21,199,986.90"
LHC,Lifehealthcare Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"34,300,000.00","43,664,000.00","43,043,000.00"
LHC,Lifehealthcare Group Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , ,--,"87,230,000.00","99,309,000.00"
LHC,Lifehealthcare Group Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , ,0.00,"15,289,000.00","17,113,000.00"
LHC,Lifehealthcare Group Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , ,0.00,"12,098,000.00","13,338,000.00"
LHC,Lifehealthcare Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"20,517,000.00","3,744,000.00"
LHC,Lifehealthcare Group Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , ,--,--,--
LHC,Lifehealthcare Group Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , ,--,8.27%,3.77%
LHC,Lifehealthcare Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,16.53%,8.70%
LHC,Lifehealthcare Group Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , ,0.00,"96,050,000.00","148,881,778.50"
M7T,Mach7 Technologies Limited,Annual Balance Sheet - Total Equity, , , , , ,"2,545,451.00","1,795,000.00","7,210,000.00","3,593,000.00","-87,240.00","-4,436,566.00","1,831,000.00","1,407,326.00","468,513.00","538,506.00","3,096,688.00"
M7T,Mach7 Technologies Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,--,"69,000.00","1,102,000.00","4,815,000.00","2,321,852.00","55,735.00","1,850,455.00",--,"2,492.00",--,"143,878.00"
M7T,Mach7 Technologies Limited,Annual Profit and Loss - EBITDA, , , , , ,0.00,"-1,618,000.00","-1,515,000.00","-4,372,000.00","-3,392,509.00","-2,747,335.00","-494,018.00","-495,599.00","-951,814.00","-304,765.00","-1,504,781.00"
M7T,Mach7 Technologies Limited,Annual Profit and Loss - EBIT, , , , , ,0.00,"-1,626,000.00","-1,515,000.00","-4,372,000.00","-3,392,509.00","-2,861,630.00","-494,018.00","-495,599.00","-951,814.00","-304,765.00","-1,512,405.00"
M7T,Mach7 Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,0.00,"-1,523,000.00","-1,519,000.00","-4,418,000.00","-3,874,198.00","-4,488,342.00","1,367,566.00","-423,674.00","-938,813.00","-302,272.00","-6,909,809.00"
M7T,Mach7 Technologies Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
M7T,Mach7 Technologies Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,--,"-2,207.25%",-177.25%,-92.48%,-132.31%,"-4,127.22%","-2,962.85%",--,--,--,"-1,035.66%"
M7T,Mach7 Technologies Limited,Annual Ratio Analysis - ROE, , , , , ,0.00%,-84.85%,-21.07%,-122.96%,-450.72%,76.27%,-25.51%,-30.10%,-200.38%,-56.13%,-48.12%
M7T,Mach7 Technologies Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,0.00,"11,351,235.00","38,999,879.60","6,517,286.42","4,883,230.53","2,940,695.06","6,343,287.46","2,775,188.26","1,585,821.86","4,279,340.37","43,234,689.88"
MDC,Medlab Clinical Limited,Annual Balance Sheet - Total Equity,"100,017,000.00","101,194,000.00","97,150,000.00", , , , , , , , , , , ,"10,458,130.00", 
MDC,Medlab Clinical Limited,Annual Profit and Loss - Total Revenue Excluding Int,"515,676,000.00","209,630,000.00","553,792,000.00", , , , , , , , , , , ,--, 
MDC,Medlab Clinical Limited,Annual Profit and Loss - EBITDA,"41,879,000.00","-1,070,000.00","20,033,000.00", , , , , , , , , , , ,0.00, 
MDC,Medlab Clinical Limited,Annual Profit and Loss - EBIT,"23,283,000.00","-6,128,000.00","8,498,000.00", , , , , , , , , , , ,0.00, 
MDC,Medlab Clinical Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"19,013,000.00","-3,932,000.00","5,729,000.00", , , , , , , , , , , ,0.00, 
MDC,Medlab Clinical Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--, , , , , , , , , , , ,--, 
MDC,Medlab Clinical Limited,Annual Ratio Analysis - Net Profit Margin,3.73%,-1.88%,1.22%, , , , , , , , , , , ,--, 
MDC,Medlab Clinical Limited,Annual Ratio Analysis - ROE,38.41%,-7.86%,7.02%, , , , , , , , , , , ,0.00%, 
MDC,Medlab Clinical Limited,Annual Ratio Analysis - Market Cap.($),"72,807,338.52","71,816,464.30","67,591,966.40", , , , , , , , , , , ,0.00, 
MDG,Medtech Global Limited,Annual Balance Sheet - Total Equity,"32,509,745.00","17,861,332.00","15,649,340.00","8,127,493.00","5,609,271.00","3,348,991.00","4,824,691.00","19,159,290.00","14,367,693.00","12,851,400.00","12,574,711.00","12,729,312.00","12,630,946.00","12,000,951.00","7,749,205.00","5,998,917.00"
MDG,Medtech Global Limited,Annual Profit and Loss - Total Revenue Excluding Int,"50,632.00","2,212,698.00","1,452,538.00","2,487,955.00","1,497,474.00","1,821,239.00","1,727,733.00","4,565,280.00","8,388,975.00","9,012,017.00","9,302,964.00","10,872,225.00","9,617,211.00","11,801,246.00","16,670,213.00","19,497,907.00"
MDG,Medtech Global Limited,Annual Profit and Loss - EBITDA,"-573,448.00","-14,923,774.00","-1,385,890.00","-1,342,162.00","-260,478.00","162,135.00","30,125.00","-169,800.00","-3,705,582.00","-601,479.00","-103,037.00","1,440,520.00","917,702.00","251,162.00","-2,012,946.00","1,437,306.00"
MDG,Medtech Global Limited,Annual Profit and Loss - EBIT,"-574,510.00","-14,950,200.00","-2,575,285.00","-3,604,718.00","-3,110,703.00","-2,464,146.00","-610,187.00","-615,449.00","-4,872,271.00","-1,689,648.00","-916,260.00","666,425.00","-14,909.00","-775,371.00","-3,244,046.00","-1,796,992.00"
MDG,Medtech Global Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-929,724.00","-14,690,000.00","-2,465,069.00","-8,461,954.00","-3,134,869.00","-2,260,280.00","-358,114.00","-315,132.00","-4,944,999.00","-1,808,720.00","-269,960.00","161,224.00","-107,184.00","-856,787.00","-4,135,234.00","-1,999,778.00"
MDG,Medtech Global Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
MDG,Medtech Global Limited,Annual Ratio Analysis - Net Profit Margin,--,-875.07%,-170.30%,-141.37%,-207.93%,-130.23%,-22.11%,-6.90%,-59.24%,-20.09%,-2.90%,1.48%,-1.04%,-6.92%,-26.80%,-11.36%
MDG,Medtech Global Limited,Annual Ratio Analysis - ROE,-2.23%,-82.21%,-15.77%,-42.84%,-54.57%,-66.44%,-7.29%,-1.64%,-34.23%,-14.07%,-2.15%,1.27%,-0.79%,-6.90%,-61.56%,-35.05%
MDG,Medtech Global Limited,Annual Ratio Analysis - Market Cap.($),"129,765,267.50","9,343,099.26","2,369,239.70","2,252,961.88","4,274,847.58","6,354,503.16","6,932,185.26","19,774,612.20","8,019,844.88","4,009,922.44","5,613,891.42","6,516,123.96","5,012,403.05","3,508,682.14","6,215,379.78","15,037,209.15"
MDR,MedAdvisor Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"3,177,612.00","3,139,470.00","2,780,558.00","11,109,810.00","310,983.00","-106,882.00"
MDR,MedAdvisor Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , ,--,--,--,--,"4,646.00",--
MDR,MedAdvisor Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , ,0.00,"-94,511.00","-1,112,965.00","-3,838,602.00","-11,153,183.00","-666,598.00"
MDR,MedAdvisor Limited,Annual Profit and Loss - EBIT, , , , , , , , , , ,0.00,"-94,511.00","-1,113,120.00","-3,840,036.00","-11,157,427.00","-667,555.00"
MDR,MedAdvisor Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,0.00,"-70,229.00","-993,412.00","-3,747,017.00","-11,144,067.00","-666,965.00"
MDR,MedAdvisor Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , ,--,--,--,--,--,--
MDR,MedAdvisor Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , ,--,--,--,--,--,--
MDR,MedAdvisor Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%,-4.47%,-35.73%,-33.73%,"-3,583.50%",624.02%
MDR,MedAdvisor Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , ,0.00,"5,025,000.60","3,465,000.36","1,756,927.08","2,220,586.78","2,046,009.72"
MDV,Medivac Limited,Annual Balance Sheet - Total Equity,"6,944,000.00","4,159,000.00","-1,520,000.00","-2,200,000.00","14,041,000.00","7,874,000.00","625,000.00","-931,316.00","3,766,179.00","3,778,246.00","5,101,792.00","5,418,692.00","3,310,423.00","-38,762.00", , 
MDV,Medivac Limited,Annual Profit and Loss - Total Revenue Excluding Int,"81,641,000.00","87,867,000.00","80,667,000.00","9,768,000.00","9,000.00","483,000.00","858,000.00","1,047,587.00","701,670.00","1,395,613.00","460,598.00","500,319.00","489,776.00","807,014.00", , 
MDV,Medivac Limited,Annual Profit and Loss - EBITDA,"3,698,000.00","-1,740,000.00","-2,847,000.00","-3,853,000.00","-2,302,000.00","-6,519,000.00","-9,135,000.00","-2,997,751.00","-1,744,050.00","-1,066,897.00","-2,258,645.00","-1,833,436.00","-1,104,111.00","-1,699,049.00", , 
MDV,Medivac Limited,Annual Profit and Loss - EBIT,"2,702,000.00","-2,744,000.00","-3,976,000.00","-3,936,000.00","-2,542,000.00","-7,164,000.00","-9,327,000.00","-3,169,820.00","-1,877,425.00","-1,119,308.00","-2,452,878.00","-1,940,349.00","-1,166,517.00","-1,722,770.00", , 
MDV,Medivac Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"2,187,000.00","-3,193,000.00","-5,657,000.00","-4,144,000.00","-2,466,000.00","-7,092,000.00","-8,375,000.00","-2,863,117.00","-1,991,596.00","-1,120,433.00","-2,529,505.00","-2,321,574.00","-3,486,209.00","-4,748,870.00", , 
MDV,Medivac Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--, , 
MDV,Medivac Limited,Annual Ratio Analysis - Net Profit Margin,2.70%,-3.67%,-7.17%,-42.42%,"-27,400.00%","-1,545.10%","-1,240.74%",-336.52%,-327.81%,-110.06%,"-1,256.89%","-1,024.65%","-1,301.82%",-237.74%, , 
MDV,Medivac Limited,Annual Ratio Analysis - ROE,31.57%,-76.66%,364.90%,188.36%,-17.56%,-90.07%,"-1,340.00%",307.43%,-52.88%,-29.65%,-49.58%,-36.26%,-35.98%,"4,549.05%", , 
MDV,Medivac Limited,Annual Ratio Analysis - Market Cap.($),"24,147,305.90","11,903,601.50","7,822,366.70","5,441,646.40","13,597,796.12","5,057,728.88","3,872,493.32","4,595,622.34","3,941,251.69","8,614,411.15","7,840,198.00","8,324,556.46","790,032.46","647,508.11", , 
MEB,Medibio Limited,Annual Balance Sheet - Total Equity,"7,552,912.00","6,047,687.00","6,051,096.00","5,150,325.00","4,857,705.00","4,436,495.00","2,258,400.00","1,881,778.00","5,675,610.00","2,461,300.00","1,097,552.00","1,177,537.00","2,444,327.00","2,538,153.00","2,710,271.00","9,111,081.00"
MEB,Medibio Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,"140,719.00","159,379.00","149,264.00","97,847.00","166,455.00","36,230.00","12,174.00","90,909.00",--,"1,456.00","441,054.00","107,780.00","20,646.00","463,194.00","255,120.00"
MEB,Medibio Limited,Annual Profit and Loss - EBITDA,"-114,233.00","-1,779,377.00","-4,137,055.00","-1,770,382.00","-1,211,918.00","-1,325,778.00","-1,043,897.00","-1,550,709.00","-4,567,834.00","-2,743,688.00","-2,823,911.00","-3,662,561.00","-3,464,117.00","-907,554.00","-328,087.00","-2,945,399.00"
MEB,Medibio Limited,Annual Profit and Loss - EBIT,"-114,233.00","-1,954,313.00","-4,495,402.00","-2,440,996.00","-1,594,346.00","-1,688,658.00","-1,053,795.00","-1,555,589.00","-4,963,477.00","-3,217,504.00","-3,146,760.00","-3,676,945.00","-3,486,891.00","-911,086.00","-328,087.00","-3,461,860.00"
MEB,Medibio Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-108,092.00","-1,882,228.00","-4,482,733.00","-3,381,332.00","-2,282,838.00","-1,828,453.00","-777,877.00","-1,429,844.00","-4,657,171.00","-3,035,460.00","-3,301,454.00","-3,220,121.00","-3,326,955.00","-1,096,713.00","-428,332.00","-7,921,702.00"
MEB,Medibio Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
MEB,Medibio Limited,Annual Ratio Analysis - Net Profit Margin,--,"-1,204.50%","-2,397.86%","-3,531.52%","-4,225.69%","-1,310.49%","-4,533.35%","-17,111.58%",--,--,"-186,569.64%","-1,095.12%","-6,349.51%","-5,703.14%",--,--
MEB,Medibio Limited,Annual Ratio Analysis - ROE,-1.43%,-27.19%,-61.97%,-39.49%,-31.97%,-33.39%,-34.44%,-75.98%,-82.06%,-123.33%,-247.50%,-273.46%,-136.11%,-43.21%,-15.80%,-39.68%
MEB,Medibio Limited,Annual Ratio Analysis - Market Cap.($),0.00,"11,568,865.50","9,805,635.63","10,870,053.38","5,542,489.63","6,109,190.41","3,676,867.69","15,039,701.38","8,766,736.99","8,279,696.05","7,320,476.34","8,932,562.78","3,224,340.69","2,873,174.37","9,519,568.12","26,940,879.60"
MEM,Memphasys Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"1,800,000.00","1,101,357.00","-398,471.00","12,843,038.00","6,995,083.00","4,562,379.00","6,990,106.00","-992,848.00","746,591.00"
MEM,Memphasys Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,"799,000.00","1,610,892.00","2,167,181.00","5,485,807.00","4,894,515.00","2,549,415.00","1,438,259.00","1,278,990.00","682,096.00"
MEM,Memphasys Limited,Annual Profit and Loss - EBITDA, , , , , , , ,"-4,292,000.00","-4,920,037.00","-2,134,106.00","3,761,373.00","1,088,856.00","-2,512,950.00","-2,070,391.00","-971,216.00","-1,611,448.00"
MEM,Memphasys Limited,Annual Profit and Loss - EBIT, , , , , , , ,"-4,967,000.00","-5,507,441.00","-2,543,214.00","3,392,184.00","-292,321.00","-3,203,905.00","-2,378,629.00","-1,069,840.00","-1,611,448.00"
MEM,Memphasys Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-4,947,000.00","-5,496,190.00","-2,741,323.00","3,291,709.00","-6,321,097.00","-6,308,215.00","-1,841,920.00","-3,842,140.00","-2,645,684.00"
MEM,Memphasys Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
MEM,Memphasys Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,-749.55%,-419.02%,-168.62%,207.04%,-24.53%,-183.34%,-293.46%,-186.73%,"-1,206.92%"
MEM,Memphasys Limited,Annual Ratio Analysis - ROE, , , , , , , ,-274.83%,-499.04%,687.96%,25.63%,-3.79%,-71.54%,-147.92%,160.03%,-306.55%
MEM,Memphasys Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,"4,263,376.00","4,936,099.80","114,945.35","12,179,407.52","6,939,861.34","5,396,075.05","6,908,157.05","10,446,821.94","7,128,180.06"
MEQ,Metlifecare Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"791,803,000.00","807,012,573.00"
MEQ,Metlifecare Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,"160,368,000.00","196,993,093.00"
MEQ,Metlifecare Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,"81,692,000.00","119,445,723.00"
MEQ,Metlifecare Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,"79,960,000.00","117,683,725.00"
MEQ,Metlifecare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"68,776,000.00","108,604,568.00"
MEQ,Metlifecare Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
MEQ,Metlifecare Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,75.70%,128.13%
MEQ,Metlifecare Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,8.69%,13.39%
MEQ,Metlifecare Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,"738,874,829.00","742,667,303.00"
MGZ,Medigard Limited,Annual Balance Sheet - Total Equity, , , ,"4,879,984.00","3,255,296.00","2,917,186.00","2,267,743.00","2,021,986.00","1,263,215.00","833,255.00","456,191.00","882,304.00","551,028.00","228,805.00","-97,938.00","-683,198.00"
MGZ,Medigard Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , ,--,"620,886.00","1,759,482.00","36,500.00","315,154.00","115,629.00","97,884.00","255,652.00","135,483.00","32,071.00",--,--,--
MGZ,Medigard Limited,Annual Profit and Loss - EBITDA, , , ,0.00,"-320,224.00","-532,259.00","-826,430.00","-385,826.00","-1,357,020.00","-783,001.00","-377,963.00","-617,110.00","-306,373.00","-290,895.00","-295,135.00","-548,228.00"
MGZ,Medigard Limited,Annual Profit and Loss - EBIT, , , ,0.00,"-331,658.00","-554,585.00","-863,418.00","-421,311.00","-1,394,585.00","-826,688.00","-422,794.00","-667,409.00","-353,745.00","-328,868.00","-321,837.00","-567,773.00"
MGZ,Medigard Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,0.00,"-201,888.00","-338,110.00","-669,393.00","-264,957.00","-1,258,995.00","-761,323.00","-400,158.00","-638,390.00","-331,276.00","-322,223.00","-326,743.00","-585,260.00"
MGZ,Medigard Limited,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
MGZ,Medigard Limited,Annual Ratio Analysis - Net Profit Margin, , , ,--,--,"-2,113.58%",--,--,"-1,088.82%",--,--,--,--,--,--,--
MGZ,Medigard Limited,Annual Ratio Analysis - ROE, , , ,0.00%,-6.20%,-11.59%,-29.52%,-13.10%,-99.67%,-91.37%,-87.72%,-72.35%,-60.12%,-140.83%,333.62%,85.66%
MGZ,Medigard Limited,Annual Ratio Analysis - Market Cap.($), , , ,0.00,"10,720,000.00","4,690,000.00","3,434,850.00","8,443,750.00","3,715,250.00","6,268,754.68","9,255,761.38","2,548,209.22","1,365,112.08","2,730,224.16","2,093,171.86","6,825,560.40"
MLA,Medical Australia Limited,Annual Balance Sheet - Total Equity, , , , , ,"2,740,148.00","1,089,719.00","566,050.00","3,826,507.00","3,815,636.00","3,060,480.00","4,375,005.00","4,956,161.00","3,607,255.00","9,407,598.00","10,348,707.00"
MLA,Medical Australia Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,"239,594.00","592,752.00","1,594,078.00","4,786,419.00","7,619,924.00","7,369,872.00","8,936,831.00","9,211,228.00","9,152,303.00","11,874,962.00","15,071,870.00"
MLA,Medical Australia Limited,Annual Profit and Loss - EBITDA, , , , , ,"-2,457,227.00","-2,262,214.00","-1,131,091.00","-1,461,873.00","-1,917,154.00","-980,584.00","-103,588.00","-388,790.00","-998,496.00","349,502.00","-531,591.00"
MLA,Medical Australia Limited,Annual Profit and Loss - EBIT, , , , , ,"-2,478,707.00","-2,308,852.00","-1,199,151.00","-1,512,761.00","-2,015,200.00","-1,118,147.00","-244,780.00","-662,261.00","-1,219,293.00","143,381.00","-726,711.00"
MLA,Medical Australia Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-2,393,196.00","-2,266,839.00","-1,183,669.00","-1,505,746.00","-2,190,381.00","-1,342,889.00","-342,723.00","-668,924.00","-1,316,146.00","73,613.00","-691,525.00"
MLA,Medical Australia Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
MLA,Medical Australia Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,-998.85%,-413.79%,-86.76%,-32.33%,-28.77%,-18.40%,-3.90%,-7.26%,-14.38%,1.09%,-1.20%
MLA,Medical Australia Limited,Annual Ratio Analysis - ROE, , , , , ,-87.34%,-208.02%,-209.11%,-39.35%,-57.41%,-43.88%,-7.83%,-13.50%,-36.49%,1.31%,-1.55%
MLA,Medical Australia Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,"4,419,114.51","6,346,555.54","5,377,034.52","9,088,218.30","8,854,208.51","4,723,350.58","10,599,253.73","5,447,109.98","8,170,664.98","16,844,726.42","10,667,750.42"
MMJ,MMJ Phytotech Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"4,904,186.00","3,593,879.00"
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,--
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"-4,930,478.00"
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"-4,930,478.00"
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-4,882,396.00"
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
MMJ,MMJ Phytotech Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,--
MMJ,MMJ Phytotech Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-181.14%
MMJ,MMJ Phytotech Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"14,291,856.00"
MSB,Mesoblast Limited,Annual Balance Sheet - Total Equity, , , , ,"20,812,400.00","19,150,467.00","11,965,045.00","20,539,339.00","26,216,132.00","25,789,962.00","37,919,260.00","515,844,173.00","478,847,783.00","630,266,000.00","571,718,000.00","609,359,000.00"
MSB,Mesoblast Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , ,--,--,"2,264,271.00","739,760.00",--,"186,295.00","5,500.00","116,272,649.00","27,808,207.00","24,184,000.00","27,529,000.00","39,283,000.00"
MSB,Mesoblast Limited,Annual Profit and Loss - EBITDA, , , , ,0.00,"-1,893,929.00","-8,702,398.00","-9,604,626.00","-10,815,427.00","-12,870,043.00","-15,367,396.00","-13,824,796.00","-58,815,686.00","-69,832,000.00","-87,574,000.00","-110,149,000.00"
MSB,Mesoblast Limited,Annual Profit and Loss - EBIT, , , , ,0.00,"-1,912,909.00","-8,745,982.00","-9,667,146.00","-10,972,186.00","-12,989,872.00","-15,520,681.00","-14,003,680.00","-59,194,224.00","-70,604,000.00","-88,694,000.00","-112,104,000.00"
MSB,Mesoblast Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , ,0.00,"-1,517,141.00","-8,298,587.00","-8,728,131.00","-10,062,379.00","-12,285,459.00","-14,780,895.00","90,606,590.00","-71,145,314.00","-61,663,000.00","-80,958,000.00","-119,368,000.00"
MSB,Mesoblast Limited,Annual Profit and Loss - Total Operating Income (ban, , , , ,--,--,--,--,--,--,--,--,--,--,--,--
MSB,Mesoblast Limited,Annual Ratio Analysis - Net Profit Margin, , , , ,--,--,"-29,945.82%","-1,199.69%",--,--,--,-37.33%,-257.00%,-337.69%,-508.58%,-582.77%
MSB,Mesoblast Limited,Annual Ratio Analysis - ROE, , , , ,0.00%,-7.92%,-69.36%,-42.49%,-38.38%,-47.64%,-38.98%,-2.13%,-14.86%,-9.78%,-14.60%,-19.59%
MSB,Mesoblast Limited,Annual Ratio Analysis - Market Cap.($), , , , ,0.00,"40,209,300.00","142,602,750.00","217,586,588.66","108,523,081.03","113,025,141.27","286,529,028.60","2,424,986,481.70","1,769,319,306.14","1,659,689,175.30","1,417,683,270.18","1,253,951,461.04"
MVF,Monash IVF Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"124,820,000.00","144,025,000.00"
MVF,Monash IVF Group Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,"114,012,000.00","124,955,000.00"
MVF,Monash IVF Group Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,"26,558,000.00","41,312,000.00"
MVF,Monash IVF Group Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,"23,667,000.00","37,895,000.00"
MVF,Monash IVF Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"4,852,000.00","21,373,000.00"
MVF,Monash IVF Group Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
MVF,Monash IVF Group Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,4.07%,19.56%
MVF,Monash IVF Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,3.72%,16.55%
MVF,Monash IVF Group Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,"407,858,122.08","301,306,160.64"
MVP,Medical Developments International Limited,Annual Balance Sheet - Total Equity, , , ,"7,502,000.00","8,374,000.00","8,400,000.00","9,872,000.00","11,021,000.00","11,801,000.00","11,814,000.00","12,712,000.00","14,455,000.00","16,169,000.00","15,744,000.00","15,824,000.00","17,407,000.00"
MVP,Medical Developments International Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , ,"5,475,000.00","3,059,000.00","5,411,000.00","6,612,000.00","7,467,000.00","9,269,000.00","8,827,000.00","8,346,000.00","10,329,000.00","11,494,000.00","11,774,000.00","9,395,000.00","11,751,000.00"
MVP,Medical Developments International Limited,Annual Profit and Loss - EBITDA, , , ,"347,000.00","1,094,000.00","1,092,000.00","1,554,000.00","2,018,000.00","1,598,000.00","1,531,000.00","1,617,000.00","2,740,000.00","3,864,000.00","3,372,000.00","1,093,000.00","2,629,000.00"
MVP,Medical Developments International Limited,Annual Profit and Loss - EBIT, , , ,0.00,"768,000.00","496,000.00","1,310,000.00","1,770,000.00","1,280,000.00","1,174,000.00","1,265,000.00","2,373,000.00","3,617,000.00","3,138,000.00","775,000.00","2,252,000.00"
MVP,Medical Developments International Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,0.00,"481,000.00","168,000.00","797,000.00","1,207,000.00","891,000.00","810,000.00","879,000.00","1,743,000.00","2,704,000.00","2,309,000.00","875,000.00","1,529,000.00"
MVP,Medical Developments International Limited,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
MVP,Medical Developments International Limited,Annual Ratio Analysis - Net Profit Margin, , , ,0.00%,15.78%,3.11%,12.07%,16.18%,9.66%,9.28%,10.60%,17.08%,23.90%,19.68%,9.34%,13.17%
MVP,Medical Developments International Limited,Annual Ratio Analysis - ROE, , , ,0.00%,5.74%,2.00%,8.07%,10.95%,7.55%,6.86%,6.91%,12.06%,16.72%,14.67%,5.53%,8.78%
MVP,Medical Developments International Limited,Annual Ratio Analysis - Market Cap.($), , , ,0.00,"50,142,400.00","47,863,200.00","17,378,900.00","33,048,400.00","19,115,987.96","7,190,071.14","11,041,894.96","20,799,848.66","43,994,654.44","72,924,292.81","76,197,188.76","154,703,383.24"
MX1,Micro-X Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"28,425,216.00"
MX1,Micro-X Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,--
MX1,Micro-X Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,0.00
MX1,Micro-X Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,0.00
MX1,Micro-X Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00
MX1,Micro-X Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
MX1,Micro-X Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
MX1,Micro-X Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
MX1,Micro-X Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
MXC,MGC Pharmaceuticals Ltd,Annual Balance Sheet - Total Equity, , , , , , ,"2,762,327.00","3,814,118.00","1,936,790.00","-8,790.00","-3,138,329.00","828,302.00","787,422.00","7,944,781.00","4,549,136.00","1,926,812.00"
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , ,--,"2,587,010.00","1,905,662.00","1,825,152.00","2,488,623.00","28,393.00","15,000.00",--,"4,255.00",--
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - EBITDA, , , , , , ,0.00,"-267,745.00","-1,603,267.00","-1,777,308.00","-2,429,998.00","-224,061.00","-328,941.00","-784,225.00","-5,224,125.00","-3,803,677.00"
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - EBIT, , , , , , ,0.00,"-308,229.00","-1,650,864.00","-1,812,776.00","-2,467,037.00","-224,061.00","-328,941.00","-792,557.00","-5,224,125.00","-3,803,677.00"
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,0.00,"-284,396.00","-1,886,078.00","-1,945,590.00","-3,180,089.00","1,935,168.00","-290,880.00","-766,897.00","-5,337,815.00","-3,797,791.00"
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - Total Operating Income (ban, , , , , , ,--,--,--,--,--,--,--,--,--,--
MXC,MGC Pharmaceuticals Ltd,Annual Ratio Analysis - Net Profit Margin, , , , , , ,--,--,--,-582.40%,-374.03%,--,--,--,--,--
MXC,MGC Pharmaceuticals Ltd,Annual Ratio Analysis - ROE, , , , , , ,0.00%,-7.46%,-97.38%,"22,108.98%",101.61%,-23.52%,-36.94%,-9.65%,-114.68%,-197.10%
MXC,MGC Pharmaceuticals Ltd,Annual Ratio Analysis - Market Cap.($), , , , , , ,0.00,"18,502,730.80","5,790,853.38","2,316,341.35","1,598,004.81","2,470,000.00","4,300,000.00","2,278,741.77","3,607,911.08","7,070,563.42"
MYX,Mayne Pharma Group Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"14,514,302.00","11,438,427.00","7,704,263.00","25,549,756.00","24,174,000.00","30,600,000.00","120,889,000.00","159,274,000.00","322,202,000.00"
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,--,--,"609,875.00","36,837,842.00","50,631,000.00","55,215,000.00","83,677,000.00","143,428,000.00","147,985,000.00"
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - EBITDA, , , , , , , ,"-1,959,116.00","-4,271,288.00","-4,528,531.00","8,488,986.00","8,800,000.00","11,187,000.00","17,591,000.00","39,217,000.00","35,435,000.00"
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - EBIT, , , , , , , ,"-1,964,087.00","-4,293,620.00","-4,555,023.00","1,878,773.00","1,049,000.00","5,599,000.00","10,261,000.00","29,358,000.00","21,933,000.00"
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-1,823,975.00","-3,472,806.00","-3,761,318.00","3,253,119.00","1,679,000.00","6,153,000.00","-2,843,000.00","21,290,000.00","7,537,000.00"
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
MYX,Mayne Pharma Group Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,--,--,--,9.18%,5.53%,8.16%,7.55%,13.03%,9.16%
MYX,Mayne Pharma Group Limited,Annual Ratio Analysis - ROE, , , , , , , ,-12.57%,-30.36%,-48.82%,12.73%,11.10%,13.58%,5.14%,11.63%,4.14%
MYX,Mayne Pharma Group Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,"45,659,400.00","28,917,620.00","13,697,820.00","82,980,072.00","78,924,924.00","53,253,565.40","242,071,284.25","498,653,755.45","774,953,213.04"
NAN,Nanosonics Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"31,317,211.00","24,559,000.00","16,312,000.00","23,582,000.00","14,306,000.00","26,003,000.00","21,707,000.00","20,435,000.00","44,676,000.00"
NAN,Nanosonics Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,"2,229,728.00","1,112,000.00","459,000.00","924,000.00","2,247,000.00","12,451,000.00","16,397,000.00","24,867,000.00","24,522,000.00"
NAN,Nanosonics Limited,Annual Profit and Loss - EBITDA, , , , , , , ,"-6,178,620.00","-8,849,000.00","-9,529,000.00","-8,188,000.00","-11,963,000.00","-4,982,000.00","-5,366,000.00","-1,845,000.00","-4,732,000.00"
NAN,Nanosonics Limited,Annual Profit and Loss - EBIT, , , , , , , ,"-6,338,883.00","-9,090,000.00","-9,948,000.00","-8,957,000.00","-12,973,000.00","-5,896,000.00","-6,410,000.00","-2,820,000.00","-5,703,000.00"
NAN,Nanosonics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-5,703,524.00","-7,147,000.00","-8,754,000.00","-8,172,000.00","-11,214,000.00","-4,679,000.00","-5,768,000.00","-2,605,000.00","-5,460,000.00"
NAN,Nanosonics Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
NAN,Nanosonics Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,"-67,705.65%",--,"-2,833.01%","-1,071.04%",-499.07%,-38.04%,-38.71%,-12.12%,-24.16%
NAN,Nanosonics Limited,Annual Ratio Analysis - ROE, , , , , , , ,-18.21%,-29.10%,-53.67%,-34.65%,-78.39%,-17.99%,-26.57%,-12.75%,-12.02%
NAN,Nanosonics Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,"125,335,911.74","39,016,724.60","78,513,178.80","119,649,106.96","176,325,297.52","132,591,288.18","158,503,174.39","208,420,822.54","480,948,513.00"
NEU,Neuren Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , ,--,--,"8,735,462.00","19,884,177.00","16,146,576.00","7,550,642.00","5,572,563.00","7,348,227.00","3,533,520.00","9,453,023.00","6,340,418.00","24,355,179.00","19,078,000.00","14,402,000.00"
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - Total Revenue Excluding Int, , ,"8,346,961.00","2,835,768.00","2,388,776.00","2,608,817.00","1,327,567.00","1,893,605.00","2,274,362.00","5,003,237.00","4,648,090.00","3,157,093.00","4,229,854.00","5,200,845.00","3,807,000.00","2,771,000.00"
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - EBITDA, , ,"-5,228,582.00","-5,325,050.00","-4,674,173.00","-8,048,757.00","-9,831,490.00","-11,445,305.00","-14,340,443.00","462,198.00","-4,626,831.00","-4,513,503.00","-5,029,346.00","-11,106,719.00","-8,777,000.00","-14,391,000.00"
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - EBIT, , ,"-5,753,577.00","-5,838,656.00","-5,703,341.00","-8,868,858.00","-10,617,867.00","-12,334,859.00","-15,462,149.00","-43,710.00","-5,028,471.00","-4,867,249.00","-5,391,021.00","-11,535,067.00","-8,877,000.00","-14,481,000.00"
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , ,"-5,458,093.00","-5,647,038.00","-5,694,111.00","-8,308,425.00","-10,115,905.00","-12,152,545.00","-15,419,489.00","-26,711.00","-4,990,509.00","-4,740,966.00","-5,190,355.00","-11,336,519.00","-8,316,000.00","-13,397,000.00"
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - Total Operating Income (ban, , ,--,--,--,--,--,--,--,--,--,--,--,--,--,--
NEU,Neuren Pharmaceuticals Limited,Annual Ratio Analysis - Net Profit Margin, , ,-257.29%,-199.14%,-375.47%,"-1,933.70%","-5,848.45%","-1,287.13%",-677.97%,1.99%,-105.28%,--,--,--,--,--
NEU,Neuren Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , ,--,--,-65.18%,-41.78%,-62.65%,-160.95%,-276.70%,1.33%,-136.92%,-48.96%,-78.56%,-46.01%,-42.99%,-93.02%
NEU,Neuren Pharmaceuticals Limited,Annual Ratio Analysis - Market Cap.($), , ,0.00,0.00,0.00,"51,201,908.75","52,437,524.00","26,053,020.00","2,574,643.13","13,033,155.69","6,796,236.83","31,208,328.00","41,397,529.95","173,940,830.74","195,028,971.12","203,205,429.87"
NRT,Novogen Limited,Annual Balance Sheet - Total Equity,"52,724,000.00","51,906,000.00","54,045,000.00","42,397,000.00","69,211,000.00","60,492,000.00","44,578,000.00","44,626,000.00","35,637,000.00","28,773,000.00","13,176,000.00","4,420,000.00","5,113,000.00","4,040,802.00","1,412,034.00","44,362,053.00"
NRT,Novogen Limited,Annual Profit and Loss - Total Revenue Excluding Int,"26,523,000.00","29,006,000.00","23,085,000.00","22,990,000.00","15,214,000.00","16,359,000.00","16,778,000.00","18,093,000.00","13,133,000.00","10,259,000.00","9,625,000.00","2,393,000.00","2,165,000.00","1,685,704.00","341,985.00","2,753,213.00"
NRT,Novogen Limited,Annual Profit and Loss - EBITDA,"-11,418,000.00","-18,040,000.00","-13,633,000.00","-9,919,000.00","-11,970,000.00","-11,916,000.00","-17,931,000.00","-25,229,000.00","-26,169,000.00","-24,381,000.00","-15,313,000.00","-10,988,000.00","-9,002,000.00","-1,099,250.00","-6,368,748.00","-6,751,721.00"
NRT,Novogen Limited,Annual Profit and Loss - EBIT,"-13,260,000.00","-20,337,000.00","-15,486,000.00","-11,807,000.00","-13,691,000.00","-13,542,000.00","-19,320,000.00","-26,205,000.00","-26,522,000.00","-24,663,000.00","-15,511,000.00","-11,071,000.00","-9,027,000.00","-1,421,122.00","-6,940,887.00","-7,326,685.00"
NRT,Novogen Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-13,679,000.00","-21,764,000.00","-14,673,000.00","-10,666,000.00","-12,579,000.00","-12,281,000.00","-17,913,000.00","-24,296,000.00","-24,777,000.00","-23,787,000.00","-15,246,000.00","-9,479,000.00","-1,350,000.00","-784,560.00","-7,568,725.00","-7,306,045.00"
NRT,Novogen Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
NRT,Novogen Limited,Annual Ratio Analysis - Net Profit Margin,0.00%,-72.11%,-74.83%,-53.26%,-85.97%,-83.03%,-120.15%,-159.66%,-212.48%,-227.06%,-154.60%,-464.16%,-523.49%,-164.38%,--,--
NRT,Novogen Limited,Annual Ratio Analysis - ROE,0.00%,-37.87%,-27.50%,-24.99%,-16.86%,-19.61%,-38.22%,-49.25%,-66.03%,-79.94%,-110.33%,-188.34%,-175.05%,-43.42%,-494.27%,-15.98%
NRT,Novogen Limited,Annual Ratio Analysis - Market Cap.($),"339,345,048.00","210,104,202.75","195,596,063.70","512,479,167.60","512,634,671.90","451,262,328.30","231,559,848.52","193,236,636.78","113,209,342.76","53,105,464.88","16,850,772.51","19,914,549.33","8,096,842.73","26,963,826.44","24,440,885.93","90,970,039.98"
NVL,National Veterinary Care Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"45,116,000.00", 
NVL,National Veterinary Care Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--, 
NVL,National Veterinary Care Ltd,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00, 
NVL,National Veterinary Care Ltd,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00, 
NVL,National Veterinary Care Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00, 
NVL,National Veterinary Care Ltd,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--, 
NVL,National Veterinary Care Ltd,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--, 
NVL,National Veterinary Care Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%, 
NVL,National Veterinary Care Ltd,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00, 
OBJ,OBJ Limited,Annual Balance Sheet - Total Equity,"8,982,432.00","3,318,172.00","357,867.00","-1,197,181.00","903,539.00","1,229,033.00","574,713.00","1,856,660.00","1,131,991.00","422,242.00","5,044,777.00","4,483,519.00","3,301,347.00","3,220,129.00","3,829,184.00","3,561,633.00"
OBJ,OBJ Limited,Annual Profit and Loss - Total Revenue Excluding Int,"6,949,754.00","4,759,552.00","5,165,792.00","3,324,926.00","1,211,841.00","10,168.00",--,"119,492.00","750,396.00","468,044.00","800,794.00","601,346.00","525,829.00","717,846.00","806,691.00","1,410,701.00"
OBJ,OBJ Limited,Annual Profit and Loss - EBITDA,"1,623,735.00","-5,547,611.00","-2,692,385.00","-1,358,104.00","-467,229.00","-1,251,890.00","-1,462,216.00","-1,489,690.00","-1,036,803.00","-1,761,272.00","-1,087,223.00","-1,149,164.00","-1,582,855.00","-1,399,003.00","-2,296,340.00","-2,420,966.00"
OBJ,OBJ Limited,Annual Profit and Loss - EBIT,"1,488,549.00","-5,809,954.00","-2,979,593.00","-1,557,723.00","-467,229.00","-1,276,302.00","-1,476,988.00","-1,505,183.00","-1,051,010.00","-1,773,377.00","-1,095,899.00","-1,166,957.00","-1,605,305.00","-1,425,421.00","-2,320,372.00","-2,458,436.00"
OBJ,OBJ Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"1,473,000.00","-5,664,345.00","-2,960,305.00","-1,555,048.00","721,109.00","-1,234,506.00","-1,433,090.00","-1,396,511.00","-925,519.00","-1,732,579.00","-954,931.00","-897,529.00","-1,411,442.00","-1,331,572.00","-2,205,354.00","-2,353,454.00"
OBJ,OBJ Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
OBJ,OBJ Limited,Annual Ratio Analysis - Net Profit Margin,22.34%,--,-71.11%,-77.30%,--,--,--,"-1,168.71%",-123.34%,-426.39%,-123.31%,-149.25%,-271.91%,-197.81%,-273.38%,-168.75%
OBJ,OBJ Limited,Annual Ratio Analysis - ROE,16.40%,-170.71%,-827.21%,129.89%,-11.04%,-100.45%,-249.36%,-75.22%,-81.76%,-410.33%,-18.93%,-20.02%,-42.75%,-41.35%,-57.59%,-66.08%
OBJ,OBJ Limited,Annual Ratio Analysis - Market Cap.($),"90,000,000.00","21,600,000.00","2,880,000.00","1,080,000.00","2,280,000.00","8,606,000.00","17,808,750.00","24,256,775.00","6,407,450.00","3,031,098.49","24,711,955.14","24,240,537.99","17,339,347.92","12,485,719.62","120,864,339.52","80,898,844.96"
OCC,Orthocell Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"7,904,118.00","76,188.00","4,383,790.00"
OCC,Orthocell Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , ,--,"1,799,729.00","1,566,939.00"
OCC,Orthocell Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , ,0.00,"-2,159,465.00","-4,964,550.00"
OCC,Orthocell Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , ,0.00,"-2,197,295.00","-5,023,905.00"
OCC,Orthocell Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"-2,182,185.00","-3,742,715.00"
OCC,Orthocell Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , ,--,--,--
OCC,Orthocell Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , ,--,-315.62%,-473.50%
OCC,Orthocell Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,"-5,728.42%",-85.38%
OCC,Orthocell Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , ,0.00,0.00,"26,400,000.00"
OHE,Orion Health Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"27,372,666.00","110,624,816.00"
OHE,Orion Health Group Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"165,931,338.00"
OHE,Orion Health Group Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"-45,766,552.00"
OHE,Orion Health Group Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"-51,012,260.00"
OHE,Orion Health Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-59,651,790.00"
OHE,Orion Health Group Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
OHE,Orion Health Group Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,-37.07%
OHE,Orion Health Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-53.92%
OHE,Orion Health Group Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"740,773,940.90"
OIL,Optiscan Imaging Limited,Annual Balance Sheet - Total Equity,"17,493,537.00","13,181,519.00","19,597,066.00","16,183,369.00","12,899,916.00","13,381,323.00","10,313,494.00","9,933,167.00","7,703,514.00","1,757,167.00","1,300,262.00","1,342,714.00","313,310.00","952,456.00","-184,662.00","-175,211.00"
OIL,Optiscan Imaging Limited,Annual Profit and Loss - Total Revenue Excluding Int,"2,430,599.00","1,231,994.00","6,637,951.00","7,502,651.00","3,859,306.00","2,328,726.00","5,163,118.00","9,107,401.00","3,614,426.00","3,767,132.00","2,252,335.00","2,418,121.00","839,650.00","2,818,341.00","931,461.00","1,036,309.00"
OIL,Optiscan Imaging Limited,Annual Profit and Loss - EBITDA,"-2,070,155.00","-4,141,264.00","-863,536.00","-1,105,737.00","-2,643,041.00","-4,805,441.00","-4,001,767.00","-2,098,049.00","-4,821,725.00","-2,844,040.00","-1,293,137.00","61,091.00","-2,518,209.00","-631,774.00","-1,404,749.00","-1,277,768.00"
OIL,Optiscan Imaging Limited,Annual Profit and Loss - EBIT,"-2,981,726.00","-5,214,304.00","-2,072,484.00","-2,619,078.00","-3,821,845.00","-5,834,933.00","-4,294,947.00","-2,403,939.00","-5,225,001.00","-3,322,687.00","-1,658,081.00","-22,413.00","-2,544,321.00","-662,115.00","-1,421,551.00","-1,289,912.00"
OIL,Optiscan Imaging Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-2,670,634.00","-4,689,847.00","-2,504,145.00","-3,426,015.00","-3,362,577.00","-5,830,434.00","-3,936,760.00","-2,139,481.00","-4,984,340.00","-6,413,370.00","-1,650,799.00","14,405.00","-2,502,450.00","-643,950.00","-1,417,712.00","-1,395,399.00"
OIL,Optiscan Imaging Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
OIL,Optiscan Imaging Limited,Annual Ratio Analysis - Net Profit Margin,-341.41%,"-3,412.63%",-615.43%,"-2,531.40%",-134.62%,-489.05%,-121.81%,-37.49%,-270.79%,-113.92%,-133.80%,0.81%,-655.45%,-49.41%,"-1,972.25%","-3,027.42%"
OIL,Optiscan Imaging Limited,Annual Ratio Analysis - ROE,-15.27%,-35.58%,-12.78%,-16.30%,-25.41%,-40.28%,-38.17%,-21.54%,-64.70%,-187.20%,-126.96%,1.07%,-798.71%,-67.61%,767.73%,796.41%
OIL,Optiscan Imaging Limited,Annual Ratio Analysis - Market Cap.($),"110,535,249.60","80,389,244.86","48,691,274.82","33,925,668.35","28,879,460.28","31,545,540.50","48,076,595.04","48,818,408.38","27,089,992.78","4,806,574.77","6,743,387.61","8,195,404.77","12,962,512.62","11,346,167.91","4,849,539.53","9,730,052.28"
ONE,Oneview Healthcare Plc,Annual Balance Sheet - Total Equity,"944,800,000.00", , , , , , , , , , , , , , ,"47,400,000.00"
ONE,Oneview Healthcare Plc,Annual Profit and Loss - Total Revenue Excluding Int,"661,300,000.00", , , , , , , , , , , , , , ,--
ONE,Oneview Healthcare Plc,Annual Profit and Loss - EBITDA,"-234,300,000.00", , , , , , , , , , , , , , ,0.00
ONE,Oneview Healthcare Plc,Annual Profit and Loss - EBIT,"-269,600,000.00", , , , , , , , , , , , , , ,0.00
ONE,Oneview Healthcare Plc,Annual Profit and Loss - Reported NPAT After Abnorma,"-291,100,000.00", , , , , , , , , , , , , , ,0.00
ONE,Oneview Healthcare Plc,Annual Profit and Loss - Total Operating Income (ban,--, , , , , , , , , , , , , , ,--
ONE,Oneview Healthcare Plc,Annual Ratio Analysis - Net Profit Margin,-39.42%, , , , , , , , , , , , , , ,--
ONE,Oneview Healthcare Plc,Annual Ratio Analysis - ROE,-27.27%, , , , , , , , , , , , , , ,0.00%
ONE,Oneview Healthcare Plc,Annual Ratio Analysis - Market Cap.($),"2,880,778,233.30", , , , , , , , , , , , , , ,0.00
ONT,1300 Smiles Limited,Annual Balance Sheet - Total Equity, , , , , ,"2,842,777.00","5,481,560.00","5,917,967.00","6,781,545.00","9,208,000.00","13,013,000.00","15,690,000.00","26,013,000.00","27,952,000.00","29,219,000.00","31,800,000.00"
ONT,1300 Smiles Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,"5,343,425.00","6,045,444.00","8,114,695.00","15,134,554.00","22,343,000.00","23,768,000.00","28,330,000.00","35,852,000.00","35,610,000.00","31,395,000.00","36,403,000.00"
ONT,1300 Smiles Limited,Annual Profit and Loss - EBITDA, , , , , ,"2,184,933.00","2,672,225.00","2,528,841.00","3,944,958.00","6,410,000.00","7,218,000.00","8,517,000.00","10,216,000.00","10,589,000.00","9,295,000.00","11,970,000.00"
ONT,1300 Smiles Limited,Annual Profit and Loss - EBIT, , , , , ,"2,072,325.00","2,515,573.00","2,284,657.00","3,341,225.00","5,453,000.00","6,203,000.00","7,215,000.00","8,443,000.00","8,469,000.00","7,017,000.00","9,253,000.00"
ONT,1300 Smiles Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"1,501,920.00","1,857,818.00","1,800,435.00","2,347,961.00","3,810,000.00","4,327,000.00","5,144,000.00","6,175,000.00","6,367,000.00","4,987,000.00","6,580,000.00"
ONT,1300 Smiles Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
ONT,1300 Smiles Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,28.11%,--,41.54%,15.54%,17.37%,18.70%,18.75%,17.27%,17.88%,15.97%,18.10%
ONT,1300 Smiles Limited,Annual Ratio Analysis - ROE, , , , , ,52.83%,33.89%,30.42%,34.62%,41.38%,33.25%,32.79%,23.74%,22.78%,17.07%,20.69%
ONT,1300 Smiles Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,"20,745,158.50","42,124,393.50","61,782,443.80","52,154,011.00","52,885,320.80","66,526,765.20","76,492,489.00","141,833,520.16","140,412,817.12","141,123,168.64","163,380,849.60"
OPT,Opthea Limited,Annual Balance Sheet - Total Equity,"25,122,180.00","47,424,163.00","41,348,205.00","36,382,174.00","41,695,543.00","37,545,530.00","56,690,576.00","60,965,707.00","51,407,413.00","38,773,219.00","31,820,094.00","21,824,173.00","20,196,855.00","14,358,946.00","10,479,256.00","21,721,612.00"
OPT,Opthea Limited,Annual Profit and Loss - Total Revenue Excluding Int,"2,124,399.00","65,589.00","843,109.00","17,500.00","7,646,836.00","75,836,056.00","67,894.00","28,233,475.00","5,034,561.00","782,726.00","3,546,727.00","461,428.00","763,999.00","1,089,692.00","1,000,666.00","840,101.00"
OPT,Opthea Limited,Annual Profit and Loss - EBITDA,"-1,769,576.00","-3,110,754.00","-2,645,470.00","-4,446,730.00","4,946,485.00","20,554,881.00","-7,163,822.00","-17,678,223.00","-4,350,283.00","-12,150,452.00","-11,279,667.00","-12,403,510.00","-8,255,509.00","-7,066,161.00","-7,085,731.00","-8,505,841.00"
OPT,Opthea Limited,Annual Profit and Loss - EBIT,"-1,798,070.00","-3,135,780.00","-2,674,883.00","-4,475,825.00","4,919,893.00","20,502,424.00","-7,177,511.00","-17,703,638.00","-4,381,617.00","-12,184,520.00","-11,308,256.00","-12,431,595.00","-8,284,088.00","-7,093,501.00","-7,123,952.00","-8,544,403.00"
OPT,Opthea Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"1,223,376.00","-1,623,000.00","-5,743,579.00","-3,506,768.00","5,802,611.00","21,764,179.00","-6,515,401.00","6,295,707.00","-2,286,119.00","-9,921,670.00","-6,948,240.00","-10,265,346.00","-4,906,456.00","-5,004,506.00","-3,989,618.00","-5,400,994.00"
OPT,Opthea Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
OPT,Opthea Limited,Annual Ratio Analysis - Net Profit Margin,--,--,--,--,"33,157.78%","124,398.25%",--,"-73,050.41%","-7,652.03%",--,--,--,--,--,--,--
OPT,Opthea Limited,Annual Ratio Analysis - ROE,-4.98%,-3.34%,-3.99%,-9.64%,13.92%,58.20%,-11.44%,-29.50%,-2.42%,-25.59%,-30.76%,-47.04%,-25.58%,-35.35%,-41.91%,-25.41%
OPT,Opthea Limited,Annual Ratio Analysis - Market Cap.($),"160,031,121.43","115,393,600.00","67,302,077.34","62,516,982.35","79,426,706.04","47,146,285.15","42,531,967.88","51,760,602.42","35,309,558.24","33,026,607.44","22,620,964.00","26,910,218.24","16,968,574.70","11,428,758.52","9,240,272.85","27,396,706.06"
OSL,Oncosil Medical Limited,Annual Balance Sheet - Total Equity, , , , , ,"899,564.00","5,457,397.00","4,679,676.00","4,087,090.00","4,282,053.00","2,577,727.00","2,913,145.00","2,482,775.00","6,050,566.00","12,160,130.00","6,961,449.00"
OSL,Oncosil Medical Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,--,"1,566,935.00","2,097,109.00","2,063,868.00","2,302,907.00","2,087,124.00","9,137.00","24,179.00","6,401.00","110,534.00","2,649,312.00"
OSL,Oncosil Medical Limited,Annual Profit and Loss - EBITDA, , , , , ,"-33,906.00","-206,443.00","-1,663,585.00","-2,819,901.00","-615,778.00","-2,119,582.00","-751,875.00","-570,235.00","-977,231.00","-4,723,436.00","-3,024,535.00"
OSL,Oncosil Medical Limited,Annual Profit and Loss - EBIT, , , , , ,"-33,982.00","-231,733.00","-1,766,928.00","-3,104,414.00","-948,583.00","-2,180,892.00","-751,875.00","-570,406.00","-979,431.00","-4,726,417.00","-3,031,244.00"
OSL,Oncosil Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-26,420.00","-128,266.00","-1,674,138.00","-2,767,299.00","-440,178.00","-1,712,021.00","-1,458,019.00","-430,970.00","-879,168.00","-4,217,103.00","-2,879,031.00"
OSL,Oncosil Medical Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
OSL,Oncosil Medical Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,--,-8.48%,-95.21%,-136.05%,-19.11%,-82.03%,--,--,--,--,--
OSL,Oncosil Medical Limited,Annual Ratio Analysis - ROE, , , , , ,-2.94%,-2.35%,-35.77%,-67.71%,-10.28%,-66.42%,-21.91%,-17.36%,-14.53%,-34.68%,-41.36%
OSL,Oncosil Medical Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,0.00,"6,329,333.44","7,966,500.12","5,173,756.56","2,126,988.81","2,069,502.59","3,879,170.96","2,133,764.03","10,405,538.78","35,514,812.20","35,616,245.10"
OSP,Osprey Medical Inc.,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,"14,597,019.00","22,421,438.00","13,543,126.00","15,934,712.00"
OSP,Osprey Medical Inc.,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , ,"15,369.00","21,127.00","43,421.00","323,495.00"
OSP,Osprey Medical Inc.,Annual Profit and Loss - EBITDA, , , , , , , , , , , , ,"-5,241,752.00","-9,533,110.00","-11,700,709.00","-16,465,847.00"
OSP,Osprey Medical Inc.,Annual Profit and Loss - EBIT, , , , , , , , , , , , ,"-5,280,633.00","-9,639,823.00","-11,853,907.00","-16,647,246.00"
OSP,Osprey Medical Inc.,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,"-5,878,507.00","-9,620,668.00","-11,854,602.00","-16,648,039.00"
OSP,Osprey Medical Inc.,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , ,--,--,--,--
OSP,Osprey Medical Inc.,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , ,--,--,"-125,947.47%","-7,027.01%"
OSP,Osprey Medical Inc.,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,-40.27%,-42.91%,-87.53%,-104.48%
OSP,Osprey Medical Inc.,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , ,"42,390,790.68","83,787,441.68","66,537,086.04","46,250,347.80"
OVN,Oventus Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"14,686,027.00"
OVN,Oventus Medical Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,--
OVN,Oventus Medical Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,0.00
OVN,Oventus Medical Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,0.00
OVN,Oventus Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00
OVN,Oventus Medical Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
OVN,Oventus Medical Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
OVN,Oventus Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
OVN,Oventus Medical Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
PAA,PharmAust Limited,Annual Balance Sheet - Total Equity, ,"4,010,108.00","3,469,794.00","1,814,000.00","741,022.00","3,868,393.00","7,686,448.00","7,835,162.00","5,914,246.00","5,856,611.00","5,807,239.00","1,147,860.00","1,212,760.00","310,877.00","7,764,157.00","8,839,066.00"
PAA,PharmAust Limited,Annual Profit and Loss - Total Revenue Excluding Int, ,--,"863,702.00","147,073.00","347,531.00","3,233,308.00","6,849,680.00","8,156,140.00","2,914,586.00","3,571,749.00","1,763,115.00","1,562,118.00","1,617,814.00","1,710,255.00","1,939,390.00","2,371,326.00"
PAA,PharmAust Limited,Annual Profit and Loss - EBITDA, ,"-2,009,243.00","-2,979,599.00","-1,150,157.00","-2,361,455.00","-2,008,700.00","-2,753,604.00","-2,963,517.00","-3,706,689.00","-1,828,958.00","-449,308.00","-5,762,319.00","-4,169,696.00","-567,502.00","-1,329,518.00","-1,893,084.00"
PAA,PharmAust Limited,Annual Profit and Loss - EBIT, ,"-2,259,916.00","-3,717,443.00","-1,974,155.00","-2,569,189.00","-2,107,827.00","-3,172,846.00","-3,492,189.00","-4,002,981.00","-1,887,690.00","-511,492.00","-5,827,497.00","-4,227,550.00","-616,210.00","-1,382,883.00","-1,970,230.00"
PAA,PharmAust Limited,Annual Profit and Loss - Reported NPAT After Abnorma, ,"-2,094,482.00","-3,705,897.00","-2,073,134.00","-2,584,719.00","-3,363,712.00","-2,752,284.00","-3,606,048.00","-5,767,973.00","-179,596.00","-438,600.00","-5,797,886.00","-4,260,420.00","-514,883.00","-1,317,853.00","-1,925,091.00"
PAA,PharmAust Limited,Annual Profit and Loss - Total Operating Income (ban, ,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
PAA,PharmAust Limited,Annual Ratio Analysis - Net Profit Margin, ,--,-545.95%,-666.29%,-727.69%,-64.55%,-52.45%,-78.64%,-145.57%,-106.59%,-26.73%,-373.46%,-263.34%,-37.37%,-70.07%,-102.99%
PAA,PharmAust Limited,Annual Ratio Analysis - ROE, ,-52.23%,-106.80%,-114.29%,-386.70%,-53.95%,-41.66%,-46.02%,-68.78%,-31.95%,-7.55%,-505.10%,-351.30%,-205.60%,-16.97%,-21.78%
PAA,PharmAust Limited,Annual Ratio Analysis - Market Cap.($), ,0.00,"7,320,609.17","1,752,816.74","4,819,998.42","11,588,340.19","11,914,551.46","8,166,421.79","5,207,573.32","5,094,157.56","20,886,112.33","9,190,533.17","2,895,039.64","4,940,052.85","15,840,072.67","12,880,046.24"
PAB,Patrys Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"818,810.00","22,975,675.00","17,717,576.00","15,232,766.00","13,465,487.00","12,445,818.00","10,772,602.00","12,434,269.00","3,970,340.00"
PAB,Patrys Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,--,--,"2,052,703.00","1,110,922.00","711,146.00","863,717.00","952,786.00","582,595.00","2,473,727.00"
PAB,Patrys Limited,Annual Profit and Loss - EBITDA, , , , , , , ,0.00,"-8,098,350.00","-8,570,019.00","-6,842,752.00","-6,530,867.00","-3,523,113.00","-3,098,347.00","-6,913,217.00","-2,630,827.00"
PAB,Patrys Limited,Annual Profit and Loss - EBIT, , , , , , , ,0.00,"-8,409,425.00","-9,227,577.00","-7,928,544.00","-7,539,944.00","-5,306,338.00","-3,745,472.00","-7,458,017.00","-3,234,403.00"
PAB,Patrys Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,0.00,"-7,323,602.00","-8,662,339.00","-7,535,123.00","-7,421,670.00","-5,108,891.00","-3,529,095.00","-7,289,090.00","-8,470,382.00"
PAB,Patrys Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
PAB,Patrys Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,--,--,"-231,923.40%","-161,906.38%","-97,666.40%","-105,316.24%","-133,526.11%",--,--
PAB,Patrys Limited,Annual Ratio Analysis - ROE, , , , , , , ,0.00%,-31.88%,-48.89%,-49.47%,-55.12%,-41.05%,-32.76%,-58.62%,-78.38%
PAB,Patrys Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,0.00,"45,855,442.50","21,339,691.75","18,626,737.10","22,429,250.82","9,099,467.89","11,161,967.89","20,911,829.58","6,269,273.87"
PAR,Paradigm Biopharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"14,464,259.00"
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,--
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,0.00
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,0.00
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
PAR,Paradigm Biopharmaceuticals Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
PAR,Paradigm Biopharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
PAR,Paradigm Biopharmaceuticals Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
PBP,Probiotec Limited,Annual Balance Sheet - Total Equity, , , , , , ,"30,535,000.00","38,022,400.00","44,079,844.00","52,284,179.00","73,453,476.00","61,315,353.00","62,474,150.00","63,519,089.00","64,320,407.00","39,631,155.00"
PBP,Probiotec Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , ,--,"54,320,543.00","66,144,816.00","87,177,035.00","80,532,975.00","72,263,482.00","69,632,095.00","68,233,927.00","72,810,952.00","65,838,821.00"
PBP,Probiotec Limited,Annual Profit and Loss - EBITDA, , , , , , ,0.00,"9,723,445.00","12,716,556.00","16,908,131.00","14,928,526.00","12,820,577.00","7,954,696.00","6,693,635.00","6,596,123.00","2,263,431.00"
PBP,Probiotec Limited,Annual Profit and Loss - EBIT, , , , , , ,0.00,"7,617,879.00","10,336,297.00","14,067,135.00","11,842,871.00","8,929,977.00","4,130,437.00","3,132,761.00","2,122,485.00","-2,087,343.00"
PBP,Probiotec Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,0.00,"4,977,524.00","6,309,098.00","8,900,922.00","9,480,874.00","-10,337,787.00","1,249,380.00","596,869.00","903,668.00","-24,742,302.00"
PBP,Probiotec Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , ,--,--,--,--,--,--,--,--,--,--
PBP,Probiotec Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , ,--,9.22%,9.54%,10.21%,12.63%,8.94%,3.38%,2.19%,1.39%,-4.10%
PBP,Probiotec Limited,Annual Ratio Analysis - ROE, , , , , , ,0.00%,13.09%,14.31%,17.02%,12.91%,10.47%,3.57%,2.32%,1.47%,-6.79%
PBP,Probiotec Limited,Annual Ratio Analysis - Market Cap.($), , , , , , ,0.00,"55,830,000.00","62,913,306.15","98,891,580.90","69,140,656.37","18,789,921.38","14,026,279.34","14,820,219.68","21,965,682.74","10,850,517.98"
PBT,Prana Biotechnology Limited,Annual Balance Sheet - Total Equity,"20,729,307.00","21,392,877.00","16,668,986.00","15,823,703.00","38,702,559.00","19,594,176.00","8,729,350.00","5,612,195.00","9,866,327.00","3,749,816.00","5,229,316.00","6,931,202.00","5,623,447.00","13,974,713.00","37,686,287.00","39,113,264.00"
PBT,Prana Biotechnology Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,"226,000.00","567,250.00","1,704,792.00","2,109,900.00","1,760,978.00","1,273,740.00","607,978.00",170.00,--,--,"6,785.00","2,419,949.00","4,488,526.00","7,845,396.00","11,125,209.00"
PBT,Prana Biotechnology Limited,Annual Profit and Loss - EBITDA,"-749,781.00","-3,288,503.00","-4,514,592.00","-3,510,551.00","-8,901,935.00","-24,735,505.00","-11,601,113.00","-11,590,888.00","-14,026,272.00","-7,918,638.00","-5,086,640.00","-6,551,985.00","-5,394,968.00","-7,897,303.00","-13,640,652.00","-6,030,324.00"
PBT,Prana Biotechnology Limited,Annual Profit and Loss - EBIT,"-1,404,758.00","-4,429,161.00","-5,675,187.00","-4,696,524.00","-10,096,941.00","-25,900,732.00","-11,719,309.00","-11,649,470.00","-14,051,621.00","-7,950,982.00","-5,121,930.00","-6,583,562.00","-5,414,589.00","-7,920,433.00","-13,663,036.00","-6,061,911.00"
PBT,Prana Biotechnology Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,326,000.00","-4,138,979.00","-5,448,467.00","-4,584,838.00","-9,885,614.00","-25,008,597.00","-11,719,309.00","-11,142,320.00","-13,560,678.00","-7,522,789.00","-4,906,922.00","-6,431,185.00","-5,239,469.00","-7,787,242.00","-13,329,239.00","-5,885,069.00"
PBT,Prana Biotechnology Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
PBT,Prana Biotechnology Limited,Annual Ratio Analysis - Net Profit Margin,--,"-1,831.41%",-960.51%,"-1,926,402.52%",--,"-397,845.96%","-1,115.82%",--,"-7,976,869.41%",--,--,--,--,--,--,--
PBT,Prana Biotechnology Limited,Annual Ratio Analysis - ROE,-6.40%,-19.35%,-32.69%,-28.97%,-25.54%,-127.63%,-134.25%,-198.54%,-137.44%,-200.62%,-93.83%,-92.79%,-93.17%,-55.72%,-35.37%,-15.05%
PBT,Prana Biotechnology Limited,Annual Ratio Analysis - Market Cap.($),"20,202,000.00","61,841,087.28","126,017,412.50","37,064,889.68","77,709,534.60","19,734,485.30","23,706,688.10","53,031,292.30","84,756,100.80","25,338,809.12","36,277,110.00","53,680,922.68","43,207,218.61","93,494,554.37","107,502,331.20","80,083,720.50"
PGC,Paragon Care Limited,Annual Balance Sheet - Total Equity,"4,263,223.00","6,336,447.00","2,166,776.00","126,763.00","579,944.00","1,943,895.00","2,080,039.00","1,182,894.00","559,847.00","3,103,302.00","3,348,625.00","5,054,878.00","6,446,067.00","10,369,476.00","18,208,265.00","20,583,582.00"
PGC,Paragon Care Limited,Annual Profit and Loss - Total Revenue Excluding Int,"2,651,521.00","34,092,229.00","33,495,352.00","455,634.00","22,770.00","256,074.00","893,163.00","367,595.00","131,633.00","1,114,568.00","9,405,009.00","16,333,263.00","15,723,928.00","17,085,975.00","19,378,728.00","32,198,600.00"
PGC,Paragon Care Limited,Annual Profit and Loss - EBITDA,"-3,467,566.00","-6,256,243.00","-4,341,048.00","-4,192,477.00","-550,021.00","-1,613,329.00","-1,315,641.00","-1,631,503.00","-1,826,436.00","-316,165.00","383,252.00","1,371,272.00","375,431.00","1,475,848.00","2,122,802.00","3,709,502.00"
PGC,Paragon Care Limited,Annual Profit and Loss - EBIT,"-4,143,372.00","-8,244,434.00","-4,869,813.00","-4,331,930.00","-550,021.00","-1,691,220.00","-1,405,030.00","-1,710,952.00","-1,865,786.00","-320,497.00","298,714.00","1,238,617.00","117,069.00","1,219,157.00","1,870,929.00","3,361,910.00"
PGC,Paragon Care Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-3,943,682.00","-8,209,438.00","-5,224,782.00","-1,789,384.00","-529,525.00","-1,645,578.00","-1,401,723.00","-1,716,555.00","-1,811,737.00","-355,832.00","147,782.00","851,183.00","-77,484.00","739,603.00","1,084,891.00","2,103,156.00"
PGC,Paragon Care Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
PGC,Paragon Care Limited,Annual Ratio Analysis - Net Profit Margin,-153.81%,-20.03%,7.16%,--,--,-659.33%,-200.50%,-590.26%,--,-32.34%,1.78%,5.81%,-2.07%,4.33%,7.67%,6.53%
PGC,Paragon Care Limited,Annual Ratio Analysis - ROE,-92.50%,429.62%,185.39%,"-2,602.26%",-91.31%,-84.65%,-67.39%,-145.11%,-323.61%,-11.47%,4.41%,16.84%,-5.04%,7.13%,8.16%,10.22%
PGC,Paragon Care Limited,Annual Ratio Analysis - Market Cap.($),"19,320,086.78","3,875,017.34","2,132,443.00","1,365,012.66","4,804,814.16","5,657,164.58","6,003,994.78","1,579,003.11","2,552,107.44","4,872,574.81","6,225,458.85","10,070,052.16","6,296,918.94","13,209,095.86","16,946,681.18","39,859,468.98"
PHG,Pulse Health Limited,Annual Balance Sheet - Total Equity, , , ,"2,780,951.00","2,627,589.00","787,556.00","221,570.00","1,161,933.00","11,305,959.00","4,787,403.00","10,571,000.00","11,005,000.00","19,610,000.00","22,285,000.00","52,074,000.00","53,448,000.00"
PHG,Pulse Health Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , ,441.00,"16,583.00","98,108.00",--,--,"23,956,212.00","31,114,383.00","34,520,000.00","37,367,000.00","39,363,000.00","52,005,000.00","52,255,000.00","57,435,000.00"
PHG,Pulse Health Limited,Annual Profit and Loss - EBITDA, , , ,"-121,600.00","-1,173,189.00","-2,136,775.00","-658,370.00","-1,243,496.00","-916,007.00","1,271,871.00","1,366,000.00","3,331,000.00","3,911,000.00","8,162,000.00","4,680,000.00","6,545,000.00"
PHG,Pulse Health Limited,Annual Profit and Loss - EBIT, , , ,"-121,600.00","-1,173,382.00","-2,140,129.00","-661,730.00","-1,248,588.00","-1,039,163.00","594,595.00","273,000.00","2,356,000.00","2,946,000.00","7,408,000.00","3,920,000.00","5,545,000.00"
PHG,Pulse Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-121,600.00","-1,281,323.00","-2,140,033.00","-631,886.00","-1,295,743.00","-1,121,808.00","-6,160,482.00","-1,311,000.00","385,000.00","697,000.00","2,734,000.00","875,000.00","2,547,000.00"
PHG,Pulse Health Limited,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
PHG,Pulse Health Limited,Annual Ratio Analysis - Net Profit Margin, , , ,"-27,573.70%","-6,863.49%","-2,181.30%",--,--,-4.68%,-9.45%,-2.70%,--,1.86%,--,4.42%,6.97%
PHG,Pulse Health Limited,Annual Ratio Analysis - ROE, , , ,-4.37%,-43.32%,-271.73%,-285.19%,-111.52%,-9.92%,-61.44%,-8.81%,6.92%,3.74%,18.67%,4.43%,7.32%
PHG,Pulse Health Limited,Annual Ratio Analysis - Market Cap.($), , , ,0.00,"2,574,900.07","1,463,458.32","7,029,375.15","10,505,250.18","11,058,543.20","13,546,715.42","10,597,995.28","10,877,058.28","22,841,827.34","34,160,805.22","89,308,866.06","93,606,085.14"
PIQ,Proteomics International Laboratories Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"4,940,699.00","1,805,285.00"
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"966,439.00"
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"-1,080,492.00"
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"-1,082,909.00"
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-1,149,202.00"
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
PIQ,Proteomics International Laboratories Ltd,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,-188.89%
PIQ,Proteomics International Laboratories Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-63.66%
PIQ,Proteomics International Laboratories Ltd,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"17,451,070.14"
PME,Pro Medicus Limited,Annual Balance Sheet - Total Equity,"3,304,000.00","5,140,000.00","7,452,000.00","10,748,000.00","11,075,000.00","12,818,000.00","13,206,000.00","14,257,000.00","15,744,000.00","16,143,000.00","16,825,000.00","15,198,000.00","16,002,000.00","20,959,000.00","20,707,000.00","21,938,000.00"
PME,Pro Medicus Limited,Annual Profit and Loss - Total Revenue Excluding Int,"8,905,000.00","9,994,000.00","10,156,000.00","9,100,000.00","7,912,000.00","10,274,000.00","11,419,000.00","12,548,000.00","14,701,000.00","16,355,000.00","19,599,000.00","13,969,000.00","12,125,000.00","12,874,000.00","15,956,000.00","19,524,000.00"
PME,Pro Medicus Limited,Annual Profit and Loss - EBITDA,"5,171,000.00","6,151,000.00","6,627,000.00","6,148,000.00","4,608,000.00","7,246,000.00","8,131,000.00","9,168,000.00","11,147,000.00","8,505,000.00","8,116,000.00","3,597,000.00","3,889,000.00","-2,174,000.00","5,539,000.00","8,141,000.00"
PME,Pro Medicus Limited,Annual Profit and Loss - EBIT,"4,986,000.00","6,000,000.00","6,510,000.00","6,049,000.00","4,529,000.00","7,160,000.00","8,049,000.00","9,081,000.00","10,620,000.00","7,238,000.00","5,435,000.00","599,000.00","953,000.00","-5,122,000.00","2,273,000.00","5,025,000.00"
PME,Pro Medicus Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"3,291,000.00","4,086,000.00","4,812,000.00","4,546,000.00","3,577,000.00","5,493,000.00","6,115,000.00","7,052,000.00","7,933,000.00","5,683,000.00","3,920,000.00","503,000.00","1,791,000.00","5,131,000.00","1,509,000.00","3,217,000.00"
PME,Pro Medicus Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
PME,Pro Medicus Limited,Annual Ratio Analysis - Net Profit Margin,36.96%,40.91%,66.30%,49.96%,45.28%,53.45%,54.12%,56.24%,86.63%,57.17%,20.42%,3.60%,6.72%,-31.17%,10.59%,18.42%
PME,Pro Medicus Limited,Annual Ratio Analysis - ROE,99.61%,79.49%,64.57%,42.30%,32.30%,42.85%,46.30%,49.46%,50.39%,35.20%,23.30%,3.31%,4.72%,-16.59%,7.29%,14.66%
PME,Pro Medicus Limited,Annual Ratio Analysis - Market Cap.($),0.00,"95,000,000.00","81,000,000.00","84,000,000.00","61,000,000.00","97,000,000.00","135,027,000.00","135,027,000.00","115,322,000.00","69,193,200.00","45,627,400.00","17,549,000.00","30,079,021.80","41,609,313.49","88,231,797.28","215,566,322.90"
PNO,PharmaNet Group Limited,Annual Balance Sheet - Total Equity,"7,182,949.00","3,455,400.00","1,749,951.00","1,071,367.00","122,424.00","1,824,533.00","-730,796.00","-569,643.00","-429,823.00","-1,072,093.00","417,891.00","211,448.00","99,475.00","-1,236,359.00","-3,410,278.00", 
PNO,PharmaNet Group Limited,Annual Profit and Loss - Total Revenue Excluding Int,"14,819.00","47,814.00","24,210.00","524,897.00","3,890,782.00","9,108,078.00","42,997.00","89,854.00","242,320.00","119,834.00","187,479.00","276,903.00","507,418.00","820,506.00","610,415.00", 
PNO,PharmaNet Group Limited,Annual Profit and Loss - EBITDA,"-1,899,010.00","-2,041,769.00","-956,767.00","-882,166.00","-1,912,676.00","1,125,450.00","-1,631,695.00","-1,093,346.00","-888,573.00","-843,073.00","-977,720.00","-1,430,313.00","-368,198.00","323,882.00","-1,693,021.00", 
PNO,PharmaNet Group Limited,Annual Profit and Loss - EBIT,"-2,116,979.00","-2,253,182.00","-997,427.00","-884,040.00","-2,061,639.00","1,018,912.00","-1,635,734.00","-1,097,514.00","-894,334.00","-867,297.00","-1,006,803.00","-1,471,460.00","-411,608.00","291,616.00","-1,723,651.00", 
PNO,PharmaNet Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-2,791,416.00","-3,907,548.00","-2,033,631.00","-698,584.00","-2,092,887.00","-833,690.00","-3,546,889.00","-1,157,963.00","-937,706.00","-948,860.00","-1,075,790.00","-1,507,621.00","-2,146,826.00","-2,245,884.00","-2,158,897.00", 
PNO,PharmaNet Group Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--, 
PNO,PharmaNet Group Limited,Annual Ratio Analysis - Net Profit Margin,"-13,638.51%","-11,464.66%","-10,787.87%","-6,834.27%",-54.84%,11.72%,"-67,087.59%","-1,300.61%",--,--,--,"-1,056.65%",-193.04%,28.89%,"-1,042.68%", 
PNO,PharmaNet Group Limited,Annual Ratio Analysis - ROE,-28.14%,-60.82%,-53.22%,-78.85%,"-1,709.54%",35.22%,229.23%,203.28%,215.25%,90.93%,-236.30%,-629.93%,-209.76%,-21.18%,65.49%, 
PNO,PharmaNet Group Limited,Annual Ratio Analysis - Market Cap.($),"10,364,159.36","1,783,966.44","1,642,474.83","1,584,261.74","1,872,387.43","5,172,197.86","6,692,920.50","6,792,350.18","2,359,917.48","3,126,570.39","7,693,588.64","9,528,728.50","4,471,792.83","1,997,540.09","2,002,565.24", 
PNV,Polynovo Limited,Annual Balance Sheet - Total Equity,"11,458,422.00","6,408,197.00","12,148,571.00","6,261,207.00","16,684,516.00","17,281,740.00","22,764,614.00","20,788,032.00","16,461,066.00","15,822,858.00","13,741,844.00","10,640,479.00","7,988,617.00","7,817,880.00","8,668,011.00","7,393,306.00"
PNV,Polynovo Limited,Annual Profit and Loss - Total Revenue Excluding Int,"120,016.00",850.00,--,"138,647.00","2,028,265.00","116,773.00","208,803.00","58,152.00","43,130.00","88,010.00","134,010.00","532,897.00","1,156,585.00","1,686,633.00","1,043,644.00","2,465,480.00"
PNV,Polynovo Limited,Annual Profit and Loss - EBITDA,"-3,941,251.00","-5,537,379.00","-4,562,216.00","-8,923,827.00","-10,168,987.00","-11,207,482.00","-12,088,468.00","-14,482,527.00","-5,453,151.00","-3,021,827.00","-2,988,678.00","-3,720,306.00","-2,928,772.00","-1,518,718.00","-2,911,179.00","-2,804,994.00"
PNV,Polynovo Limited,Annual Profit and Loss - EBIT,"-3,945,236.00","-5,547,065.00","-4,600,137.00","-9,010,795.00","-10,333,937.00","-11,440,104.00","-12,374,785.00","-14,780,885.00","-5,719,427.00","-3,196,559.00","-3,222,423.00","-3,959,864.00","-3,156,787.00","-1,735,553.00","-3,126,356.00","-3,010,153.00"
PNV,Polynovo Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-3,563,405.00","-5,071,000.00","-5,731,276.00","-8,570,079.00","-9,543,526.00","-10,764,589.00","-11,293,869.00","-13,406,939.00","-4,441,167.00","-1,830,175.00","-2,305,353.00","-2,944,402.00","-2,702,726.00","-1,497,555.00","-2,941,975.00","-1,414,321.00"
PNV,Polynovo Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
PNV,Polynovo Limited,Annual Ratio Analysis - Net Profit Margin,--,--,--,--,"-1,141,570.10%",--,"-6,344,870.22%","-307,076.02%",--,--,"-1,526.99%",-751.45%,--,--,"-5,302.72%","-92,663.20%"
PNV,Polynovo Limited,Annual Ratio Analysis - ROE,-31.10%,-79.13%,-34.83%,-136.88%,-57.20%,-62.29%,-49.61%,-64.49%,-26.98%,-12.55%,-13.54%,-27.32%,-33.62%,-18.98%,-33.68%,-36.79%
PNV,Polynovo Limited,Annual Ratio Analysis - Market Cap.($),"71,579,884.65","112,355,798.40","114,287,687.28","115,989,329.92","216,590,124.75","152,087,749.10","110,980,538.37","39,090,498.33","12,658,973.08","8,139,594.02","8,665,806.92","22,531,098.00","20,797,936.62","25,610,413.29","43,943,489.73","37,665,848.34"
POH,Phosphagenics Limited,Annual Balance Sheet - Total Equity,"20,674,736.00","18,340,983.00","14,808,464.00","29,383,188.00","113,222,855.00","132,184,000.00","135,474,000.00","133,762,000.00","51,553,000.00","49,989,000.00","39,007,000.00","72,946,000.00","62,612,000.00","40,771,000.00","49,028,000.00","28,928,000.00"
POH,Phosphagenics Limited,Annual Profit and Loss - Total Revenue Excluding Int,"-87,061.00","34,684.00","-101,220.00","227,882.00","168,247.00","3,056,000.00","3,453,000.00","3,686,000.00","3,160,000.00","1,284,000.00","5,153,000.00","4,123,000.00","5,042,000.00","6,324,000.00","6,739,000.00","4,636,000.00"
POH,Phosphagenics Limited,Annual Profit and Loss - EBITDA,"-1,363,025.00","-2,729,958.00","-4,436,928.00","-2,733,733.00","-3,248,255.00","-8,762,000.00","-6,516,000.00","-9,687,000.00","-8,490,000.00","-8,465,000.00","-13,521,000.00","-10,501,000.00","-7,272,000.00","-10,284,000.00","-6,064,000.00","-8,279,000.00"
POH,Phosphagenics Limited,Annual Profit and Loss - EBIT,"-1,373,539.00","-2,764,862.00","-4,464,963.00","-2,757,676.00","-3,269,656.00","-8,826,000.00","-6,675,000.00","-9,877,000.00","-9,348,000.00","-8,931,000.00","-13,887,000.00","-13,151,000.00","-12,188,000.00","-14,167,000.00","-9,847,000.00","-11,547,000.00"
POH,Phosphagenics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,174,000.00","-5,365,120.00","-4,348,764.00","-2,661,601.00","-3,148,261.00","-7,323,000.00","-6,125,000.00","-8,844,000.00","-91,206,000.00","-8,501,000.00","-11,275,000.00","1,106,000.00","-11,055,000.00","-12,673,000.00","-8,935,000.00","-20,120,000.00"
POH,Phosphagenics Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
POH,Phosphagenics Limited,Annual Ratio Analysis - Net Profit Margin,--,--,"-3,128.29%",--,--,"-3,979.89%",-444.16%,-557.63%,492.62%,"-1,268.81%",-241.95%,43.96%,-860.98%,-989.39%,-457.62%,-586.97%
POH,Phosphagenics Limited,Annual Ratio Analysis - ROE,-5.68%,-14.09%,-29.37%,-9.06%,-2.78%,-5.54%,-4.52%,-6.61%,23.97%,-17.01%,-28.91%,1.52%,-17.66%,-33.39%,-19.16%,-38.15%
POH,Phosphagenics Limited,Annual Ratio Analysis - Market Cap.($),"49,300,565.44","47,099,458.56","36,275,603.76","37,862,190.74","149,950,203.30","133,955,826.62","197,235,988.32","144,825,817.44","51,092,765.26","50,299,328.00","88,763,520.00","213,688,850.97","147,931,175.00","117,353,475.00","94,647,375.00","15,143,580.00"
PRR,Prima BioMed Limited,Annual Balance Sheet - Total Equity,"1,876,400.00","4,142,832.00","5,460,409.00","3,093,448.00","5,126,211.00","8,343,101.00","6,316,598.00","4,080,070.00","2,633,433.00","1,812,522.00","16,787,514.00","55,099,130.00","37,157,871.00","29,248,418.00","22,592,320.00","24,689,743.00"
PRR,Prima BioMed Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,--,"351,569.00","98,092.00","211,003.00","782,231.00","3,608,392.00","156,122.00",--,--,"48,697.00","1,066,196.00","1,520,019.00","3,066,338.00","2,426,755.00","1,873,760.00"
PRR,Prima BioMed Limited,Annual Profit and Loss - EBITDA,"-728,280.00","-827,867.00","-3,943,083.00","-5,694,600.00","-5,656,932.00","-7,209,202.00","-4,555,174.00","-3,083,223.00","-1,892,457.00","-2,926,136.00","-8,856,457.00","-14,621,062.00","-22,246,209.00","-15,823,830.00","-13,596,725.00","-12,806,953.00"
PRR,Prima BioMed Limited,Annual Profit and Loss - EBIT,"-734,464.00","-829,896.00","-4,020,580.00","-5,830,345.00","-5,804,548.00","-7,362,458.00","-4,626,392.00","-3,139,034.00","-1,945,318.00","-2,975,554.00","-8,909,496.00","-14,685,349.00","-22,623,508.00","-16,077,854.00","-14,043,085.00","-14,148,155.00"
PRR,Prima BioMed Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-703,845.00","-2,064,636.00","-3,965,058.00","-5,781,644.00","-5,664,015.00","-7,076,303.00","-4,357,874.00","-3,139,034.00","-1,887,378.00","-2,946,442.00","-12,159,115.00","-21,081,167.00","-19,940,960.00","-15,225,671.00","-13,343,381.00","-32,151,696.00"
PRR,Prima BioMed Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
PRR,Prima BioMed Limited,Annual Ratio Analysis - Net Profit Margin,--,--,--,"-173,339.14%","-2,354.76%","-1,544.13%","-4,903.82%","-2,408.21%",--,--,--,"-1,977.23%","-77,392.53%",--,"-83,767.85%","-19,101.30%"
PRR,Prima BioMed Limited,Annual Ratio Analysis - ROE,-37.51%,-25.22%,-69.15%,-140.14%,-98.07%,-74.60%,-67.34%,-76.94%,-71.67%,-162.53%,-60.90%,-38.26%,-53.67%,-52.06%,-59.06%,-130.22%
PRR,Prima BioMed Limited,Annual Ratio Analysis - Market Cap.($),"3,295,699.68","2,653,170.05","18,260,732.49","13,635,496.80","12,893,502.65","16,511,476.59","11,657,615.31","5,149,385.15","3,050,799.15","21,028,747.05","73,419,947.48","262,153,066.39","122,597,289.62","77,733,984.98","49,148,373.64","110,344,159.86"
PRY,Primary Health Care Limited,Annual Balance Sheet - Total Equity,"110,253,000.00","111,333,000.00","172,539,000.00","186,287,000.00","198,554,000.00","320,013,000.00","392,415,000.00","409,406,000.00","1,761,145,000.00","2,116,704,000.00","2,470,237,000.00","2,504,389,000.00","2,573,113,000.00","2,682,097,000.00","2,747,557,000.00","2,447,384,000.00"
PRY,Primary Health Care Limited,Annual Profit and Loss - Total Revenue Excluding Int,"69,231,000.00","89,763,000.00","113,583,000.00","179,914,000.00","151,117,000.00","203,721,000.00","241,636,000.00","279,405,000.00","656,427,000.00","1,361,169,000.00","1,293,818,000.00","1,320,819,000.00","1,391,341,000.00","1,455,772,000.00","1,523,598,000.00","1,618,469,000.00"
PRY,Primary Health Care Limited,Annual Profit and Loss - EBITDA,"16,854,000.00","24,927,000.00","30,372,000.00","44,580,000.00","51,117,000.00","74,486,000.00","93,697,000.00","113,926,000.00","219,186,000.00","382,929,000.00","328,182,000.00","317,300,000.00","350,333,000.00","384,614,000.00","389,198,000.00","400,505,000.00"
PRY,Primary Health Care Limited,Annual Profit and Loss - EBIT,"10,755,000.00","15,239,000.00","16,491,000.00","26,237,000.00","29,762,000.00","47,900,000.00","74,444,000.00","92,803,000.00","179,216,000.00","315,152,000.00","255,265,000.00","235,104,000.00","264,467,000.00","293,917,000.00","295,244,000.00","238,420,000.00"
PRY,Primary Health Care Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"5,438,000.00","6,325,000.00","6,329,000.00","12,590,000.00","18,041,000.00","27,936,000.00","47,480,000.00","56,762,000.00","7,589,000.00","110,705,000.00","134,153,000.00","79,763,000.00","118,942,000.00","152,008,000.00","162,554,000.00","136,495,000.00"
PRY,Primary Health Care Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
PRY,Primary Health Care Limited,Annual Ratio Analysis - Net Profit Margin,8.64%,7.05%,6.47%,9.93%,10.26%,14.11%,19.52%,20.98%,8.72%,8.62%,10.26%,7.92%,8.38%,10.31%,10.69%,16.60%
PRY,Primary Health Care Limited,Annual Ratio Analysis - ROE,4.93%,5.68%,3.86%,6.76%,7.78%,8.73%,11.97%,13.91%,3.22%,5.42%,5.35%,4.15%,4.54%,5.61%,5.92%,10.96%
PRY,Primary Health Care Limited,Annual Ratio Analysis - Market Cap.($),"474,441,608.00","377,967,972.20","395,599,720.97","420,038,203.75","586,374,800.00","1,082,526,900.00","1,465,937,200.00","1,592,275,200.00","1,929,694,000.00","2,261,427,000.00","1,749,262,960.00","1,706,150,600.00","1,480,065,150.00","2,408,747,160.00","2,295,696,400.00","2,600,634,960.00"
PSQ,Pacific Smiles Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"36,800,000.00","41,009,000.00"
PSQ,Pacific Smiles Group Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"76,467,000.00"
PSQ,Pacific Smiles Group Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"16,409,000.00"
PSQ,Pacific Smiles Group Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"12,160,000.00"
PSQ,Pacific Smiles Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"8,360,000.00"
PSQ,Pacific Smiles Group Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
PSQ,Pacific Smiles Group Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,11.16%
PSQ,Pacific Smiles Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,20.39%
PSQ,Pacific Smiles Group Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"357,184,478.25"
PTX,Prescient Therapeutics Limited,Annual Balance Sheet - Total Equity,"1,276,550.00","3,614,450.00","1,456,015.00","953,603.00","3,637,243.00","2,830,018.00","2,027,114.00","1,767,898.00","73,052.00","-604,478.00","278,829.00","-832,034.00","-1,787,000.00",0.00,"5,026,822.00","4,450,486.00"
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - Total Revenue Excluding Int,--,"420,000.00","435,000.00","322,796.00","46,000.00","1,420,838.00","208,693.00","3,753,645.00","1,006,477.00","600,133.00","411,135.00","767,170.00","137,839.00","2,240,152.00",--,"211,119.00"
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - EBITDA,"-2,551,699.00","-2,577,983.00","-2,738,869.00","-3,178,221.00","-4,028,996.00","-3,825,086.00","-4,793,442.00","-2,549,739.00","-1,754,959.00","-1,102,491.00","-1,688,382.00","-1,305,220.00","-1,828,824.00","1,788,926.00","-1,305,038.00","-2,173,342.00"
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - EBIT,"-2,554,790.00","-2,585,517.00","-2,751,080.00","-3,195,043.00","-4,092,845.00","-4,183,475.00","-4,798,004.00","-2,562,111.00","-1,765,148.00","-1,106,268.00","-1,689,688.00","-1,307,210.00","-1,830,752.00","1,786,998.00","-1,305,038.00","-2,173,342.00"
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-2,282,318.00","-2,293,200.00","-2,647,494.00","-3,135,288.00","-3,963,451.00","-3,998,826.00","-4,625,343.00","-2,667,326.00","-1,773,449.00","-1,345,933.00","-1,864,246.00","-1,361,594.00","-1,892,370.00","1,787,000.00","-1,296,896.00","-2,133,375.00"
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
PTX,Prescient Therapeutics Limited,Annual Ratio Analysis - Net Profit Margin,--,--,--,"-2,035.29%",--,--,"-2,216.34%",-172.82%,-486.04%,--,--,--,--,--,--,--
PTX,Prescient Therapeutics Limited,Annual Ratio Analysis - ROE,-178.79%,-63.45%,-181.83%,-328.78%,-108.97%,-141.30%,-228.17%,-150.88%,"-2,427.65%",222.66%,-668.60%,163.65%,105.90%,--,-25.80%,-47.94%
PTX,Prescient Therapeutics Limited,Annual Ratio Analysis - Market Cap.($),"30,166,139.84","13,424,212.35","10,892,154.00","5,800,512.37","27,378,081.68","19,785,488.04","6,150,538.75","11,808,781.82","2,898,529.46","4,571,081.06","11,755,553.00","3,655,006.80","2,128,228.35","2,128,228.35","5,525,684.23","3,663,886.14"
PVA,pSivida Corp,Annual Balance Sheet - Total Equity, , , , , , , ,"88,265,000.00","31,246,623.00","29,012,817.00","38,766,866.00","34,857,063.00","13,380,433.00","8,301,886.00","15,842,887.00","30,427,083.00"
PVA,pSivida Corp,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,--,"12,662,580.00","16,236,135.00","27,047,987.00","4,623,335.00","3,626,729.00","2,310,512.00","3,686,836.00","34,593,750.00"
PVA,pSivida Corp,Annual Profit and Loss - EBITDA, , , , , , , ,0.00,"-79,258,258.00","-4,466,354.00","10,265,164.00","-8,265,201.00","-22,387,400.00","-11,901,886.00","-13,348,195.00","9,513,020.00"
PVA,pSivida Corp,Annual Profit and Loss - EBIT, , , , , , , ,0.00,"-79,258,258.00","-4,466,354.00","10,265,164.00","-8,265,201.00","-24,572,662.00","-12,973,584.00","-14,321,656.00","8,364,583.00"
PVA,pSivida Corp,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,0.00,"-78,610,014.00","-3,094,651.00","10,269,858.00","-8,034,267.00","-24,369,541.00","-12,830,188.00","-14,177,282.00","8,264,322.00"
PVA,pSivida Corp,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
PVA,pSivida Corp,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,--,"-2,273.74%",-20.83%,38.78%,-238.87%,--,--,-384.54%,23.89%
PVA,pSivida Corp,Annual Ratio Analysis - ROE, , , , , , , ,0.00%,-251.58%,-10.67%,26.49%,-23.05%,-182.13%,-154.55%,-89.49%,27.16%
PVA,pSivida Corp,Annual Ratio Analysis - Market Cap.($), , , , , , , ,0.00,"49,490,954.95","36,770,861.61","65,045,185.92","82,579,595.16","45,765,702.40","93,188,044.00","123,932,900.34","147,061,825.00"
PXS,Pharmaxis Ltd,Annual Balance Sheet - Total Equity, , , ,"29,190,061.00","26,780,231.00","35,568,726.00","98,888,000.00","76,559,000.00","119,121,000.00","137,691,000.00","115,016,000.00","70,830,000.00","109,803,000.00","67,895,000.00","18,067,000.00","36,321,000.00"
PXS,Pharmaxis Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , ,"1,019,032.00","1,152,618.00","1,172,262.00","1,307,000.00","2,357,000.00","2,103,000.00","1,118,000.00","1,444,000.00","1,375,000.00","5,205,000.00","8,912,000.00","8,751,000.00","58,526,000.00"
PXS,Pharmaxis Ltd,Annual Profit and Loss - EBITDA, , , ,"-1,496,472.00","-6,586,241.00","-11,308,104.00","-21,218,000.00","-28,499,000.00","-26,786,000.00","-39,080,000.00","-46,354,000.00","-42,907,000.00","-36,095,000.00","-38,465,000.00","-31,995,000.00","19,013,000.00"
PXS,Pharmaxis Ltd,Annual Profit and Loss - EBIT, , , ,"-1,752,206.00","-7,076,049.00","-11,934,235.00","-22,010,000.00","-29,438,000.00","-27,810,000.00","-40,345,000.00","-49,375,000.00","-47,933,000.00","-40,999,000.00","-43,285,000.00","-46,148,000.00","15,368,000.00"
PXS,Pharmaxis Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-1,467,789.00","-6,000,669.00","-10,232,357.00","-17,733,000.00","-24,179,000.00","-20,440,000.00","-35,171,000.00","-46,345,000.00","-45,758,000.00","-38,644,000.00","-43,537,000.00","-51,818,000.00","18,466,000.00"
PXS,Pharmaxis Ltd,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
PXS,Pharmaxis Ltd,Annual Ratio Analysis - Net Profit Margin, , , ,"-3,541.88%",--,"-2,046,471.40%","-221,662.50%","-11,794.63%","-3,878.56%","-5,911.09%","-3,961.11%","-3,806.82%","-2,636.02%","-1,344.98%","-1,028.95%",32.46%
PXS,Pharmaxis Ltd,Annual Ratio Analysis - ROE, , , ,-5.03%,-22.41%,-28.77%,-17.93%,-31.58%,-17.16%,-25.54%,-40.29%,-64.60%,-35.19%,-64.12%,-286.81%,51.60%
PXS,Pharmaxis Ltd,Annual Ratio Analysis - Market Cap.($), , , ,0.00,"54,008,000.00","231,804,558.24","364,421,399.52","587,232,416.10","295,662,438.24","524,558,452.69","464,345,082.04","191,763,859.56","315,321,763.72","43,196,074.46","20,427,980.03","69,259,070.54"
PYC,Phylogica Limited,Annual Balance Sheet - Total Equity, , , , , ,"5,780,882.00","2,114,304.00","2,196,662.00","2,694,638.00","1,911,244.00","-437,080.00","4,352,723.00","2,693,858.00","1,194,873.00","3,718,659.00","962,034.00"
PYC,Phylogica Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , ,"52,556.00","488,702.00","943,335.00","874,373.00","1,274,942.00","596,256.00","2,358,532.00","1,918,368.00","711,891.00","739,391.00","829,134.00"
PYC,Phylogica Limited,Annual Profit and Loss - EBITDA, , , , , ,"-1,656,315.00","-4,491,174.00","-4,064,023.00","-4,740,717.00","-4,481,310.00","-4,597,542.00","-3,563,153.00","-3,869,772.00","-5,118,474.00","-4,921,882.00","-4,821,043.00"
PYC,Phylogica Limited,Annual Profit and Loss - EBIT, , , , , ,"-1,698,617.00","-4,509,309.00","-4,090,301.00","-4,790,194.00","-4,595,340.00","-4,664,483.00","-3,717,689.00","-4,066,070.00","-5,392,639.00","-5,136,138.00","-5,033,278.00"
PYC,Phylogica Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-1,587,323.00","-3,991,475.00","-3,888,673.00","-4,483,938.00","-4,490,920.00","-4,572,825.00","-3,605,169.00","-3,904,524.00","-3,439,624.00","-3,257,695.00","-2,991,479.00"
PYC,Phylogica Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , ,--,--,--,--,--,--,--,--,--,--,--
PYC,Phylogica Limited,Annual Ratio Analysis - Net Profit Margin, , , , , ,"-3,020.25%",--,"-1,412.09%","-4,940.87%",-352.25%,-766.92%,-152.86%,-203.53%,--,-470.66%,-391.87%
PYC,Phylogica Limited,Annual Ratio Analysis - ROE, , , , , ,-27.46%,-188.78%,-177.03%,-166.40%,-234.97%,"1,046.22%",-82.83%,-144.94%,-287.87%,-87.60%,-310.95%
PYC,Phylogica Limited,Annual Ratio Analysis - Market Cap.($), , , , , ,"16,718,910.39","70,029,114.80","42,983,849.65","11,623,642.88","12,082,098.78","16,502,623.48","29,174,208.91","20,543,192.74","7,937,142.65","12,024,832.40","21,043,456.71"
QRX,QRxPharma Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"61,980,473.00","28,337,000.00","16,995,000.00","11,779,000.00","6,527,000.00","18,198,000.00","9,847,000.00","9,070,000.00","2,812,000.00"
QRX,QRxPharma Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,"4,950,574.00",--,"5,474,000.00","405,000.00","748,000.00","4,071,000.00","4,753,000.00","670,000.00","973,000.00"
QRX,QRxPharma Limited,Annual Profit and Loss - EBITDA, , , , , , , ,"522,409.00","-37,914,000.00","-14,185,000.00","-28,075,000.00","-25,746,000.00","-16,094,000.00","-10,076,000.00","-13,349,000.00","-4,939,000.00"
QRX,QRxPharma Limited,Annual Profit and Loss - EBIT, , , , , , , ,"439,521.00","-38,736,000.00","-14,214,000.00","-28,140,000.00","-25,812,000.00","-16,159,000.00","-10,140,000.00","-13,419,000.00","-4,951,000.00"
QRX,QRxPharma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-405,300.00","-36,602,000.00","-13,495,000.00","-27,474,000.00","-25,635,000.00","-16,045,000.00","-10,080,000.00","-13,341,000.00","-5,392,000.00"
QRX,QRxPharma Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
QRX,QRxPharma Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,--,--,--,--,--,--,-242.42%,"-2,252.53%",--
QRX,QRxPharma Limited,Annual Ratio Analysis - ROE, , , , , , , ,-0.65%,-129.17%,-79.41%,-237.73%,-394.83%,-87.42%,-101.79%,-146.10%,-171.50%
QRX,QRxPharma Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,"126,750,000.00","44,250,000.00","29,250,000.00","120,920,500.00","210,126,292.09","84,577,665.51","152,024,886.30","13,135,277.52","4,597,347.13"
RAC,Race Oncology Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"7,053,071.00"
RAC,Race Oncology Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,--
RAC,Race Oncology Ltd,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,0.00
RAC,Race Oncology Ltd,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,0.00
RAC,Race Oncology Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00
RAC,Race Oncology Ltd,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
RAC,Race Oncology Ltd,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
RAC,Race Oncology Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
RAC,Race Oncology Ltd,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
RAP,ResApp Health Limited,Annual Balance Sheet - Total Equity, , , ,--,"8,759,317.00","7,991,990.00","6,177,319.00","4,327,256.00","651,898.00","-599,018.00","-379,876.00","1,734,161.00","1,086,921.00","171,180.00","121,412.00","484,941.00"
RAP,ResApp Health Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , ,456.00,--,--,"472,846.00","1,405,352.00",--,502.00,"845,761.00","54,152.00","2,108.00",50.00,--,"150,621.00"
RAP,ResApp Health Limited,Annual Profit and Loss - EBITDA, , , ,"-501,215.00","-766,278.00","-576,972.00","-2,007,877.00","-3,859,464.00","-1,453,521.00","-1,246,487.00","212,846.00","-552,504.00","-890,831.00","-938,730.00","-470,337.00","-653,760.00"
RAP,ResApp Health Limited,Annual Profit and Loss - EBIT, , , ,"-567,624.00","-832,687.00","-647,309.00","-2,096,521.00","-3,990,484.00","-1,537,528.00","-1,315,937.00","212,846.00","-552,504.00","-890,831.00","-938,730.00","-470,337.00","-653,760.00"
RAP,ResApp Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-822,794.00","-1,180,530.00","-706,467.00","-1,815,829.00","-3,682,615.00","-3,658,685.00","-1,331,985.00","224,122.00","-527,165.00","-832,000.00","-922,808.00","-578,388.00","-489,321.00"
RAP,ResApp Health Limited,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
RAP,ResApp Health Limited,Annual Ratio Analysis - Net Profit Margin, , , ,"-180,437.28%",--,--,"-1,278.03%",-261.32%,--,"-238,262.55%",--,--,"-39,468.69%","-1,845,616.00%",--,--
RAP,ResApp Health Limited,Annual Ratio Analysis - ROE, , , ,--,-13.48%,-8.84%,-29.40%,-89.48%,-253.10%,181.28%,-49.54%,-30.40%,-76.55%,-539.09%,-386.92%,-130.24%
RAP,ResApp Health Limited,Annual Ratio Analysis - Market Cap.($), , , ,0.00,0.00,"12,587,379.79","15,169,406.42","9,046,953.49","3,146,766.43","3,146,766.43","3,218,766.43","12,473,403.15","3,440,938.80","860,234.70","1,938,917.63","1,994,186.82"
RCE,Recce Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"4,714,110.00"
RCE,Recce Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,--
RCE,Recce Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,0.00
RCE,Recce Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,0.00
RCE,Recce Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00
RCE,Recce Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
RCE,Recce Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
RCE,Recce Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
RCE,Recce Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
REG,Regis Healthcare Limited,Annual Balance Sheet - Total Equity,"97,923,481.00","100,952,479.00","103,137,485.00","109,329,418.00","112,299,229.00", , , , , , , , , ,"167,600,000.00","209,221,000.00"
REG,Regis Healthcare Limited,Annual Profit and Loss - Total Revenue Excluding Int,"46,567,977.00","56,167,394.00","57,293,744.00","59,924,259.00","64,926,639.00", , , , , , , , , ,--,"459,603,000.00"
REG,Regis Healthcare Limited,Annual Profit and Loss - EBITDA,"14,908,787.00","17,651,053.00","18,426,408.00","20,212,086.00","22,014,095.00", , , , , , , , , ,0.00,"129,948,000.00"
REG,Regis Healthcare Limited,Annual Profit and Loss - EBIT,"12,598,115.00","14,809,535.00","15,819,728.00","17,700,736.00","19,504,611.00", , , , , , , , , ,0.00,"111,034,000.00"
REG,Regis Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"6,554,114.00","7,217,328.00","8,199,039.00","9,628,523.00","10,468,988.00", , , , , , , , , ,0.00,"57,514,000.00"
REG,Regis Healthcare Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--, , , , , , , , , ,--,--
REG,Regis Healthcare Limited,Annual Ratio Analysis - Net Profit Margin,14.14%,12.87%,14.35%,16.18%,16.71%, , , , , , , , , ,--,62.12%
REG,Regis Healthcare Limited,Annual Ratio Analysis - ROE,6.69%,7.15%,7.95%,8.81%,9.64%, , , , , , , , , ,0.00%,36.79%
REG,Regis Healthcare Limited,Annual Ratio Analysis - Market Cap.($),0.00,"131,735,950.00","120,280,650.00","143,764,015.00","171,503,264.38", , , , , , , , , ,0.00,"1,549,784,312.52"
RGS,Regeneus Ltd,Annual Balance Sheet - Total Equity,"161,094,000.00","196,209,000.00","40,538,000.00", , , , , , , , , ,"15,704,000.00", ,"8,308,028.00","8,272,134.00"
RGS,Regeneus Ltd,Annual Profit and Loss - Total Revenue Excluding Int,"186,940,000.00","202,509,000.00","90,923,000.00", , , , , , , , , ,--, ,"5,769,702.00","5,318,398.00"
RGS,Regeneus Ltd,Annual Profit and Loss - EBITDA,"76,429,000.00","63,328,000.00","14,444,000.00", , , , , , , , , ,0.00, ,"-7,032,947.00","-6,387,101.00"
RGS,Regeneus Ltd,Annual Profit and Loss - EBIT,"49,949,000.00","32,999,000.00","28,000.00", , , , , , , , , ,0.00, ,"-7,366,623.00","-6,791,816.00"
RGS,Regeneus Ltd,Annual Profit and Loss - Reported NPAT After Abnorma,"30,057,000.00","21,652,000.00","-87,165,000.00", , , , , , , , , ,0.00, ,"-7,523,218.00","-6,606,521.00"
RGS,Regeneus Ltd,Annual Profit and Loss - Total Operating Income (ban,--,--,--, , , , , , , , , ,--, ,--,--
RGS,Regeneus Ltd,Annual Ratio Analysis - Net Profit Margin,16.22%,11.10%,-0.63%, , , , , , , , , ,--, ,-753.80%,-362.93%
RGS,Regeneus Ltd,Annual Ratio Analysis - ROE,19.34%,11.85%,-1.36%, , , , , , , , , ,0.00%, ,-60.37%,-79.86%
RGS,Regeneus Ltd,Annual Ratio Analysis - Market Cap.($),"131,064,032.00",0.00,"38,047,603.76", , , , , , , , , ,0.00, ,"71,913,300.03","31,332,771.45"
RHC,Ramsay Health Care Limited,Annual Balance Sheet - Total Equity,"161,315,000.00","201,206,000.00","223,076,000.00","253,129,000.00","270,589,000.00","800,117,000.00","838,574,000.00","883,637,000.00","914,164,000.00","909,162,000.00","1,223,943,000.00","1,303,863,000.00","1,406,201,000.00","1,541,815,000.00","1,743,644,000.00","1,833,087,000.00"
RHC,Ramsay Health Care Limited,Annual Profit and Loss - Total Revenue Excluding Int,"328,219,000.00","430,345,000.00","548,559,000.00","662,740,000.00","768,489,000.00","1,444,766,000.00","1,983,764,000.00","2,135,379,000.00","2,715,279,000.00","3,296,578,000.00","3,428,524,000.00","3,780,771,000.00","4,016,525,000.00","4,179,725,000.00","4,930,216,000.00","7,361,233,000.00"
RHC,Ramsay Health Care Limited,Annual Profit and Loss - EBITDA,"52,261,000.00","59,678,000.00","80,834,000.00","91,083,000.00","105,236,000.00","169,499,000.00","251,222,000.00","275,007,000.00","341,003,000.00","395,993,000.00","461,388,000.00","521,059,000.00","591,099,000.00","631,580,000.00","748,048,000.00","1,067,108,000.00"
RHC,Ramsay Health Care Limited,Annual Profit and Loss - EBIT,"31,642,000.00","39,872,000.00","57,945,000.00","66,358,000.00","76,931,000.00","112,751,000.00","191,218,000.00","212,187,000.00","252,823,000.00","285,921,000.00","324,236,000.00","387,998,000.00","444,205,000.00","484,574,000.00","578,328,000.00","761,167,000.00"
RHC,Ramsay Health Care Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"6,616,000.00","16,004,000.00","31,071,000.00","37,055,000.00","38,353,000.00","30,398,000.00","87,636,000.00","107,105,000.00","92,236,000.00","106,505,000.00","148,846,000.00","200,366,000.00","245,858,000.00","268,375,000.00","310,064,000.00","419,086,000.00"
RHC,Ramsay Health Care Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
RHC,Ramsay Health Care Limited,Annual Ratio Analysis - Net Profit Margin,2.65%,4.43%,5.69%,5.65%,5.53%,2.88%,3.91%,4.49%,3.91%,3.95%,5.04%,5.64%,5.92%,6.66%,6.77%,5.08%
RHC,Ramsay Health Care Limited,Annual Ratio Analysis - ROE,5.22%,8.30%,13.74%,14.64%,15.54%,5.15%,9.21%,10.76%,11.53%,14.22%,13.89%,16.11%,16.62%,17.84%,19.51%,19.99%
RHC,Ramsay Health Care Limited,Annual Ratio Analysis - Market Cap.($),"90,290,608.78","331,790,791.30","535,735,225.20","473,570,942.08","701,371,072.64","1,509,553,226.48","1,663,002,360.33","1,939,881,005.13","1,517,528,771.72","2,022,452,647.48","2,839,241,590.60","3,673,837,161.36","4,534,637,158.59","7,156,094,716.14","9,130,666,954.50","12,421,934,560.44"
RHS,Reproductive Health Science Limited,Annual Balance Sheet - Total Equity,"4,025,969.00","4,163,427.00","6,764,501.00","8,282,000.00","-1,305,000.00","-1,368,407.00","1,317,177.00","4,209,742.00","4,484,269.00","9,412,174.00","2,427,295.00","2,192,944.00","504,865.00","456,874.00","1,735,310.00","1,350,384.00"
RHS,Reproductive Health Science Limited,Annual Profit and Loss - Total Revenue Excluding Int,"2,260.00","9,667.00","1,382,813.00","6,215,000.00","8,672,000.00","5,077,584.00",--,"12,000.00",--,--,--,"45,920.00",--,"1,083.00","199,174.00","401,429.00"
RHS,Reproductive Health Science Limited,Annual Profit and Loss - EBITDA,"-1,472,390.00","-739,540.00","-1,598,300.00","-2,696,000.00","-1,901,000.00","-1,790,609.00","-1,712,960.00","-344,717.00","-699,702.00","-610,921.00","-6,974,305.00","-586,415.00","-1,982,345.00","-1,469,113.00","-5,956,421.00","-1,573,835.00"
RHS,Reproductive Health Science Limited,Annual Profit and Loss - EBIT,"-1,492,499.00","-775,583.00","-2,046,130.00","-3,918,000.00","-3,653,000.00","-2,083,029.00","-1,729,925.00","-353,283.00","-700,533.00","-611,951.00","-6,975,266.00","-586,514.00","-1,983,826.00","-1,479,585.00","-5,996,842.00","-1,656,431.00"
RHS,Reproductive Health Science Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,467,360.00","-724,177.00","-2,004,696.00","-4,260,000.00","-16,806,000.00","-49,074.00","-1,697,323.00","-331,961.00","-781,645.00","-880,921.00","-6,972,361.00","-585,134.00","-3,291,616.00","-1,474,578.00","-6,091,210.00","-1,635,179.00"
RHS,Reproductive Health Science Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
RHS,Reproductive Health Science Limited,Annual Ratio Analysis - Net Profit Margin,--,--,-149.14%,-68.54%,-45.16%,-242.10%,--,"-2,766.34%",--,--,--,--,--,--,--,"-2,228.89%"
RHS,Reproductive Health Science Limited,Annual Ratio Analysis - ROE,-36.45%,-17.39%,-30.49%,-51.44%,300.08%,151.81%,-257.72%,-7.89%,-17.43%,-9.36%,-287.25%,-26.05%,-391.42%,-322.75%,-342.98%,-121.09%
RHS,Reproductive Health Science Limited,Annual Ratio Analysis - Market Cap.($),0.00,0.00,0.00,0.00,0.00,0.00,0.00,"8,832,450.06","3,627,613.42","8,724,315.60","8,724,315.60","4,551,949.05",0.00,"2,985,708.79","8,209,626.40","7,375,645.62"
RHT,Resonance Health Limited,Annual Balance Sheet - Total Equity,"9,609,214.00", ,"-7,140,283.00","690,968.00","2,869,125.00","14,106,799.00","510,356.00","2,721,143.00","2,675,129.00","3,302,259.00","3,208,505.00","2,895,562.00","2,566,016.00","2,240,961.00","3,338,595.00","4,405,288.00"
RHT,Resonance Health Limited,Annual Profit and Loss - Total Revenue Excluding Int,"7,915,622.00", ,"1,614,634.00",--,"3,300.00","233,334.00","549,140.00","2,018,790.00","3,457,666.00","2,265,701.00","1,914,227.00","1,855,169.00","1,747,390.00","1,829,823.00","2,284,565.00","2,754,672.00"
RHT,Resonance Health Limited,Annual Profit and Loss - EBITDA,"-7,394,798.00", ,"-1,461,126.00","-403,726.00","-1,997,274.00","-2,742,310.00","-3,520,189.00","-1,010,225.00","-367,232.00","468,906.00","-299,652.00","-560,402.00","-511,668.00","-344,148.00","127,888.00","317,816.00"
RHT,Resonance Health Limited,Annual Profit and Loss - EBIT,"-7,715,662.00", ,"-1,461,126.00","-403,726.00","-2,066,112.00","-3,065,770.00","-3,570,523.00","-1,053,171.00","-401,434.00","442,873.00","-324,234.00","-581,571.00","-531,966.00","-397,300.00","19,320.00","183,115.00"
RHT,Resonance Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-7,675,000.00", ,"-2,461,126.00","6,102,558.00","-2,020,277.00","-3,015,925.00","-16,060,845.00","-725,319.00","-41,392.00","617,051.00","-102,335.00","-316,829.00","-268,601.00","-204,481.00","-72,415.00","463,234.00"
RHT,Resonance Health Limited,Annual Profit and Loss - Total Operating Income (ban,--, ,--,--,--,--,--,--,--,--,--,--,--,--,--,--
RHT,Resonance Health Limited,Annual Ratio Analysis - Net Profit Margin,-95.48%, ,--,--,"-38,278.58%","-1,568.10%","-1,035.83%",-38.81%,-1.20%,27.31%,-5.57%,-18.15%,-17.19%,-13.39%,2.06%,18.96%
RHT,Resonance Health Limited,Annual Ratio Analysis - ROE,-92.75%, ,17.23%,-55.68%,-41.16%,-13.51%,-641.50%,-26.65%,-1.55%,18.69%,-3.19%,-10.94%,-10.47%,-9.12%,1.41%,10.52%
RHT,Resonance Health Limited,Annual Ratio Analysis - Market Cap.($),"37,694,706.22", ,"10,176,342.24","2,171,144.04","6,363,372.02","25,969,163.22","4,853,357.50","6,000,115.63","3,750,072.27","5,040,910.07","6,127,340.18","6,136,853.20","4,331,896.38","3,609,913.65","15,461,671.36","16,865,780.53"
RMD,ResMed Inc.,Annual Balance Sheet - Total Equity,"142,468,162.00","197,765,517.00","341,589,943.00","429,177,404.00","524,748,149.00","620,747,675.00","993,068,747.00","1,097,233,415.00","1,123,805,318.00","1,374,404,732.00","1,510,660,565.00","1,611,637,023.00","1,577,496,810.00","1,736,405,390.00","1,866,505,307.00","2,066,805,989.00"
RMD,ResMed Inc.,Annual Profit and Loss - Total Revenue Excluding Int,"175,900,545.00","309,733,990.00","374,146,600.00","411,224,153.00","495,457,976.00","557,313,081.00","817,664,469.00","845,605,043.00","872,869,312.00","1,136,188,070.00","1,288,906,488.00","1,167,602,197.00","1,355,106,466.00","1,633,038,274.00","1,651,652,866.00","2,194,221,354.00"
RMD,ResMed Inc.,Annual Profit and Loss - EBITDA,"62,178,593.00","107,877,832.00","122,411,473.00","123,252,921.00","151,281,753.00","172,512,766.00","187,710,211.00","186,276,658.00","167,327,030.00","244,686,960.00","298,722,280.00","268,004,469.00","397,057,207.00","476,043,126.00","515,659,235.00","552,378,979.00"
RMD,ResMed Inc.,Annual Profit and Loss - EBIT,"50,583,687.00","91,237,438.00","104,755,665.00","104,399,160.00","125,346,204.00","134,327,615.00","179,198,170.00","178,150,111.00","159,233,326.00","235,985,950.00","289,287,809.00","258,556,662.00","299,098,223.00","380,709,433.00","437,682,590.00","540,997,395.00"
RMD,ResMed Inc.,Annual Profit and Loss - Reported NPAT After Abnorma,"33,696,179.00","22,916,256.00","66,405,807.00","68,518,130.00","83,152,852.00","84,830,430.00","118,674,828.00","78,121,833.00","114,588,614.00","180,488,045.00","223,025,929.00","211,366,048.00","250,073,594.00","331,140,700.00","366,531,847.00","459,486,979.00"
RMD,ResMed Inc.,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
RMD,ResMed Inc.,Annual Ratio Analysis - Net Profit Margin,19.22%,19.24%,18.43%,16.72%,16.88%,16.04%,14.68%,14.89%,13.65%,15.93%,17.41%,18.26%,18.76%,20.31%,22.61%,21.02%
RMD,ResMed Inc.,Annual Ratio Analysis - ROE,23.65%,29.75%,20.14%,15.96%,15.85%,14.39%,12.05%,11.46%,10.55%,13.13%,14.76%,13.11%,15.97%,19.10%,20.00%,22.23%
RMD,ResMed Inc.,Annual Ratio Analysis - Market Cap.($),"1,425,370,779.39","3,266,867,788.40","1,701,761,839.80","1,995,578,923.00","2,478,425,510.40","3,003,046,332.00","4,385,057,260.00","3,637,595,295.60","2,731,618,886.70","3,905,537,747.10","5,471,136,499.20","4,352,894,158.20","4,360,045,682.40","7,100,687,650.00","7,688,689,011.20","10,212,511,053.50"
RNO,Rhinomed Limited ,Annual Balance Sheet - Total Equity, , , , , , , , ,"1,819,953.00","953,041.00","444,395.00","15,245,076.00","20,401,549.00","5,675,695.00","6,561,625.00","5,967,479.00"
RNO,Rhinomed Limited ,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , ,"3,030.00",--,--,"33,720.00","5,476,240.00","291,989.00","259,895.00","438,036.00"
RNO,Rhinomed Limited ,Annual Profit and Loss - EBITDA, , , , , , , , ,"-1,427,371.00","-919,975.00","-875,074.00","-1,178,513.00","-679,161.00","-4,514,748.00","-3,713,448.00","-5,460,314.00"
RNO,Rhinomed Limited ,Annual Profit and Loss - EBIT, , , , , , , , ,"-1,428,913.00","-925,130.00","-878,248.00","-1,180,792.00","-694,333.00","-4,522,178.00","-3,954,100.00","-5,911,335.00"
RNO,Rhinomed Limited ,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"-1,317,984.00","-881,025.00","-858,411.00","-1,128,712.00","-1,308,494.00","-19,559,713.00","-3,534,577.00","-5,316,992.00"
RNO,Rhinomed Limited ,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , ,--,--,--,--,--,--,--,--
RNO,Rhinomed Limited ,Annual Ratio Analysis - Net Profit Margin, , , , , , , , ,"-43,497.82%",--,--,"-3,191.73%",--,--,"-1,676.31%","-1,222.34%"
RNO,Rhinomed Limited ,Annual Ratio Analysis - ROE, , , , , , , , ,-72.42%,-92.44%,-193.16%,-7.92%,-3.70%,-71.53%,-53.87%,-88.58%
RNO,Rhinomed Limited ,Annual Ratio Analysis - Market Cap.($), , , , , , , , ,"5,413,029.50","2,248,489.18","1,495,146.81","11,048,204.95","15,196,985.68","7,637,563.99","9,093,727.24","16,183,159.05"
RSH,Respiri Limited,Annual Balance Sheet - Total Equity,"7,596,502.00","13,280,760.00","1,379,789.00","-949,924.00","1,142,262.00","1,511,162.00","388,369.00","2,405,630.00","4,852,716.00","3,929,387.00","2,866,724.00","2,109,796.00","2,114,439.00","1,622,417.00","9,076,405.00","3,900,397.00"
RSH,Respiri Limited,Annual Profit and Loss - Total Revenue Excluding Int,"977,476.00","321,745.00","59,839.00","343,708.00","549,924.00",--,--,"287,591.00","241,225.00","356,909.00","414,718.00","403,731.00","557,832.00","370,910.00","18,975.00","93,988.00"
RSH,Respiri Limited,Annual Profit and Loss - EBITDA,"-6,180,790.00","-9,246,832.00","-10,574,692.00","-4,207,071.00","-283,982.00","-776,101.00","-1,053,027.00","-5,134,806.00","-12,190,240.00","-6,504,231.00","-5,803,192.00","-6,509,309.00","-4,875,899.00","-5,289,464.00","-10,316,196.00","-5,280,761.00"
RSH,Respiri Limited,Annual Profit and Loss - EBIT,"-6,180,790.00","-9,482,753.00","-10,866,771.00","-4,334,576.00","-283,982.00","-776,101.00","-1,224,909.00","-5,160,371.00","-12,367,947.00","-6,771,282.00","-6,058,104.00","-6,732,357.00","-5,141,758.00","-5,458,978.00","-10,560,800.00","-5,496,964.00"
RSH,Respiri Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-6,094,780.00","-8,695,000.00","-11,862,496.00","-4,293,066.00","-225,446.00","-724,190.00","-1,191,338.00","-5,124,413.00","-11,678,053.00","-6,701,092.00","-5,939,761.00","-6,677,311.00","-5,585,172.00","-5,580,768.00","-10,309,957.00","-5,464,443.00"
RSH,Respiri Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
RSH,Respiri Limited,Annual Ratio Analysis - Net Profit Margin,"-1,505.52%","-2,702.45%","-20,872.52%","-148,036.76%",--,--,--,"-3,435.22%","-11,655.79%","-2,972.56%","-1,704.41%","-2,010.71%","-40,709.99%","-49,984.11%","-54,334.42%","-1,092,888.60%"
RSH,Respiri Limited,Annual Ratio Analysis - ROE,-80.23%,-65.47%,-767.68%,451.94%,-19.74%,-47.92%,-306.75%,-213.00%,-240.65%,-170.54%,-207.20%,-316.49%,-249.68%,-334.55%,-113.59%,-140.10%
RSH,Respiri Limited,Annual Ratio Analysis - Market Cap.($),0.00,"182,285,919.30","6,968,986.52","2,310,846.86","2,439,427.47","237,804.62","1,936,409.02","22,700,765.67","27,108,633.72","22,570,552.64","12,370,972.30","10,579,182.24","7,003,971.13","79,083,116.28","64,839,779.42","17,740,095.41"
RVA,Reva Medical Inc,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"80,632,687.00","63,590,980.00","42,975,731.00","23,273,357.00","-32,247,012.00","-110,271,010.00"
RVA,Reva Medical Inc,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , ,"35,422.00",--,--,--,"89,002.00","80,755.00"
RVA,Reva Medical Inc,Annual Profit and Loss - EBITDA, , , , , , , , , , ,"-23,966,348.00","-20,771,957.00","-22,333,397.00","-30,241,394.00","-59,780,541.00","-108,955,652.00"
RVA,Reva Medical Inc,Annual Profit and Loss - EBIT, , , , , , , , , , ,"-23,966,348.00","-20,771,957.00","-22,985,362.00","-31,238,265.00","-61,032,674.00","-110,455,789.00"
RVA,Reva Medical Inc,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,"-23,129,981.00","-20,586,845.00","-22,896,764.00","-31,204,738.00","-62,225,067.00","-113,049,548.00"
RVA,Reva Medical Inc,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , ,--,--,--,--,--,--
RVA,Reva Medical Inc,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , ,--,--,--,--,"-69,913.70%","-139,989.83%"
RVA,Reva Medical Inc,Annual Ratio Analysis - ROE, , , , , , , , , , ,-149.89%,-32.37%,-53.28%,-134.08%,192.96%,102.52%
RVA,Reva Medical Inc,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , ,"406,230,237.20","203,425,118.60","175,600,675.90","159,696,254.40","135,795,600.90","328,141,479.60"
SCU,Stemcell United Limited,Annual Balance Sheet - Total Equity,"5,191,691.00","11,290,000.00","11,552,633.00","12,636,060.00","17,947,961.00","61,151,000.00","67,481,000.00","67,970,000.00", , , , , , ,"-76,251,378.00","149,845.00"
SCU,Stemcell United Limited,Annual Profit and Loss - Total Revenue Excluding Int,"867,341.00","13,415,000.00","10,557,579.00","134,620,342.00","321,861,614.00","483,299,000.00","785,460,000.00","1,024,527,000.00", , , , , , ,--,"76,272,483.00"
SCU,Stemcell United Limited,Annual Profit and Loss - EBITDA,"-235,924.00","730,000.00","882,565.00","919,031.00","7,706,723.00","14,555,000.00","17,413,000.00","30,799,000.00", , , , , , ,0.00,"-1,009,178.00"
SCU,Stemcell United Limited,Annual Profit and Loss - EBIT,"-298,985.00","200,000.00","384,740.00","-677,523.00","3,470,072.00","5,612,000.00","3,440,000.00","7,653,000.00", , , , , , ,0.00,"-1,009,178.00"
SCU,Stemcell United Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-293,306.00","-97,000.00","256,077.00","1,083,427.00","2,329,531.00","2,649,000.00","-9,967,000.00","402,000.00", , , , , , ,0.00,"75,041,240.00"
SCU,Stemcell United Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--, , , , , , ,--,--
SCU,Stemcell United Limited,Annual Ratio Analysis - Net Profit Margin,-35.81%,-0.76%,2.66%,-0.61%,0.74%,0.08%,-0.66%,-0.28%, , , , , , ,--,--
SCU,Stemcell United Limited,Annual Ratio Analysis - ROE,-5.65%,-0.86%,2.22%,-6.15%,12.98%,1.70%,-54.51%,-11.28%, , , , , , ,0.00%,-754.94%
SCU,Stemcell United Limited,Annual Ratio Analysis - Market Cap.($),"7,764,448.00","6,429,779.20","2,973,772.88","7,389,779.20","38,192,229.00","39,053,218.40","16,585,583.75","16,638,707.75", , , , , , ,"5,324,410.51","31,201,570.73"
SDI,SDI Limited,Annual Balance Sheet - Total Equity,"12,844,000.00","14,861,000.00","17,665,000.00","22,030,000.00","28,119,000.00","28,522,000.00","30,397,000.00","34,103,000.00","34,832,000.00","38,300,000.00","40,696,000.00","39,941,000.00","42,407,000.00","47,356,000.00","52,075,000.00","58,091,000.00"
SDI,SDI Limited,Annual Profit and Loss - Total Revenue Excluding Int,"22,658,000.00","27,510,000.00","34,808,000.00","37,780,000.00","44,698,000.00","47,067,000.00","45,561,000.00","48,727,000.00","50,470,000.00","59,490,000.00","54,034,000.00","54,965,000.00","56,643,000.00","57,324,000.00","65,433,000.00","68,871,000.00"
SDI,SDI Limited,Annual Profit and Loss - EBITDA,"4,589,000.00","4,838,000.00","7,171,000.00","9,538,000.00","13,099,000.00","5,344,000.00","8,830,000.00","8,268,000.00","4,642,000.00","7,770,000.00","7,137,000.00","4,340,000.00","5,574,000.00","9,242,000.00","10,704,000.00","12,338,000.00"
SDI,SDI Limited,Annual Profit and Loss - EBIT,"3,096,000.00","3,706,000.00","5,911,000.00","8,082,000.00","11,331,000.00","3,092,000.00","7,361,000.00","6,501,000.00","2,599,000.00","5,531,000.00","4,918,000.00","2,017,000.00","2,982,000.00","6,484,000.00","7,957,000.00","9,112,000.00"
SDI,SDI Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"1,943,000.00","2,697,000.00","4,008,000.00","5,451,000.00","8,028,000.00","2,148,000.00","5,119,000.00","4,060,000.00","1,129,000.00","3,120,000.00","3,473,000.00","1,206,000.00","1,967,000.00","4,690,000.00","6,467,000.00","6,200,000.00"
SDI,SDI Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
SDI,SDI Limited,Annual Ratio Analysis - Net Profit Margin,8.84%,9.91%,11.52%,14.85%,18.52%,4.67%,11.26%,8.33%,2.30%,5.52%,6.54%,2.20%,3.49%,8.28%,9.90%,9.03%
SDI,SDI Limited,Annual Ratio Analysis - ROE,15.13%,18.15%,22.69%,24.74%,28.55%,7.53%,16.84%,11.91%,3.24%,8.15%,8.53%,3.02%,4.64%,9.90%,12.42%,10.67%
SDI,SDI Limited,Annual Ratio Analysis - Market Cap.($),"10,033,189.57","16,566,429.29","68,451,946.27","135,890,188.77","205,088,787.12","88,105,204.50","74,138,892.66","56,158,485.72","20,157,944.14","26,679,631.95","21,395,795.40","20,801,467.75","12,480,880.65","60,621,420.30","51,112,177.90","59,432,765.00"
SHL,Sonic Healthcare Limited,Annual Balance Sheet - Total Equity,"268,735,000.00","608,420,000.00","837,465,000.00","831,292,000.00","847,787,000.00","882,633,000.00","1,302,345,000.00","1,438,445,000.00","1,962,079,000.00","2,532,083,000.00","2,558,741,000.00","2,516,435,000.00","2,610,199,000.00","2,918,101,000.00","3,108,994,000.00","3,325,998,000.00"
SHL,Sonic Healthcare Limited,Annual Profit and Loss - Total Revenue Excluding Int,"388,117,000.00","626,579,000.00","857,935,000.00","973,095,000.00","1,036,279,000.00","1,380,491,000.00","1,653,877,000.00","1,882,252,000.00","2,371,418,000.00","3,001,313,000.00","2,980,651,000.00","3,090,079,000.00","3,342,799,000.00","3,481,490,000.00","3,910,230,000.00","4,196,729,000.00"
SHL,Sonic Healthcare Limited,Annual Profit and Loss - EBITDA,"81,661,000.00","139,321,000.00","189,272,000.00","213,930,000.00","238,240,000.00","310,680,000.00","360,307,000.00","405,667,000.00","478,568,000.00","578,999,000.00","543,857,000.00","570,095,000.00","624,129,000.00","646,819,000.00","733,020,000.00","697,129,000.00"
SHL,Sonic Healthcare Limited,Annual Profit and Loss - EBIT,"55,368,000.00","80,328,000.00","102,871,000.00","114,497,000.00","137,237,000.00","192,996,000.00","304,210,000.00","340,929,000.00","396,753,000.00","477,716,000.00","435,411,000.00","455,177,000.00","492,075,000.00","505,804,000.00","572,431,000.00","517,927,000.00"
SHL,Sonic Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"21,910,000.00","26,127,000.00","32,207,000.00","39,945,000.00","57,883,000.00","89,408,000.00","185,815,000.00","210,054,000.00","250,406,000.00","172,555,000.00","293,784,000.00","294,489,000.00","317,685,000.00","339,668,000.00","388,860,000.00","354,037,000.00"
SHL,Sonic Healthcare Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
SHL,Sonic Healthcare Limited,Annual Ratio Analysis - Net Profit Margin,4.87%,4.21%,3.97%,4.24%,5.62%,5.70%,10.54%,10.63%,10.46%,10.61%,9.96%,9.61%,9.56%,9.74%,9.99%,8.46%
SHL,Sonic Healthcare Limited,Annual Ratio Analysis - ROE,6.96%,4.36%,4.06%,4.92%,6.70%,8.76%,13.39%,13.95%,12.57%,12.46%,11.47%,11.71%,12.20%,11.57%,12.49%,10.70%
SHL,Sonic Healthcare Limited,Annual Ratio Analysis - Market Cap.($),"1,154,134,225.67","1,799,640,683.75","1,326,277,846.85","1,701,453,617.05","2,441,875,257.60","3,453,489,945.36","4,191,883,949.00","4,520,262,042.12","4,852,458,188.55","4,730,521,180.00","4,051,323,596.25","4,999,092,491.25","4,965,317,412.50","5,881,912,660.61","6,946,064,265.48","8,590,467,468.39"
SIE,SciGen Limited,Annual Balance Sheet - Total Equity, , ,"41,465,906.00","30,714,893.00","26,856,249.00","79,604,945.00","27,311,464.00","23,341,651.00","17,735,277.00","-28,641,989.00","-38,180,655.00","-55,869,436.00","-51,196,070.00","-61,936,745.00","-71,420,385.00","-78,547,768.00"
SIE,SciGen Limited,Annual Profit and Loss - Total Revenue Excluding Int, , ,--,"2,269,787.00","5,215,921.00","5,288,125.00","7,648,561.00","12,296,960.00","20,173,210.00","14,672,761.00","13,603,266.00","17,980,504.00","18,335,901.00","23,798,614.00","29,368,446.00","32,503,421.00"
SIE,SciGen Limited,Annual Profit and Loss - EBITDA, , ,0.00,"-3,900,425.00","-3,401,504.00","-4,326,152.00","991,510.00","-2,632,713.00","-6,844,688.00","-42,323,558.00","-13,640,657.00","-3,463,962.00","1,539,869.00","1,840,634.00","4,724,457.00","4,935,669.00"
SIE,SciGen Limited,Annual Profit and Loss - EBIT, , ,0.00,"-4,125,957.00","-3,884,898.00","-4,598,335.00","771,449.00","-2,991,152.00","-7,517,321.00","-43,514,327.00","-15,602,676.00","-4,658,330.00","926,425.00","1,318,730.00","4,124,603.00","4,344,374.00"
SIE,SciGen Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , ,0.00,"-4,154,042.00","-3,643,201.00","-4,325,375.00","217,588.00","-4,608,666.00","-12,245,958.00","-45,001,672.00","-10,034,438.00","-17,454,706.00","3,989,791.00","-790,120.00","-2,075,103.00","1,735,559.00"
SIE,SciGen Limited,Annual Profit and Loss - Total Operating Income (ban, , ,--,--,--,--,--,--,--,--,--,--,--,--,--,--
SIE,SciGen Limited,Annual Ratio Analysis - Net Profit Margin, , ,--,-183.01%,-69.85%,-81.79%,10.19%,-47.47%,-58.46%,-343.41%,-78.85%,-35.07%,0.62%,1.98%,10.86%,5.39%
SIE,SciGen Limited,Annual Ratio Analysis - ROE, , ,0.00%,-13.52%,-13.57%,-5.43%,3.12%,-22.69%,-125.05%,129.18%,22.83%,9.20%,-0.19%,-0.68%,-4.38%,-2.21%
SIE,SciGen Limited,Annual Ratio Analysis - Market Cap.($), , ,0.00,"35,634,105.00","23,881,030.25","18,728,774.15","45,838,410.00","50,808,840.00","19,329,461.20","193,294,500.00","71,795,100.00","37,554,360.00","22,090,800.00","30,374,850.00","8,284,050.00","11,045,406.40"
SIP,Sigma Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, ,"10,816,866.00","14,727,000.00","27,265,000.00","34,108,000.00", ,"1,269,167,000.00","1,344,456,000.00","1,200,653,000.00","1,197,932,000.00","1,066,954,000.00","832,919,000.00","682,527,000.00","610,806,000.00","578,829,000.00","573,001,000.00"
SIP,Sigma Pharmaceuticals Limited,Annual Profit and Loss - Total Revenue Excluding Int, ,"137,795,615.00","247,876,000.00","263,445,000.00","336,477,000.00", ,"2,207,672,000.00","2,744,894,000.00","3,006,274,000.00","3,124,745,000.00","3,271,540,000.00","2,950,739,000.00","2,892,055,000.00","2,981,226,000.00","3,025,155,000.00","3,194,495,000.00"
SIP,Sigma Pharmaceuticals Limited,Annual Profit and Loss - EBITDA, ,"8,010,202.00","13,927,000.00","19,000,000.00","29,010,000.00", ,"150,829,000.00","215,976,000.00","212,471,000.00","234,761,000.00","213,462,000.00","50,906,000.00","74,223,000.00","78,042,000.00","78,240,000.00","85,914,000.00"
SIP,Sigma Pharmaceuticals Limited,Annual Profit and Loss - EBIT, ,"7,534,380.00","12,842,000.00","17,976,000.00","28,073,000.00", ,"129,924,000.00","181,424,000.00","175,577,000.00","190,260,000.00","167,634,000.00","46,695,000.00","68,714,000.00","72,377,000.00","71,160,000.00","78,356,000.00"
SIP,Sigma Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, ,"5,301,985.00","9,037,000.00","12,537,000.00","19,294,000.00", ,"104,848,000.00","101,788,000.00","77,154,000.00","80,124,000.00","-389,042,000.00","-235,382,000.00","49,172,000.00","18,686,000.00","53,536,000.00","52,772,000.00"
SIP,Sigma Pharmaceuticals Limited,Annual Profit and Loss - Total Operating Income (ban, ,--,--,--,--, ,--,--,--,--,--,--,--,--,--,--
SIP,Sigma Pharmaceuticals Limited,Annual Ratio Analysis - Net Profit Margin, ,3.84%,3.65%,4.76%,5.74%, ,3.49%,4.08%,3.17%,2.60%,2.72%,-0.59%,1.69%,2.30%,1.70%,1.69%
SIP,Sigma Pharmaceuticals Limited,Annual Ratio Analysis - ROE, ,48.91%,61.36%,45.98%,56.57%, ,5.56%,8.30%,7.84%,6.69%,8.21%,-2.07%,7.13%,11.13%,8.82%,9.26%
SIP,Sigma Pharmaceuticals Limited,Annual Ratio Analysis - Market Cap.($), ,0.00,"229,412,209.20","454,301,535.10","770,914,803.60", ,"2,653,761,177.99","2,535,569,915.40","1,293,291,718.50","1,044,045,730.80","1,102,015,844.82","524,488,824.54","707,175,943.20","773,175,293.31","631,536,074.36","874,739,893.60"
SNZ,Summerset Group Holdings Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"259,134,111.00","317,597,017.00","384,162,369.00"
SNZ,Summerset Group Holdings Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , ,--,--,--
SNZ,Summerset Group Holdings Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , ,--,--,--
SNZ,Summerset Group Holdings Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , ,--,--,--
SNZ,Summerset Group Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"31,457,854.00","51,780,730.00","78,977,219.00"
SNZ,Summerset Group Holdings Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , ,--,--,--
SNZ,Summerset Group Holdings Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , ,49.23%,45.24%,55.40%
SNZ,Summerset Group Holdings Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,7.86%,7.35%,9.22%
SNZ,Summerset Group Holdings Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , ,"627,974,963.90","474,793,000.00","801,759,161.84"
SOM,SomnoMed Limited,Annual Balance Sheet - Total Equity, , , , ,"-160,077.00","7,201,392.00","3,234,356.00","3,913,116.00","6,008,676.00","4,333,246.00","5,650,638.00","6,217,082.00","8,919,747.00","11,572,722.00","12,569,702.00","21,507,982.00"
SOM,SomnoMed Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , ,"40,617.00","377,373.00","1,785,921.00","2,422,414.00","3,658,173.00","7,995,474.00","10,956,785.00","12,583,738.00","15,349,470.00","18,581,690.00","25,894,846.00","35,220,348.00"
SOM,SomnoMed Limited,Annual Profit and Loss - EBITDA, , , , ,"-561,613.00","-3,576,366.00","-4,270,519.00","-2,564,222.00","-2,592,681.00","-1,712,195.00","181,455.00","795,070.00","906,112.00","818,270.00","826,458.00","603,792.00"
SOM,SomnoMed Limited,Annual Profit and Loss - EBIT, , , , ,"-562,534.00","-3,638,994.00","-4,412,535.00","-3,258,574.00","-3,016,037.00","-2,030,976.00","25,059.00","574,250.00","464,547.00","314,987.00","216,801.00","-26,023.00"
SOM,SomnoMed Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , ,"-556,997.00","-3,266,637.00","-4,188,304.00","-3,274,364.00","-2,731,119.00","-1,818,673.00","786,143.00","739,537.00","699,745.00","704,675.00","214,956.00","533,761.00"
SOM,SomnoMed Limited,Annual Profit and Loss - Total Operating Income (ban, , , , ,--,--,--,--,--,--,--,--,--,--,--,--
SOM,SomnoMed Limited,Annual Ratio Analysis - Net Profit Margin, , , , ,"-1,978.89%",-866.20%,-234.52%,-144.03%,-74.66%,-22.75%,7.21%,5.91%,3.42%,3.18%,1.57%,0.01%
SOM,SomnoMed Limited,Annual Ratio Analysis - ROE, , , , ,"1,391.82%",-45.36%,-129.49%,-83.68%,-45.45%,-41.97%,13.91%,11.90%,6.01%,5.37%,3.29%,0.01%
SOM,SomnoMed Limited,Annual Ratio Analysis - Market Cap.($), , , , ,0.00,"23,554,503.28","7,928,101.10","9,199,801.15","24,564,888.54","17,656,013.64","31,349,041.02","50,584,695.00","36,976,209.60","39,391,933.49","65,490,314.80","134,979,340.00"
SPL,Starpharma Holdings Limited,Annual Balance Sheet - Total Equity,"28,853,274.00","24,915,653.00","17,266,327.00","9,243,130.00","17,592,496.00","9,965,965.00","21,315,986.00","25,724,030.00","20,383,000.00","25,499,000.00","34,844,000.00","27,693,000.00","48,651,000.00","45,968,000.00","32,951,000.00","37,558,000.00"
SPL,Starpharma Holdings Limited,Annual Profit and Loss - Total Revenue Excluding Int,"1,344,173.00","887,598.00","384,703.00","951,746.00","750,357.00","1,433,255.00","6,422,566.00","8,954,390.00","9,624,000.00","9,710,000.00","5,209,000.00","2,322,000.00","1,085,000.00","865,000.00","280,000.00","808,000.00"
SPL,Starpharma Holdings Limited,Annual Profit and Loss - EBITDA,"-2,022,277.00","-4,920,469.00","-8,729,832.00","-7,483,224.00","-5,522,996.00","-7,499,880.00","-7,105,508.00","-6,513,612.00","-6,393,000.00","-2,379,000.00","-5,365,000.00","-8,363,000.00","-14,327,000.00","-5,739,000.00","-14,505,000.00","-18,613,000.00"
SPL,Starpharma Holdings Limited,Annual Profit and Loss - EBIT,"-2,037,591.00","-4,982,980.00","-8,903,204.00","-8,087,866.00","-6,126,085.00","-8,193,745.00","-8,070,841.00","-8,533,049.00","-8,492,000.00","-4,406,000.00","-7,062,000.00","-9,895,000.00","-15,469,000.00","-6,789,000.00","-15,601,000.00","-19,834,000.00"
SPL,Starpharma Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,772,014.00","-3,906,427.00","-7,959,289.00","-7,544,721.00","-5,497,850.00","-7,585,992.00","-7,522,789.00","-7,244,996.00","-7,491,000.00","-4,127,000.00","-6,378,000.00","-8,930,000.00","-13,658,000.00","-5,229,000.00","-14,635,000.00","-18,950,000.00"
SPL,Starpharma Holdings Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
SPL,Starpharma Holdings Limited,Annual Ratio Analysis - Net Profit Margin,--,--,"-2,055.13%",-847.09%,"-34,951.37%","-54,489.24%","-1,504,557.80%",-838.68%,-530.52%,-204.41%,-454.27%,-780.59%,"-31,040.91%","-26,145.00%","-5,360.81%","-2,356.97%"
SPL,Starpharma Holdings Limited,Annual Ratio Analysis - ROE,-6.14%,-15.68%,-46.48%,-83.52%,-31.25%,-76.12%,-35.29%,-28.16%,-36.75%,-16.18%,-18.30%,-32.25%,-28.07%,-11.38%,-44.41%,-50.46%
SPL,Starpharma Holdings Limited,Annual Ratio Analysis - Market Cap.($),0.00,"52,451,000.00","53,340,000.00","29,337,000.00","83,426,250.00","54,505,150.00","62,050,482.90","62,937,744.75","49,421,667.08","70,454,158.42","128,974,792.32","371,615,367.00","384,699,357.87","231,309,182.62","165,363,614.40","232,971,105.73"
SRX,Sirtex Medical Limited,Annual Balance Sheet - Total Equity,"3,383,554.00","16,194,000.00","12,778,000.00","16,293,000.00","18,170,000.00","16,781,000.00","19,077,000.00","21,764,000.00","23,287,000.00","39,179,000.00","51,543,000.00","60,142,000.00","73,548,000.00","88,138,000.00","107,583,000.00","144,636,000.00"
SRX,Sirtex Medical Limited,Annual Profit and Loss - Total Revenue Excluding Int,"553,692.00","428,000.00","783,000.00","10,315,000.00","9,569,000.00","12,069,000.00","23,503,000.00","34,121,000.00","38,937,000.00","73,285,000.00","69,625,000.00","70,564,000.00","84,258,000.00","97,884,000.00","129,416,000.00","178,212,000.00"
SRX,Sirtex Medical Limited,Annual Profit and Loss - EBITDA,"-1,005,682.00","-2,458,000.00","-3,541,000.00","1,237,000.00","-818,000.00","-1,550,000.00","5,410,000.00","4,087,000.00","2,625,000.00","18,662,000.00","17,418,000.00","12,935,000.00","21,223,000.00","23,494,000.00","30,826,000.00","53,258,000.00"
SRX,Sirtex Medical Limited,Annual Profit and Loss - EBIT,"-1,198,164.00","-2,711,000.00","-3,932,000.00","955,000.00","-1,117,000.00","-1,920,000.00","5,031,000.00","3,690,000.00","2,060,000.00","17,792,000.00","16,639,000.00","11,960,000.00","19,801,000.00","22,088,000.00","29,234,000.00","50,879,000.00"
SRX,Sirtex Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,133,000.00","-1,978,000.00","-3,416,000.00","3,150,000.00","697,000.00","-1,442,000.00","1,807,000.00","1,566,000.00","1,210,000.00","18,229,000.00","16,080,000.00","11,479,000.00","17,103,000.00","18,270,000.00","23,868,000.00","40,345,000.00"
SRX,Sirtex Medical Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
SRX,Sirtex Medical Limited,Annual Ratio Analysis - Net Profit Margin,-451.80%,-523.28%,-436.27%,30.83%,7.32%,-12.19%,7.87%,4.66%,3.17%,22.00%,24.99%,16.32%,20.70%,18.88%,18.45%,22.91%
SRX,Sirtex Medical Limited,Annual Ratio Analysis - ROE,-33.49%,-12.21%,-26.73%,19.33%,3.84%,-8.59%,9.47%,7.20%,5.20%,36.97%,31.20%,19.09%,23.25%,20.73%,22.19%,27.89%
SRX,Sirtex Medical Limited,Annual Ratio Analysis - Market Cap.($),0.00,"78,570,000.00","96,120,000.00","226,658,544.32","127,284,081.50","77,540,374.80","129,317,115.52","189,611,662.40","167,304,408.00","186,823,255.60","273,263,866.40","273,263,866.40","339,627,948.24","668,102,269.28","947,110,450.32","1,642,203,210.55"
SUD,Suda Ltd,Annual Balance Sheet - Total Equity, ,"6,113,488.00","2,997,918.00","3,767,226.00","13,274,895.00","11,724,581.00","13,351,404.00","14,327,171.00","10,509,687.00","8,842,200.00","8,345,615.00","11,032,235.00","7,012,033.00","6,690,080.00","15,991,556.00","19,300,587.00"
SUD,Suda Ltd,Annual Profit and Loss - Total Revenue Excluding Int, ,"7,363.00",--,"190,996.00","5,149,134.00","8,169,920.00","10,339,121.00","10,481,009.00","11,856,715.00","161,916.00","54,836.00","3,152,681.00","3,963,804.00","4,049,276.00","8,648,187.00","5,761,232.00"
SUD,Suda Ltd,Annual Profit and Loss - EBITDA, ,"-79,187.00","-785,380.00","-926,447.00","-680,808.00","-1,468,207.00","328,940.00","-1,356,754.00","-8,632,974.00","-2,734,111.00","-3,527,287.00","-2,750,630.00","-1,939,155.00","-1,761,261.00","-2,120,412.00","-3,801,578.00"
SUD,Suda Ltd,Annual Profit and Loss - EBIT, ,"-79,187.00","-785,725.00","-1,093,076.00","-1,030,670.00","-1,877,750.00","170,263.00","-1,728,281.00","-9,320,730.00","-2,812,836.00","-3,597,451.00","-2,846,138.00","-1,994,979.00","-1,794,834.00","-2,187,559.00","-3,982,822.00"
SUD,Suda Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, ,"-79,187.00","-751,340.00","-1,064,905.00","-967,848.00","-1,928,929.00","26,079.00","-2,007,363.00","-9,647,554.00","-3,168,182.00","-4,856,312.00","-4,423,195.00","-4,437,023.00","-1,667,519.00","-2,060,850.00","-3,378,331.00"
SUD,Suda Ltd,Annual Profit and Loss - Total Operating Income (ban, ,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
SUD,Suda Ltd,Annual Ratio Analysis - Net Profit Margin, ,--,--,-756.50%,-20.39%,-23.60%,0.30%,-21.11%,-81.25%,"-15,034.56%","-25,981.21%",-96.91%,-42.46%,-41.22%,-23.73%,-59.86%
SUD,Suda Ltd,Annual Ratio Analysis - ROE, ,-1.30%,-25.06%,-28.27%,-7.29%,-16.45%,0.20%,-14.01%,-93.57%,-32.91%,-44.25%,-26.39%,-23.67%,-24.93%,-14.71%,-19.50%
SUD,Suda Ltd,Annual Ratio Analysis - Market Cap.($), ,0.00,"9,466,600.66","48,148,797.00","38,168,273.43","19,604,857.44","20,548,357.44","22,243,974.06","31,725,087.37","7,539,569.04","12,733,261.05","14,264,935.94","7,727,123.56","16,341,217.28","47,513,145.65","31,808,296.44"
SVA,Simavita Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"14,284,217.00","7,530,763.00","10,190,987.00"
SVA,Simavita Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , ,--,"445,104.00","808,932.00"
SVA,Simavita Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , ,0.00,"-9,353,304.00","-11,020,076.00"
SVA,Simavita Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , ,0.00,"-9,493,203.00","-11,150,292.00"
SVA,Simavita Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"-10,491,790.00","-9,463,209.00"
SVA,Simavita Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , ,--,--,--
SVA,Simavita Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , ,--,"-2,423.09%","-1,215.45%"
SVA,Simavita Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,-112.58%,-92.86%
SVA,Simavita Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , ,0.00,"30,200,529.96","45,200,164.17"
TDL,TBG Diagnostics Limited,Annual Balance Sheet - Total Equity,"15,857,107.00","25,160,000.00","18,501,000.00","14,631,000.00","16,780,000.00","25,491,000.00","17,920,000.00","97,977,000.00","75,259,000.00","30,790,000.00","15,017,000.00","8,991,000.00","5,673,002.00","9,722,511.00","8,013,922.00","3,461,752.00"
TDL,TBG Diagnostics Limited,Annual Profit and Loss - Total Revenue Excluding Int,"3,939,288.00","2,451,000.00","4,935,000.00","7,662,000.00","5,528,000.00","2,294,000.00","1,719,000.00","2,033,000.00","2,456,000.00","8,745,000.00","2,123,000.00","3,116,000.00","2,613,713.00","3,451,990.00","6,225,839.00","4,266,955.00"
TDL,TBG Diagnostics Limited,Annual Profit and Loss - EBITDA,"-6,391,789.00","-1,738,000.00","-6,285,000.00","-7,276,000.00","-5,462,000.00","-6,171,000.00","-8,155,000.00","-23,684,000.00","-30,947,000.00","-7,916,000.00","-15,923,000.00","-6,407,000.00","-3,586,295.00","-2,865,200.00","-1,753,876.00","-4,383,424.00"
TDL,TBG Diagnostics Limited,Annual Profit and Loss - EBIT,"-6,827,674.00","-2,241,000.00","-6,875,000.00","-8,058,000.00","-6,110,000.00","-6,740,000.00","-8,687,000.00","-24,185,000.00","-31,521,000.00","-8,676,000.00","-16,575,000.00","-6,645,000.00","-3,756,783.00","-3,004,119.00","-2,024,180.00","-4,780,492.00"
TDL,TBG Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-7,322,244.00","-1,147,000.00","-6,156,000.00","-7,578,000.00","-4,781,000.00","-5,937,000.00","-7,609,000.00","-22,454,000.00","-26,148,000.00","-5,467,000.00","-15,839,000.00","-6,098,000.00","-3,440,398.00","-2,092,134.00","-1,806,945.00","-4,684,104.00"
TDL,TBG Diagnostics Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
TDL,TBG Diagnostics Limited,Annual Ratio Analysis - Net Profit Margin,-261.44%,-47.12%,-159.90%,-136.69%,-156.50%,-259.71%,-840.77%,"-2,440.65%","-2,407.73%",-317.11%,-802.79%,-235.90%,-171.32%,-74.29%,-33.39%,-140.20%
TDL,TBG Diagnostics Limited,Annual Ratio Analysis - ROE,-40.25%,-4.56%,-33.27%,-51.79%,-32.55%,-23.29%,-42.46%,-22.92%,-34.74%,-17.76%,-105.47%,-67.82%,-60.65%,-21.52%,-22.55%,-135.31%
TDL,TBG Diagnostics Limited,Annual Ratio Analysis - Market Cap.($),"54,753,928.57","37,612,262.00","24,635,787.69","22,875,409.48","122,549,780.75","109,097,773.17","109,592,441.10","273,315,564.20","83,343,569.58","21,002,732.45","9,883,638.80","5,683,092.31","3,459,273.58","12,439,195.88","44,228,252.00","9,674,930.12"
TDX,Tyrian Diagnostics Limited,Annual Balance Sheet - Total Equity, ,--,--,--, ,"6,407,276.00","7,247,443.00","3,332,532.00","7,553,986.00","2,934,323.00","3,336,273.00","2,762,219.00","916,734.00","784,374.00","864,083.00","558,459.00"
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - Total Revenue Excluding Int, ,"5,376,000.00","7,379,000.00",--, ,"5,016,902.00","6,635,545.00","4,217,418.00","2,785,401.00","1,738,495.00","2,383,758.00","1,233,001.00","900,061.00","264,201.00","461,211.00","22,383.00"
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - EBITDA, ,"-7,282,000.00","-14,144,000.00","-13,901,000.00", ,"-15,990,738.00","-9,359,801.00","-8,358,918.00","-8,458,936.00","-6,375,251.00","-4,109,961.00","-4,350,447.00","-1,886,132.00","-163,520.00","58,726.00","-321,626.00"
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - EBIT, ,"-8,198,000.00","-16,291,000.00","-16,393,000.00", ,"-19,947,149.00","-10,522,373.00","-9,061,754.00","-9,003,586.00","-6,678,455.00","-4,308,884.00","-4,501,726.00","-1,906,218.00","-163,520.00","58,726.00","-321,626.00"
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, ,"-7,473,000.00","-16,248,000.00","-16,397,000.00", ,"-19,766,147.00","-10,214,981.00","-8,772,571.00","-8,726,511.00","-6,995,002.00","-4,155,911.00","-4,383,868.00","-1,865,210.00","-132,360.00","79,709.00","-305,624.00"
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - Total Operating Income (ban, ,--,--,--, ,--,--,--,--,--,--,--,--,--,--,--
TDX,Tyrian Diagnostics Limited,Annual Ratio Analysis - Net Profit Margin, ,-188.28%,-300.98%,--, ,-541.57%,-224.11%,-261.63%,-562.47%,-811.62%,-272.33%,-933.54%,"-1,833.27%",--,17.29%,"-1,365.43%"
TDX,Tyrian Diagnostics Limited,Annual Ratio Analysis - ROE, ,--,--,--, ,-151.49%,-140.95%,-263.24%,-115.52%,-218.67%,-123.81%,-158.04%,-203.48%,-16.87%,9.22%,-54.73%
TDX,Tyrian Diagnostics Limited,Annual Ratio Analysis - Market Cap.($), ,0.00,0.00,0.00, ,"33,669,249.04","41,069,497.20","54,682,742.80","26,907,088.44","6,469,554.29","4,486,647.07","5,086,597.59","1,022,027.09","1,022,027.09","1,022,027.09","1,022,027.09"
TPE,TPI Enterprises Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"38,800,000.00"
TPE,TPI Enterprises Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,"3,993,047.00"
TPE,TPI Enterprises Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,"-10,414,370.00"
TPE,TPI Enterprises Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,"-13,970,666.00"
TPE,TPI Enterprises Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-25,899,838.00"
TPE,TPI Enterprises Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
TPE,TPI Enterprises Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,-729.64%
TPE,TPI Enterprises Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-146.06%
TPE,TPI Enterprises Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,"195,507,872.00"
TTC,Traditional Therapies Clinics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"31,963,000.00","46,528,000.00"
TTC,Traditional Therapies Clinics Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , ,--,"45,518,000.00"
TTC,Traditional Therapies Clinics Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , ,0.00,"25,911,000.00"
TTC,Traditional Therapies Clinics Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , ,0.00,"24,727,000.00"
TTC,Traditional Therapies Clinics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"17,127,000.00"
TTC,Traditional Therapies Clinics Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , ,--,--
TTC,Traditional Therapies Clinics Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , ,--,37.67%
TTC,Traditional Therapies Clinics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,36.27%
TTC,Traditional Therapies Clinics Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , ,0.00,"151,228,820.00"
UBI,"Universal Biosensors, Inc.",Annual Balance Sheet - Total Equity, , , , , , ,"35,277,044.00","52,675,265.00","48,703,230.00","51,314,002.00","47,219,079.00","35,022,606.00","39,372,139.00","29,683,940.00","19,740,945.00","13,255,705.00"
UBI,"Universal Biosensors, Inc.",Annual Profit and Loss - Total Revenue Excluding Int, , , , , , ,"2,527,486.00","999,981.00","5,688,476.00","22,042,570.00","18,180,036.00","14,726,895.00","29,646,443.00","22,013,488.00","18,534,218.00","26,480,010.00"
UBI,"Universal Biosensors, Inc.",Annual Profit and Loss - EBITDA, , , , , , ,"-3,113,959.00","-8,107,265.00","-14,528,663.00","3,481,925.00","-4,812,556.00","-12,076,899.00","-6,901,989.00","-8,816,666.00","-4,402,088.00","-798,665.00"
UBI,"Universal Biosensors, Inc.",Annual Profit and Loss - EBIT, , , , , , ,"-3,113,959.00","-8,701,792.00","-14,528,663.00","630,640.00","-7,803,414.00","-15,375,440.00","-9,539,130.00","-11,314,011.00","-6,915,034.00","-3,495,816.00"
UBI,"Universal Biosensors, Inc.",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,"-2,804,295.00","-7,372,049.00","-11,995,886.00","1,430,463.00","-6,610,525.00","-14,692,117.00","-9,131,222.00","-11,633,807.00","-9,316,127.00","-6,576,416.00"
UBI,"Universal Biosensors, Inc.",Annual Profit and Loss - Total Operating Income (ban, , , , , , ,--,--,--,--,--,--,--,--,--,--
UBI,"Universal Biosensors, Inc.",Annual Ratio Analysis - Net Profit Margin, , , , , , ,-110.95%,-737.22%,-263.23%,6.49%,-36.36%,-99.97%,-30.80%,-77.10%,-97.76%,-39.20%
UBI,"Universal Biosensors, Inc.",Annual Ratio Analysis - ROE, , , , , , ,-7.95%,-14.00%,-24.63%,2.79%,-14.00%,-41.95%,-23.19%,-39.19%,-47.19%,-49.61%
UBI,"Universal Biosensors, Inc.",Annual Ratio Analysis - Market Cap.($), , , , , , ,"143,359,973.12","232,299,041.76","92,616,392.24","290,738,476.05","241,484,672.40","119,354,973.75","159,173,274.64","80,776,278.30","31,609,976.04","79,250,662.80"
UCM,USCOM Ltd,Annual Balance Sheet - Total Equity, , , ,"15,442,741.00","14,292,725.00","11,746,807.00","8,509,267.00","5,496,266.00","3,405,526.00","3,056,217.00","2,450,035.00","3,135,605.00","1,470,066.00","2,354,667.00","3,319,393.00","2,288,661.00"
UCM,USCOM Ltd,Annual Profit and Loss - Total Revenue Excluding Int, , , ,--,"519,209.00","631,675.00","1,259,881.00","1,520,994.00","1,052,839.00","1,840,414.00","999,055.00","839,550.00","802,699.00","626,993.00","1,056,576.00","2,026,774.00"
UCM,USCOM Ltd,Annual Profit and Loss - EBITDA, , , ,0.00,"-1,773,622.00","-3,388,458.00","-3,960,499.00","-3,637,834.00","-2,486,145.00","-1,603,548.00","-2,043,009.00","-2,968,720.00","-2,188,735.00","-1,676,610.00","-1,453,341.00","-996,519.00"
UCM,USCOM Ltd,Annual Profit and Loss - EBIT, , , ,0.00,"-1,830,749.00","-3,475,789.00","-4,100,221.00","-3,829,476.00","-2,628,783.00","-1,718,369.00","-2,148,156.00","-3,072,132.00","-2,292,200.00","-1,755,632.00","-1,663,371.00","-1,168,538.00"
UCM,USCOM Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,0.00,"-1,251,684.00","-2,545,918.00","-3,374,210.00","-3,196,824.00","-2,174,484.00","-1,099,889.00","-1,757,677.00","-2,685,913.00","-1,824,547.00","-1,371,683.00","-1,520,500.00","-1,215,654.00"
UCM,USCOM Ltd,Annual Profit and Loss - Total Operating Income (ban, , , ,--,--,--,--,--,--,--,--,--,--,--,--,--
UCM,USCOM Ltd,Annual Ratio Analysis - Net Profit Margin, , , ,--,-325.63%,-530.28%,-301.37%,-366.92%,-206.76%,-67.46%,-210.02%,-320.52%,-229.75%,-237.01%,-127.04%,-76.28%
UCM,USCOM Ltd,Annual Ratio Analysis - ROE, , , ,0.00%,-8.76%,-21.67%,-39.65%,-58.16%,-63.85%,-35.99%,-71.74%,-85.66%,-124.11%,-58.25%,-40.44%,-50.50%
UCM,USCOM Ltd,Annual Ratio Analysis - Market Cap.($), , , ,0.00,"119,700,000.00","41,800,000.00","17,100,000.00","13,680,000.00","7,030,000.00","30,800,000.00","14,631,416.45","11,467,387.36","4,899,701.87","11,589,237.45","17,921,087.80","15,524,803.10"
UNS,Unilife Corporation,Annual Balance Sheet - Total Equity, , ,"-42,951.00","10,375,632.00","20,374,483.00","22,071,918.00","18,992,626.00","20,173,367.00","17,877,101.00","36,277,965.00","52,059,134.00","49,885,464.00","42,925,130.00","38,380,592.00","6,508,492.00","-23,325,520.00"
UNS,Unilife Corporation,Annual Profit and Loss - Total Revenue Excluding Int, , ,"394,913.00","184,500.00","401,688.00","55,300.00","176,818.00","3,147,061.00","3,943,650.00","39,931,068.00","13,401,384.00","6,739,919.00","5,575,507.00","3,170,889.00","16,451,167.00","17,427,083.00"
UNS,Unilife Corporation,Annual Profit and Loss - EBITDA, , ,"182,368.00","-1,349,285.00","-5,631,333.00","-6,889,634.00","-9,099,177.00","-10,606,833.00","-7,696,423.00","12,799,057.00","-33,292,267.00","-34,045,069.00","-44,867,039.00","-55,388,679.00","-49,371,549.00","-103,591,145.00"
UNS,Unilife Corporation,Annual Profit and Loss - EBIT, , ,"182,368.00","-1,752,361.00","-6,443,264.00","-7,718,595.00","-9,284,615.00","-10,877,493.00","-8,500,304.00","11,589,035.00","-36,007,274.00","-37,778,191.00","-49,363,163.00","-65,617,250.00","-53,701,698.00","-110,001,302.00"
UNS,Unilife Corporation,Annual Profit and Loss - Reported NPAT After Abnorma, , ,"182,368.00","-1,442,965.00","-5,770,982.00","-7,399,919.00","-9,208,122.00","-10,906,076.00","-8,617,238.00","12,806,494.00","-34,903,203.00","-37,882,484.00","-51,321,754.00","-68,138,005.00","-61,463,906.00","-118,292,968.00"
UNS,Unilife Corporation,Annual Profit and Loss - Total Operating Income (ban, , ,--,--,--,--,--,--,--,--,--,--,--,--,--,--
UNS,Unilife Corporation,Annual Ratio Analysis - Net Profit Margin, , ,46.18%,--,--,--,--,-507.10%,-247.47%,308.26%,-260.44%,"-1,210.41%","-85,740.98%","-52,665.00%",-394.17%,-690.45%
UNS,Unilife Corporation,Annual Ratio Analysis - ROE, , ,-141.53%,-13.91%,-28.32%,-33.53%,-48.48%,-54.06%,-48.20%,35.30%,-67.05%,-75.94%,-119.56%,-177.53%,-944.36%,507.14%
UNS,Unilife Corporation,Annual Ratio Analysis - Market Cap.($), , ,"595,006.30","189,666,299.36","159,761,798.47","55,026,176.15","25,654,623.80","50,112,386.50","94,656,182.60","68,123,990.79","61,333,269.76","297,158,496.45","295,700,999.10","326,960,748.36","51,779,969.00","364,175,053.08"
VBS,Vectus Biosystems Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"11,218,005.00"
VBS,Vectus Biosystems Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,--
VBS,Vectus Biosystems Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,0.00
VBS,Vectus Biosystems Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,0.00
VBS,Vectus Biosystems Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00
VBS,Vectus Biosystems Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
VBS,Vectus Biosystems Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
VBS,Vectus Biosystems Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
VBS,Vectus Biosystems Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
VHT,Volpara Health Technologies Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"11,170,000.00"
VHT,Volpara Health Technologies Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , , , , ,--
VHT,Volpara Health Technologies Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , , , , ,0.00
VHT,Volpara Health Technologies Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , , , , ,0.00
VHT,Volpara Health Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00
VHT,Volpara Health Technologies Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , , , , ,--
VHT,Volpara Health Technologies Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , , , , ,--
VHT,Volpara Health Technologies Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%
VHT,Volpara Health Technologies Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , , , , ,0.00
VLA,Viralytics Limited,Annual Balance Sheet - Total Equity,"213,877.00","613,627.00","1,782,938.00","3,046,131.00","8,159,907.00","8,703,198.00","9,533,294.00","11,695,864.00","8,694,450.00","4,892,184.00","8,614,325.00","9,058,460.00","9,559,874.00","8,977,885.00","28,876,542.00","24,872,281.00"
VLA,Viralytics Limited,Annual Profit and Loss - Total Revenue Excluding Int,"1,081,845.00","1,069,122.00","1,003,911.00","1,268,974.00","1,115,751.00","583,240.00","27,041.00","359,473.00","201,277.00",--,"17,416.00","1,405,503.00","874,603.00","2,493,235.00","2,507,612.00","4,136,399.00"
VLA,Viralytics Limited,Annual Profit and Loss - EBITDA,"-578,458.00","-3,334,683.00","-1,284,524.00","-1,257,196.00","-1,999,207.00","-5,269,915.00","-6,842,880.00","-3,891,540.00","-3,306,167.00","-4,131,351.00","-4,335,882.00","-2,493,903.00","-4,667,991.00","-3,979,971.00","-5,406,630.00","-4,356,791.00"
VLA,Viralytics Limited,Annual Profit and Loss - EBIT,"-660,793.00","-3,423,988.00","-1,348,444.00","-2,370,762.00","-3,165,039.00","-7,060,088.00","-9,303,625.00","-4,353,400.00","-3,827,859.00","-4,657,028.00","-4,826,926.00","-2,940,835.00","-5,095,538.00","-4,392,303.00","-5,824,909.00","-4,781,833.00"
VLA,Viralytics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-887,629.00","-3,455,250.00","-1,425,760.00","-2,436,978.00","-3,129,315.00","-6,940,616.00","-9,272,383.00","-4,195,590.00","-3,681,125.00","-4,585,443.00","-4,804,370.00","-2,701,287.00","-4,778,819.00","-4,129,729.00","-5,528,629.00","-4,254,777.00"
VLA,Viralytics Limited,Annual Profit and Loss - Total Operating Income (ban,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--,--
VLA,Viralytics Limited,Annual Ratio Analysis - Net Profit Margin,-82.69%,-323.19%,-131.07%,-130.83%,6.14%,"-1,406.63%","-123,090.18%","-1,167.15%",--,--,--,-192.19%,-548.28%,--,--,--
VLA,Viralytics Limited,Annual Ratio Analysis - ROE,-415.02%,-563.09%,-178.29%,-64.78%,1.71%,-67.76%,-97.26%,-35.87%,-42.34%,-93.73%,-55.77%,-29.82%,-49.99%,-46.00%,-19.15%,-17.11%
VLA,Viralytics Limited,Annual Ratio Analysis - Market Cap.($),"33,173,569.13","6,373,068.97","2,624,463.53","23,644,236.82","17,370,736.70","26,499,367.62","29,165,345.40","19,749,413.33","14,061,075.20","9,970,569.18","18,796,428.24","43,096,442.57","19,989,999.40","21,380,808.47","49,668,735.87","139,956,341.56"
VRT,Virtus Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,"205,700,000.00","214,589,000.00","239,626,000.00","246,321,000.00"
VRT,Virtus Health Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , , , , , , ,--,"192,121,000.00","201,202,000.00","234,543,000.00"
VRT,Virtus Health Limited,Annual Profit and Loss - EBITDA, , , , , , , , , , , , ,0.00,"43,429,000.00","59,404,000.00","64,072,000.00"
VRT,Virtus Health Limited,Annual Profit and Loss - EBIT, , , , , , , , , , , , ,0.00,"34,684,000.00","51,212,000.00","54,078,000.00"
VRT,Virtus Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,0.00,"10,104,000.00","30,957,000.00","30,441,000.00"
VRT,Virtus Health Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , , , , , , ,--,--,--,--
VRT,Virtus Health Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , , , , , , ,--,5.45%,15.48%,13.75%
VRT,Virtus Health Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,0.00%,9.42%,13.50%,14.05%
VRT,Virtus Health Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , , , , , , ,0.00,"513,011,076.45","650,537,052.48","429,255,987.06"
VSC,Vita Life Sciences Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"2,879,728.00","3,845,624.00","3,900,881.00","8,129,883.00","8,956,045.00","11,342,000.00","16,269,000.00","21,565,000.00","22,876,000.00"
VSC,Vita Life Sciences Limited,Annual Profit and Loss - Total Revenue Excluding Int, , , , , , , ,"12,401,004.00","15,501,606.00","17,276,239.00","26,290,078.00","24,476,995.00","30,354,000.00","35,490,000.00","36,751,000.00","38,621,000.00"
VSC,Vita Life Sciences Limited,Annual Profit and Loss - EBITDA, , , , , , , ,"-241,357.00","-415,181.00","39,806.00","5,022,271.00","1,582,256.00","2,959,000.00","5,624,000.00","7,000,000.00","6,209,000.00"
VSC,Vita Life Sciences Limited,Annual Profit and Loss - EBIT, , , , , , , ,"-375,505.00","-577,101.00","-107,466.00","4,904,663.00","1,488,947.00","2,865,000.00","5,511,000.00","6,882,000.00","6,095,000.00"
VSC,Vita Life Sciences Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-204,265.00","353,477.00","-328,193.00","4,459,519.00","1,212,521.00","2,316,000.00","4,746,000.00","7,284,000.00","4,351,000.00"
VSC,Vita Life Sciences Limited,Annual Profit and Loss - Total Operating Income (ban, , , , , , , ,--,--,--,--,--,--,--,--,--
VSC,Vita Life Sciences Limited,Annual Ratio Analysis - Net Profit Margin, , , , , , , ,-5.13%,-4.80%,-1.93%,22.09%,5.00%,7.84%,13.41%,19.90%,11.38%
VSC,Vita Life Sciences Limited,Annual Ratio Analysis - ROE, , , , , , , ,-50.64%,-21.36%,-9.62%,58.28%,14.28%,21.03%,29.35%,33.91%,19.24%
VSC,Vita Life Sciences Limited,Annual Ratio Analysis - Market Cap.($), , , , , , , ,"6,579,184.50","2,429,011.40","11,942,767.54","13,561,326.75","16,775,067.40","32,190,543.66","88,876,027.00","83,569,959.72","79,504,996.21"
